



Deposited via The University of York.

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/id/eprint/135391/>

Version: Published Version

---

**Article:**

Aveyard, Paul, Lindson, Nicola, Tearne, Sarah et al. (2018) Nicotine preloading for smoking cessation: the Preloading RCT. Health technology assessment. pp. 1-84. ISSN: 2046-4924

<https://doi.org/10.3310/hta22410>

---

**Reuse**

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

**Takedown**

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk) including the URL of the record and the reason for the withdrawal request.

## Nicotine preloading for smoking cessation: the Preloading RCT

*Paul Aveyard, Nicola Lindson, Sarah Tearne, Rachel Adams, Khaled Ahmed, Rhona Alekna, Miriam Banting, Mike Healy, Shahnaz Khan, Gurmail Rai, Carmen Wood, Emma C Anderson, Alia Ataya-Williams, Angela Attwood, Kayleigh Easey, Megan Fluharty, Therese Freuler, Megan Hurse, Jasmine Khouja, Lindsey Lacey, Marcus Munafò, Deborah Lycett, Andy McEwen, Tim Coleman, Anne Dickinson, Sarah Lewis, Sophie Orton, Johanna Perdue, Clare Randall, Rebecca Anderson, Natalie Bisal, Peter Hajek, Celine Homsey, Hayden J McRobbie, Katherine Myers-Smith, Anna Phillips, Dunja Przulj, Jinshuo Li, Doug Coyle, Katherine Coyle and Subhash Pokhrel*



**National Institute for  
Health Research**



# Nicotine preloading for smoking cessation: the Preloading RCT

Paul Aveyard,<sup>1\*</sup> Nicola Lindson,<sup>1</sup> Sarah Tearne,<sup>1</sup>  
Rachel Adams,<sup>2</sup> Khaled Ahmed,<sup>2</sup> Rhona Alekna,<sup>2</sup>  
Miriam Banting,<sup>2</sup> Mike Healy,<sup>2</sup> Shahnaz Khan,<sup>2</sup>  
Gurmail Rai,<sup>2</sup> Carmen Wood,<sup>2</sup> Emma C Anderson,<sup>3</sup>  
Alia Ataya-Williams,<sup>3</sup> Angela Attwood,<sup>3</sup>  
Kayleigh Easey,<sup>3</sup> Megan Fluharty,<sup>3</sup> Therese Freuler,<sup>3</sup>  
Megan Hurse,<sup>3</sup> Jasmine Khouja,<sup>3</sup> Lindsey Lacey,<sup>3</sup>  
Marcus Munafò,<sup>3</sup> Deborah Lycett,<sup>4</sup> Andy McEwen,<sup>5</sup>  
Tim Coleman,<sup>6</sup> Anne Dickinson,<sup>6</sup> Sarah Lewis,<sup>6</sup>  
Sophie Orton,<sup>6</sup> Johanna Perdue,<sup>6</sup> Clare Randall,<sup>6</sup>  
Rebecca Anderson,<sup>7</sup> Natalie Bisal,<sup>7</sup> Peter Hajek,<sup>7</sup>  
Celine Homsey,<sup>7</sup> Hayden J McRobbie,<sup>7</sup>  
Katherine Myers-Smith,<sup>7</sup> Anna Phillips,<sup>7</sup> Dunja Przulj,<sup>7</sup>  
Jinshuo Li,<sup>8</sup> Doug Coyle,<sup>9</sup> Katherine Coyle<sup>9</sup>  
and Subhash Pokhrel<sup>9</sup>

<sup>1</sup>Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK

<sup>2</sup>Primary Care Clinical Sciences, University of Birmingham, Birmingham, UK

<sup>3</sup>School of Experimental Psychology, University of Bristol, Bristol, UK

<sup>4</sup>Faculty of Health and Life Sciences, Coventry University, Coventry, UK

<sup>5</sup>National Centre for Smoking Cessation and Training (NCSCT), Dorchester, UK

<sup>6</sup>School of Medicine, University of Nottingham, Nottingham, UK

<sup>7</sup>Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, UK

<sup>8</sup>Health Sciences, University of York, York, UK

<sup>9</sup>Institute of Environment, Health and Societies, Brunel University, Uxbridge, UK

\*Corresponding author



**Declared competing interests of authors:** All contributors participated in this trial, to which GlaxoSmithKline plc donated free patches. Paul Aveyard is funded by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre and CLAHRC. Peter Hajek and Hayden J McRobbie have provided research and consultancy to several manufacturers of smoking cessation treatments and have been paid for doing so. Tim Coleman is a member of the NIHR Health Technology Assessment Clinical Evaluation and Trials Board. Sarah Lewis is a member of the NIHR Health Services and Delivery Research funding board. Peter Hajek reports a research grant to Queen Mary University of London from Pfizer and personal consultancy fees from Pfizer. Andy McEwen reports grants from Pfizer and hospitality from North 51. Hayden J McRobbie reports a grant and honorarium from Pfizer for speaking at education meetings and an honorarium from Johnson & Johnson for speaking at education meetings and an advisory board meeting.

**Disclaimer:** Authors are listed in alphabetical order by centre. The list does not reflect relative contribution.

**Published August 2018**

DOI: 10.3310/hta22410

This report should be referenced as follows:

Aveyard P, Lindson N, Tearne S, Adams R, Ahmed K, Alekna R, *et al.* Nicotine preloading for smoking cessation: the Preloading RCT. *Health Technol Assess* 2018;**22**(41).

*Health Technology Assessment* is indexed and abstracted in *Index Medicus/MEDLINE*, *Excerpta Medica/EMBASE*, *Science Citation Index Expanded (SciSearch®)* and *Current Contents®/Clinical Medicine*.



ISSN 1366-5278 (Print)

ISSN 2046-4924 (Online)

Impact factor: 4.513

*Health Technology Assessment* is indexed in MEDLINE, CINAHL, EMBASE, The Cochrane Library and the Clarivate Analytics Science Citation Index.

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) ([www.publicationethics.org/](http://www.publicationethics.org/)).

Editorial contact: [journals.library@nhr.ac.uk](mailto:journals.library@nhr.ac.uk)

The full HTA archive is freely available to view online at [www.journalslibrary.nhr.ac.uk/hta](http://www.journalslibrary.nhr.ac.uk/hta). Print-on-demand copies can be purchased from the report pages of the NIHR Journals Library website: [www.journalslibrary.nhr.ac.uk](http://www.journalslibrary.nhr.ac.uk)

## Criteria for inclusion in the *Health Technology Assessment* journal

Reports are published in *Health Technology Assessment* (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

Reviews in *Health Technology Assessment* are termed 'systematic' when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

## HTA programme

The HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.

The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.

For more information about the HTA programme please visit the website: <http://www.nets.nhr.ac.uk/programmes/hta>

## This report

The research reported in this issue of the journal was funded by the HTA programme as project number 09/110/01. The contractual start date was in March 2012. The draft report began editorial review in April 2017 and was accepted for publication in October 2017. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors' report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health and Social Care. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health and Social Care.

© Queen's Printer and Controller of HMSO 2018. This work was produced by Aveyard *et al.* under the terms of a commissioning contract issued by the Secretary of State for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Published by the NIHR Journals Library ([www.journalslibrary.nhr.ac.uk](http://www.journalslibrary.nhr.ac.uk)), produced by Prepress Projects Ltd, Perth, Scotland ([www.prepress-projects.co.uk](http://www.prepress-projects.co.uk)).

## NIHR Journals Library Editor-in-Chief

**Professor Tom Walley** Director, NIHR Evaluation, Trials and Studies and Director of the EME Programme, UK

## NIHR Journals Library Editors

**Professor Ken Stein** Chair of HTA and EME Editorial Board and Professor of Public Health, University of Exeter Medical School, UK

**Professor Andrée Le May** Chair of NIHR Journals Library Editorial Group (HS&DR, PGfAR, PHR journals)

**Dr Martin Ashton-Key** Consultant in Public Health Medicine/Consultant Advisor, NETSCC, UK

**Professor Matthias Beck** Professor of Management, Cork University Business School, Department of Management and Marketing, University College Cork, Ireland

**Dr Tessa Crilly** Director, Crystal Blue Consulting Ltd, UK

**Dr Eugenia Cronin** Senior Scientific Advisor, Wessex Institute, UK

**Dr Peter Davidson** Director of the NIHR Dissemination Centre, University of Southampton, UK

**Ms Tara Lamont** Scientific Advisor, NETSCC, UK

**Dr Catriona McDaid** Senior Research Fellow, York Trials Unit, Department of Health Sciences, University of York, UK

**Professor William McGuire** Professor of Child Health, Hull York Medical School, University of York, UK

**Professor Geoffrey Meads** Professor of Wellbeing Research, University of Winchester, UK

**Professor John Norrie** Chair in Medical Statistics, University of Edinburgh, UK

**Professor John Powell** Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK

**Professor James Raftery** Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, University of Southampton, UK

**Dr Rob Riemsma** Reviews Manager, Kleijnen Systematic Reviews Ltd, UK

**Professor Helen Roberts** Professor of Child Health Research, UCL Great Ormond Street Institute of Child Health, UK

**Professor Jonathan Ross** Professor of Sexual Health and HIV, University Hospital Birmingham, UK

**Professor Helen Snooks** Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

**Professor Jim Thornton** Professor of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, University of Nottingham, UK

**Professor Martin Underwood** Director, Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, UK

Please visit the website for a list of editors: [www.journalslibrary.nihr.ac.uk/about/editors](http://www.journalslibrary.nihr.ac.uk/about/editors)

**Editorial contact:** [journals.library@nihr.ac.uk](mailto:journals.library@nihr.ac.uk)

# Abstract

## Nicotine preloading for smoking cessation: the Preloading RCT

Paul Aveyard,<sup>1\*</sup> Nicola Lindson,<sup>1</sup> Sarah Tearne,<sup>1</sup> Rachel Adams,<sup>2</sup> Khaled Ahmed,<sup>2</sup> Rhona Alekna,<sup>2</sup> Miriam Banting,<sup>2</sup> Mike Healy,<sup>2</sup> Shahnaz Khan,<sup>2</sup> Gurmail Rai,<sup>2</sup> Carmen Wood,<sup>2</sup> Emma C Anderson,<sup>3</sup> Alia Ataya-Williams,<sup>3</sup> Angela Attwood,<sup>3</sup> Kayleigh Easey,<sup>3</sup> Megan Fluharty,<sup>3</sup> Therese Freuler,<sup>3</sup> Megan Hurse,<sup>3</sup> Jasmine Khouja,<sup>3</sup> Lindsey Lacey,<sup>3</sup> Marcus Munafò,<sup>3</sup> Deborah Lycett,<sup>4</sup> Andy McEwen,<sup>5</sup> Tim Coleman,<sup>6</sup> Anne Dickinson,<sup>6</sup> Sarah Lewis,<sup>6</sup> Sophie Orton,<sup>6</sup> Johanna Perdue,<sup>6</sup> Clare Randall,<sup>6</sup> Rebecca Anderson,<sup>7</sup> Natalie Bisal,<sup>7</sup> Peter Hajek,<sup>7</sup> Celine Homsey,<sup>7</sup> Hayden J McRobbie,<sup>7</sup> Katherine Myers-Smith,<sup>7</sup> Anna Phillips,<sup>7</sup> Dunja Przulj,<sup>7</sup> Jinshuo Li,<sup>8</sup> Doug Coyle,<sup>9</sup> Katherine Coyle<sup>9</sup> and Subhash Pokhrel<sup>9</sup>

<sup>1</sup>Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK

<sup>2</sup>Primary Care Clinical Sciences, University of Birmingham, Birmingham, UK

<sup>3</sup>School of Experimental Psychology, University of Bristol, Bristol, UK

<sup>4</sup>Faculty of Health and Life Sciences, Coventry University, Coventry, UK

<sup>5</sup>National Centre for Smoking Cessation and Training (NCSCT), Dorchester, UK

<sup>6</sup>School of Medicine, University of Nottingham, Nottingham, UK

<sup>7</sup>Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, UK

<sup>8</sup>Health Sciences, University of York, York, UK

<sup>9</sup>Institute of Environment, Health and Societies, Brunel University, Uxbridge, UK

\*Corresponding author [paul.aveyard@phc.ox.ac.uk](mailto:paul.aveyard@phc.ox.ac.uk)

**Background:** Nicotine preloading means using nicotine replacement therapy prior to a quit date while smoking normally. The aim is to reduce the drive to smoke, thereby reducing cravings for smoking after quit day, which are the main cause of early relapse. A prior systematic review showed inconclusive and heterogeneous evidence that preloading was effective and little evidence of the mechanism of action, with no cost-effectiveness data.

**Objectives:** To assess (1) the effectiveness, safety and tolerability of nicotine preloading in a routine NHS setting relative to usual care, (2) the mechanisms of the action of preloading and (3) the cost-effectiveness of preloading.

**Design:** Open-label randomised controlled trial with examination of mediation and a cost-effectiveness analysis.

**Setting:** NHS smoking cessation clinics.

**Participants:** People seeking help to stop smoking.

**Interventions:** Nicotine preloading comprised wearing a 21 mg/24 hour nicotine patch for 4 weeks prior to quit date. In addition, minimal behavioural support was provided to explain the intervention rationale and to support adherence. In the comparator group, participants received equivalent behavioural support. Randomisation was stratified by centre and concealed from investigators.

**Main outcome measures:** The primary outcome was 6-month prolonged abstinence assessed using the Russell Standard. The secondary outcomes were 4-week and 12-month abstinence. Adverse events (AEs) were assessed from baseline to 1 week after quit day. In a planned analysis, we adjusted for the use of varenicline (Champix®; Pfizer Inc., New York, NY, USA) as post-cessation medication. Cost-effectiveness analysis took a health-service perspective. The within-trial analysis assessed health-service costs during the 13 months of trial enrolment relative to the previous 6 months comparing trial arms. The base case was based on multiple imputation for missing cost data. We modelled long-term health outcomes of smoking-related diseases using the European-study on Quantifying Utility of Investment in Protection from Tobacco (EQUIPT) model.

**Results:** In total, 1792 people were eligible and were enrolled in the study, with 893 randomised to the control group and 899 randomised to the intervention group. In the intervention group, 49 (5.5%) people discontinued preloading prematurely and most others used it daily. The primary outcome, biochemically validated 6-month abstinence, was achieved by 157 (17.5%) people in the intervention group and 129 (14.4%) people in the control group, a difference of 3.02 percentage points [95% confidence interval (CI) -0.37 to 6.41 percentage points; odds ratio (OR) 1.25, 95% CI 0.97 to 1.62;  $p = 0.081$ ]. Adjusted for use of post-quit day varenicline, the OR was 1.34 (95% CI 1.03 to 1.73;  $p = 0.028$ ). Secondary abstinence outcomes were similar. The OR for the occurrence of serious AEs was 1.12 (95% CI 0.42 to 3.03). Moderate-severity nausea occurred in an additional 4% of the preloading group compared with the control group. There was evidence that reduced urges to smoke and reduced smoke inhalation mediated the effect of preloading on abstinence. The incremental cost-effectiveness ratio at the 6-month follow-up for preloading relative to control was £710 (95% CI -£13,674 to £23,205), but preloading was dominant at 12 months and in the long term, with an 80% probability that it is cost saving.

**Limitations:** The open-label design could partially account for the mediation results. Outcome assessment could not be blinded but was biochemically verified.

**Conclusions:** Use of nicotine-patch preloading for 4 weeks prior to attempting to stop smoking can increase the proportion of people who stop successfully, but its benefit is undermined because it reduces the use of varenicline after preloading. If this latter effect could be overcome, then nicotine preloading appears to improve health and reduce health-service costs in the long term. Future work should determine how to ensure that people using nicotine preloading opt to use varenicline as cessation medication.

**Trial registration:** Current Controlled Trials ISRCTN33031001.

**Funding:** This project was funded by the NIHR Health Technology Assessment programme and will be published in full in *Health Technology Assessment*; Vol. 22, No. 41. See the NIHR Journals Library website for further project information.

# Contents

<b>List of tables</b>	<b>xiii</b>
<b>List of figures</b>	<b>xv</b>
<b>List of boxes</b>	<b>xvii</b>
<b>List of abbreviations</b>	<b>xix</b>
<b>Plain English summary</b>	<b>xxi</b>
<b>Scientific summary</b>	<b>xxiii</b>
<b>Chapter 1 Introduction</b>	<b>1</b>
Smoking cessation and cessation medication	1
Nicotine preloading effectiveness	1
Mechanisms of action of preloading	2
Cost-effectiveness	3
Aims of the trial	3
<b>Chapter 2 Methods</b>	<b>5</b>
Design	5
Participants and settings	5
Interventions	6
<i>Intervention group</i>	6
<i>Control group</i>	7
<i>Standard smoking cessation treatment common to both arms</i>	7
Outcomes	7
<i>Primary outcome</i>	8
<i>Secondary outcomes</i>	8
<i>Adverse events</i>	8
Sample size	9
Randomisation	9
Blinding	10
Statistical analysis	10
Design features classified by PRECIS-2	10
<b>Chapter 3 Results of the trial</b>	<b>13</b>
Participant flow	13
Baseline characteristics	13
Medication adherence	13
Primary and secondary outcomes	18
Subgroup analysis	20
Adverse events	20
<b>Chapter 4 Moderators and mediators of the effect of nicotine preloading</b>	<b>27</b>
Introduction	27
<i>Effect modification</i>	27
<i>Mechanism of action of preloading</i>	27

Method	27
<i>Design</i>	27
<i>Outcomes</i>	28
<i>Statistical analysis</i>	29
Results	30
<i>Modification of the effect of preloading on abstinence by baseline tobacco dependence</i>	30
<i>Effect of preloading on potential mediators</i>	30
<i>Effect of preloading on the outcome, controlled for mediators</i>	32
<b>Chapter 5 People's reactions to nicotine preloading</b>	<b>37</b>
Introduction	37
Methods	37
Results	37
Discussion	37
<i>Conclusion</i>	37
<b>Chapter 6 A within-trial cost-effectiveness analysis of nicotine preloading</b>	<b>39</b>
Introduction	39
Methods	39
<i>Costs</i>	39
<i>Outcome</i>	42
<i>Analysis</i>	42
Results	43
<i>Costs</i>	43
<i>Analysis</i>	46
<b>Chapter 7 The modelled cost-effectiveness of nicotine preloading</b>	<b>53</b>
Introduction	53
Methods	53
<i>Clinical trial</i>	53
<i>Economic model</i>	53
Methods	53
<i>Design of the model</i>	53
<i>Transition probabilities</i>	54
<i>Prevalence of smoking-related diseases</i>	55
<i>Costs</i>	55
<i>Utility values</i>	55
<i>Outcomes</i>	55
<i>Key assumptions</i>	55
<i>Handling uncertainty</i>	56
Results	56
<i>Base-case analysis</i>	56
<i>Additional analysis</i>	57
<i>Deterministic sensitivity analysis</i>	58
<i>Probabilistic sensitivity analysis</i>	58
<b>Chapter 8 Discussion and conclusions</b>	<b>61</b>
Effectiveness of preloading	61
<i>Summary of main findings</i>	61
<i>Public involvement</i>	61
<i>Strengths and limitations</i>	62
<i>Comparison with other literature</i>	63
<i>Interpretation</i>	63

Mediation	64
<i>Summary of findings</i>	64
<i>Strengths and limitations</i>	65
<i>Comparison with other studies</i>	65
<i>Interpretation</i>	66
Within-trial cost-effectiveness	66
<i>Summary of main findings</i>	66
<i>Strengths and limitations</i>	66
<i>Interpretation</i>	68
Modelling the long-term cost-effectiveness of preloading	68
<i>Summary of findings</i>	68
<i>Strengths and limitations</i>	68
Research recommendations	69
Recommendations for practice	69
Conclusion	69
<b>Acknowledgements</b>	<b>71</b>
<b>References</b>	<b>75</b>
<b>Appendix 1 Supplementary tables for the long-term cost-effectiveness modelling</b>	<b>81</b>



# List of tables

<b>TABLE 1</b> Schedule of contacts with participants	<b>8</b>
<b>TABLE 2</b> Sample size required for 80% and 90% power for different combinations of control and intervention group prolonged abstinence rates	<b>9</b>
<b>TABLE 3</b> Participant characteristics by trial group	<b>15</b>
<b>TABLE 4</b> Participant self-reported patch use during preloading	<b>17</b>
<b>TABLE 5</b> Medication used to support cessation among those who made a quit attempt	<b>17</b>
<b>TABLE 6</b> Primary and secondary smoking cessation outcomes presented as ORs for the primary analysis	<b>18</b>
<b>TABLE 7</b> Primary and secondary outcomes expressed as RRs and RDs	<b>19</b>
<b>TABLE 8</b> Reported AEs of moderate or severe intensity in the trial groups	<b>21</b>
<b>TABLE 9</b> Serious adverse events	<b>25</b>
<b>TABLE 10</b> Effect of the intervention on potential mediators	<b>31</b>
<b>TABLE 11</b> Association of mediators with abstinence at 4 weeks and 6 months	<b>33</b>
<b>TABLE 12</b> Effect of preloading on smoking abstinence at 4 weeks and 6 months, controlling for potential mediators	<b>35</b>
<b>TABLE 13</b> Perceived helpfulness of the intervention in those randomised to preloading (of those contacted at +1 weeks)	<b>38</b>
<b>TABLE 14</b> Weighted average cost per prescription item for pharmacotherapies for smoking cessation	<b>40</b>
<b>TABLE 15</b> National average costs of health resource use	<b>41</b>
<b>TABLE 16</b> Breakdown of the trial intervention cost in both trial groups	<b>43</b>
<b>TABLE 17</b> Use of NHS Stop Smoking Services, including behavioural support and pharmacotherapies, by trial group	<b>44</b>
<b>TABLE 18</b> Usage and cost of smoking cessation help during the 6-month period prior to baseline and the 6-month and 12-month follow-ups, by trial group	<b>45</b>
<b>TABLE 19</b> Usage and cost of hospital-related services during the 6-month period prior to baseline and the 6-month and 12-month follow-ups, by trial group	<b>45</b>
<b>TABLE 20</b> Usage and cost of primary and community services during the 6-month period prior to baseline and the 6-month and 12-month follow-ups, by trial group	<b>46</b>

<b>TABLE 21</b> Proportion of participants on medication and mean cost of medication during the 4-week intervention period and months 1–6 and 7–12 post quit date, by trial group	<b>46</b>
<b>TABLE 22</b> Number and percentage of missing data for variables included in the multiple imputation (total number of sample $N = 1792$ )	<b>47</b>
<b>TABLE 23</b> Summary of results based on the imputed data set	<b>48</b>
<b>TABLE 24</b> Summary of results based on complete cases only	<b>51</b>
<b>TABLE 25</b> Comparison of mean health resource use costs between the base-case (imputed) data, complete cases and available cases	<b>51</b>
<b>TABLE 26</b> Cost-effectiveness results for the base-case analysis comparing the intervention group with the control group	<b>57</b>
<b>TABLE 27</b> Cost-effectiveness results comparing the intervention group with the control group after adjustment for varenicline imbalance	<b>57</b>
<b>TABLE 28</b> Results of the deterministic sensitivity analyses	<b>58</b>
<b>TABLE 29</b> Annual death rates (per 1000 population) by age and smoking status	<b>81</b>
<b>TABLE 30</b> Cancer prevalence in the UK: estimates for 2008	<b>81</b>
<b>TABLE 31</b> Chronic obstructive pulmonary disease prevalence in the UK	<b>81</b>
<b>TABLE 32</b> Coronary heart disease prevalence in the UK	<b>82</b>
<b>TABLE 33</b> Stroke prevalence in the UK	<b>82</b>
<b>TABLE 34</b> Prevalence of smoking in the UK	<b>82</b>
<b>TABLE 35</b> Relative risks of lung cancer, COPD, CHD and stroke in current and former smokers vs. non-smokers	<b>83</b>
<b>TABLE 36</b> Annual costs of treating smoking-related diseases	<b>84</b>
<b>TABLE 37</b> Inflation rates	<b>84</b>
<b>TABLE 38</b> Utility values	<b>84</b>

# List of figures

<b>FIGURE 1</b> Development of tobacco addiction	<b>2</b>
<b>FIGURE 2</b> The PRECIS-2 domains	<b>11</b>
<b>FIGURE 3</b> Consolidated Standards of Reporting Trials (CONSORT) flow diagram	<b>14</b>
<b>FIGURE 4</b> Prevalence and severity of symptoms experienced in the last 24 hours, reported after having been in the preloading group or control group for 1 week	<b>22</b>
<b>FIGURE 5</b> Effect of preloading compared with control on the primary outcome, depending on baseline tobacco dependence	<b>29</b>
<b>FIGURE 6</b> Cost-effectiveness plane of incremental costs and incremental abstinence rate at 6 months post quit date, comparing the preloading group with the control group	<b>49</b>
<b>FIGURE 7</b> Cost-effectiveness acceptability curve of the probability of preloading being cost-effective compared with the control group	<b>50</b>
<b>FIGURE 8</b> Model schematic	<b>54</b>
<b>FIGURE 9</b> Scatterplot of incremental costs vs. incremental QALYs for the intervention group vs. the control group	<b>58</b>
<b>FIGURE 10</b> Cost-effectiveness acceptability curve for the probability that the intervention is cost-effective with a relapse rate of 0% after year 1	<b>59</b>
<b>FIGURE 11</b> Cost-effectiveness acceptability curve for the probability that the intervention is cost-effective with a relapse rate of 30% after year 1	<b>59</b>



# List of boxes

**BOX 1** Assumptions in the EQUIPTMOD model

**56**



## List of abbreviations

AE	adverse event	MPSS-M	Mood and Physical Symptoms Scale – Mood
CEAC	cost-effectiveness acceptability curve	NICE	National Institute for Health and Care Excellence
CHD	coronary heart disease	NIHR	National Institute for Health Research
CI	confidence interval	NRT	nicotine replacement therapy
COPD	chronic obstructive pulmonary disease	OR	odds ratio
CRF	case report form	p.p.m.	parts per million
EQUIPT	European-study on Quantifying Utility of Investment in Protection from Tobacco	PRECIS-2	PRagmatic Explanatory Continuum Indicator Summary
FTCD	Fagerström Test for Cigarette Dependence	QALY	quality-adjusted life-year
GP	general practitioner	RD	risk difference
HRG	Healthcare Resource Groups	ROI	return on investment
HTA	Health Technology Assessment	RR	relative risk
ICER	incremental cost-effectiveness ratio	SAE	serious adverse event
ITT	intention to treat	SD	standard deviation
mCEQ	modified Cigarette Evaluation Questionnaire	SE	standard error
MPSS-C	Mood and Physical Symptoms Scale – Craving	UKCTAS	UK Centre for Tobacco and Alcohol Studies
		WTP	willingness to pay



## Plain English summary

**N**icotine preloading means using a nicotine patch before stopping smoking, while smoking normally. This may reduce a person's drive to smoke and weaken the addiction, thereby reducing cravings after stopping smoking and increasing the chance of stopping smoking successfully. As previous studies have reported conflicting outcomes, a new, bigger study was needed.

We decided by chance whether a person who wanted help to stop smoking should use a full-strength nicotine patch for 4 weeks or receive an extra preparation for their quit day. People then attended a NHS Stop Smoking Service and used medication and behavioural support to help them quit.

Altogether, 1792 people joined the study. On average, they were somewhat more deprived than the average English person and most of them smoked more than the average English person who smokes.

Of the people who used preloading, 18% stopped smoking for at least 6 months, compared with 15% of those who did not use it, a small difference that may be due to chance. More people who used preloading were prescribed nicotine to use after quit day, whereas more people who had not used preloading used varenicline (Champix®; Pfizer Inc., New York, NY, USA). Varenicline helps more people stop smoking than nicotine; taking account of this difference, preloading looks more effective, with a difference of 4 percentage points, and we can be more confident that this difference is not due to chance. Only about 6% of people stopped using preloading and it appeared to be safe and well tolerated.

Preloading slightly increased NHS costs in the first 6 months but reduced them in the longer term. Modelling predicted that preloading reduces the incidence of smoking-related illness and reduces overall health-service costs.

Our study also clarified that preloading works through reducing the drive to smoke; Stop Smoking advisors could monitor this in people who are using preloading and adjust the treatment according to the drive to smoke.



# Scientific summary

## Background

Nicotine preloading means using nicotine replacement therapy (NRT) prior to quitting smoking while continuing either to try to smoke the same amount or to smoke freely. It is quite distinct from the licensed indication for NRT, which is called 'cut down to quit', where people who feel that they cannot set a quit day reduce their cigarette consumption with the aid of NRT. With preloading, users are working towards a quit day and, in the past, have used NRT for 2–4 weeks prior to this quit day.

In a systematic review and meta-analysis in 2011, we compiled all of the previous studies of the effectiveness of preloading and also looked at what evidence was available showing how preloading was exerting an effect on people to increase the chance of abstinence. There were several possible mechanisms of action; knowing the mechanism of action is important, partly to help with future studies to maximise benefit and partly to allow therapists to monitor the effect of preloading in clinical practice and either modify the treatment dose or abandon preloading. This review found a relative risk (RR) of 1.05 [95% confidence interval (CI) of 0.92 to 1.19] for achieving short-term abstinence with preloading, with a high level of heterogeneity ( $I^2 = 69\%$ ;  $p = 0.002$ ). The effect on long-term abstinence was given by a RR of 1.16 (95% CI 0.97 to 1.38), with a lower level of heterogeneity ( $I^2 = 36\%$ ;  $p = 0.14$ ). However, patches may be more effective because using a patch while smoking can lead to higher blood concentrations of nicotine than smoking alone; this may reduce the drive to smoke more than other forms of NRT that do not result in higher nicotine levels. The patch studies did show stronger evidence that patch preloading was effective, with a RR of 1.26 (95% CI 1.03 to 1.55) for longer-term abstinence. There was some evidence that preloading reduced the positive feelings that people get from smoking and the urge to smoke but no study had carried out a full mediation analysis.

## Objectives

We, therefore, planned to carry out a trial to investigate the effectiveness of preloading, investigate its mechanisms of action and examine its cost-effectiveness.

## Methods

Four centres, Nottingham, Birmingham, Bristol and London, recruited participants to the trial. In three centres, general practitioners (GPs) in local practices spoke to, wrote to, e-mailed or texted patients listed as smokers on the electronic health record to inform them about the trial. GPs encouraged their patients who wished to quit smoking with the help of pharmacotherapy and behavioural support to enrol in the trial and interested people telephoned the trial team. The fourth centre was a NHS Stop Smoking Service and offered trial enrolment to people seeking help to quit or who responded to advertisements in the press. Participants were eligible for the trial if they were seeking help to stop smoking and showed signs of dependence on smoking, such as finding it difficult to stop smoking, smoking at least one cigarette per day, having a high level of exhaled carbon monoxide (CO) or smoking soon after waking. We excluded people who could not tolerate nicotine patch glue on their skin, were pregnant or breastfeeding, had had a stroke or myocardial infarction in the last 3 weeks or had uncontrolled hyperthyroidism or pheochromocytoma.

An independent statistician generated a randomisation list stratified by trial centre. Participants were randomised to either the preloading group or the control group by investigators using a database that concealed the next allocation until after enrolment. In the preloading group, participants used a

21 mg/24 hour nicotine patch for between 3 and 5 weeks prior to a planned quit day and received behavioural support at baseline and 1 week later to support adherence. Dose adjustments downwards in the event of adverse effects were allowed. To ensure commitment to the trial and the quit attempt, we provided equivalent-intensity behavioural support for the control group, designed to help them prepare for abstinence.

During preloading, we ensured that participants made an appointment with their local NHS Stop Smoking Service and set a quit date within the desired time window. Participants were free to use any medication to support their quit attempt. In the case of bupropion and varenicline (Champix®; Pfizer Inc., New York, NY, USA), normal use to support a quit attempt starts about 1 week before the quit date and, therefore, necessitates concurrent use with preloading. We knew from experience that this would deter NHS Stop Smoking advisors from prescribing these medications as National Institute for Health and Care Excellence guidance recommends not using these medications concurrently with preloading. We provided support for services and participants to try to prevent this from happening because varenicline is more effective than other medications and the trial results would be confounded if this effect occurred. NHS Stop Smoking Services provided behavioural support and medication as standard to participants in both arms.

The primary outcome was 6 months' prolonged abstinence assessed using the Russell Standard criteria. This allows a grace period of 2 weeks after quit day during which lapses do not count against abstinence and no more than five lapses thereafter, which are validated by measurement of exhaled CO levels. The secondary outcomes were 4-week and 12-month abstinence, both 7-day point prevalence abstinence, and Russell Standard abstinence.

We assessed adverse events (AEs) in the weeks between enrolment and 1 week after quit day. We collected information on serious adverse events (SAEs) (deaths or unplanned hospitalisations) and asked participants 1 week after treatment started and 1 week after treatment ended about AEs that they may have suffered; we reported on events of moderate severity or above (i.e. those that interfere to some extent with normal functioning). We also asked participants in both arms to complete a checklist of symptoms of excessive nicotine use 1 week after commencing treatment.

Based on the proportion of people achieving 6-month prolonged abstinence in previous UK-based trials, we determined that a trial of 1786 participants would have 90% power to detect a RR of 1.4, increasing the 6-month abstinence rate from 15% to 21%. We used binary logistic regression to examine the outcomes, with the addition of a term for centre to account for stratified randomisation. In a planned adjunct to the main analysis, we adjusted for two predictors of achieving abstinence and use of varenicline as post-cessation pharmacotherapy. We also examined whether or not the use of varenicline reduced the apparent effect of preloading, because its actions mimic those of nicotine preloading, and whether or not the relative effect of nicotine preloading would be greater in people with a higher level of dependence, as measured at baseline.

For the cost-effectiveness analysis, we used a NHS and personal and social care perspective. At baseline and 6 and 12 months, we assessed participants' use of health and social care services over the previous 6 months, including services to assist with smoking cessation. At these assessments, we also recorded participants' use of prescribed medication. At the follow-ups to 1 week past quit day, we assessed participants' use of nicotine preloading and their use of other pharmacotherapy to try to stop smoking. We costed these using standard sources for health services or the Prescription Cost Analysis database. For the analysis, we imputed missing data using the multiple imputation technique. We calculated incremental cost-effectiveness ratios (ICERs) relative to the control group for achieving 6- and 12-month abstinence, using bootstrapping to examine uncertainties.

We modelled the long-term effectiveness of preloading using the EQUIPTMOD model. This examines the likelihood that the cohort of people enrolled will develop the major smoking-related illnesses, given that participants either stop smoking or continue smoking and taking account of the natural quit rate. The

model includes data on the quality-adjusted life-years (QALYs) that accrue from these illnesses and the costs of treating them. We used this to determine the total health service spend and the total number of QALYs accruing as a result of the intervention relative to the control condition.

For the mediation analysis, we collected data 1 week after baseline (1 week after starting preloading) on the positive and negative rewards from smoking, urges to smoke, smoke inhalation (exhaled CO concentration), addiction score and cigarette consumption. Using the Baron and Kenny method, we examined the effect of preloading on change in the mediator variable. We also examined the association between the mediators and the outcome of abstinence. Finally, we examined the effect of treatment status on smoking abstinence while controlling for potential mediators. Although the primary hypothesis of this analysis related to features of tobacco dependence, we tested three other competing hypotheses: (1) that the effect was the result of increased confidence in the ability to quit, (2) that the effect was the result of improving adherence to cessation medication and (3) that the effect occurred because preloading produced an aversive smoking experience.

## Results

Between 13 August 2012 and 10 March 2015, 1792 participants were enrolled in the study. AEs were recorded 1 week after baseline and 5 weeks later; 1702 (95.0%) and 1456 (81.3%) participants provided data at these assessments respectively. We obtained data on 1585 (88.4%) participants at 4 weeks, 1461 (81.5%) at 6 months and 1389 (77.5%) at 12 months. The proportion successfully followed up was similar in each group. For abstinence outcomes, we imputed, following the Russell Standard procedure, that people who were not followed up were smoking, but we knew from the earlier follow-up that 151 people who were not followed up at 6 months (primary outcome) were already smoking. Thus, altogether, we were certain of the primary outcome in 1612 (90.0%) participants.

The mean [standard deviation (SD)] age of participants was 48.9 (13.4) years. Men constituted 52.6% of the population and 75.6% identified as white British. The proportion of participants with advanced levels of education was lower than the UK average. Fifty-two per cent were in employment. Participants smoked a mean of 18.9 (SD 9.3) cigarettes per day at baseline and had a mean nicotine dependence score that indicated a moderate level of addiction. One-third (32.5%) of participants had used behavioural support or pharmacotherapy to try to quit in the past 6 months. The baseline characteristics were well balanced between the trial arms.

One week after baseline, nearly three-quarters of participants in the active group reported using the patch daily, whereas > 80% reported using the patch daily in the subsequent 3 weeks of preloading. During preloading, 49 (5.5%) people discontinued preloading prematurely.

The primary outcome, biochemically validated 6-month abstinence, was achieved by 157 (17.5%) participants in the intervention group and 129 (14.5%) participants in the control group, a difference of 3.0 percentage points (95% CI -0.4 to 6.4 percentage points). The odds ratio (OR) was 1.25 (95% CI 0.97 to 1.62;  $p = 0.081$ ). After adjustment for use of post-cessation varenicline, the OR was 1.34 (95% CI 1.03 to 1.73;  $p = 0.028$ ).

The secondary outcomes showed similar modest differences. At 4 weeks, 319 (35.5%) participants in the intervention group achieved 7-day point prevalence abstinence, whereas 288 (32.3%) participants in the control group did so. At 12 months, 126 (14.0%) participants in the intervention group achieved validated prolonged abstinence, whereas 101 (11.3%) participants in the control group achieved validated prolonged abstinence. The ORs were similar, showing no significant difference in the primary analysis but, again, adjustment for use of varenicline revealed a statistically significant benefit of preloading. There was no evidence that the benefit of preloading depended on whether or not varenicline had been used to assist cessation or on how dependent on smoking participants were at baseline.

Adverse events were uncommon in both groups. Around 4% of participants suffered AEs that are well established in people who use a patch after cessation (sleep disturbance and headaches) and an additional 4% experienced nausea, which most people using the patch after smoking cessation do not experience. The checklist of symptoms of nicotine toxicity revealed a similar pattern of a small excess of AEs in the preloading group: 5.6% and 3.0% were somewhat or very dizzy in the intervention and control groups, respectively, 3.9% and 1.9%, respectively, had palpitations and 8.1% and 3.1%, respectively, experienced nausea.

There were nine unexpected hospitalisations or deaths (SAEs) in the intervention group and eight in the control group during the 5-week observation period, giving an OR of 1.12 (95% CI 0.42 to 3.03). Of these, one was judged to be potentially the result of preloading: an acute coronary syndrome suffered by a 64-year old woman.

In total, the intervention cost amounted to £59 per participant in the intervention group and £11 per participant in the control group. At 6 months, the adjusted difference in overall cost was £22 (95% CI –£160 to £259). The ICER was £710 (95% CI –£13,674 to £23,205) per additional person achieving 6-month prolonged abstinence. At 12 months, preloading showed lower overall costs and improved abstinence, leading to a dominance over the control group, but with a wide degree of uncertainty (95 % CI –£135,032 to £7125).

Over the long term, participants' total discounted health-service spend in the preloading group was projected to be £13,111 compared with £13,177 in the control group. This would accrue 17.977 discounted life-years and 14.300 QALYs in the preloading group compared with 17.957 life-years and 14.267 QALYs in the control group. Thus, preloading was dominant, improving long-term health while reducing overall health-service spend. Changing the relapse rate and reducing the discount rate did not change the results and probabilistic sensitivity analysis revealed an 80% chance of dominance and a 93% chance of cost-effectiveness at a willingness-to-pay threshold of £20,000 per QALY.

Although there was evidence that many possible mediators were influenced by preloading, only three potential mediators were associated with abstinence: (1) noticing a reduction in urges to smoke before quitting, (2) a reduced CO level before quitting, which is a marker of a reduced rate of smoking and (3) a reduced intensity of urges after cessation. Together, in an analysis adjusted for the effect of varenicline, these changes explained 78% of the effect of preloading on 6-month abstinence. There was no evidence that the effect of preloading was mediated through increased confidence, improved medication adherence or an aversion to smoking.

## Conclusions

There is evidence that nicotine preloading is modestly effective at increasing long-term smoking abstinence, but its impact in the current NHS is limited. This is because using nicotine preloading reduces the use of varenicline, which is the most effective smoking cessation pharmacotherapy. Preloading appears to be safe and it is well tolerated, with only 1 in 20 or fewer people experiencing AEs because of it. Preloading appears to have a similar cost per quitter as the control intervention and, as such, is likely to be cost neutral. In the long term, it improves health and is likely to be cost saving.

The main mechanism of action of preloading appears to be that it reduces the intensity of urges to smoke and this leads to reduced consumption, undermining the learnt drive to smoke. After quit day, this reduced drive means that the intensity of cravings for cigarettes is reduced and, hence, the chance of abstinence is increased. The pre-quit changes could allow treating clinicians to monitor the effectiveness of preloading and adjust treatment to improve outcomes or abort preloading prematurely if it is proving unhelpful.

Further research needs to identify if changes to guidelines and advice to patients can change the choice of post-quit medication. Varenicline preloading looks likely to be equally or more effective than NRT and clinical trials to examine this would be helpful.

## Trial registration

This trial is registered as ISRCTN33031001.

## Funding

Funding for this study was provided by the Health Technology Assessment programme of the National Institute for Health Research.



# Chapter 1 Introduction

## Smoking cessation and cessation medication

Most people who try to stop smoking fail within the first few weeks of the attempt.<sup>1</sup> This is because they experience urges to smoke that drive them to return to smoking. The aim of smoking cessation treatment, which typically starts just before or on the quit day, is to reduce the intensity of urges so that more people can overcome the difficult first few weeks.<sup>2,3</sup> Over time, the urges to smoke reduce in frequency and intensity and treatment can stop.<sup>4</sup>

There are three medications for smoking cessation that are licensed widely around the world: (1) nicotine replacement therapy (NRT), (2) bupropion and (3) varenicline (Champix®; Pfizer Inc., New York, NY, USA). All three have strong evidence of effectiveness and are safe, although bupropion has rather more contraindications to its use and results in more severe adverse effects than the other two medications.<sup>5</sup> In the UK, bupropion fell out of favour because of unjustified concerns about its safety and is now rarely used. Thus, when people who smoke use medication to assist them, they typically use either varenicline or NRT.

Conventionally, people stopping smoking commence NRT on quit day. However, people stopping smoking with the aid of either bupropion or varenicline begin to take the medication about 1 week prior to quit day. This allows the dose to be escalated in order to reduce the number of adverse events (AEs) that can occur with rapid escalation of the dose of either medication. Thus, the original aim of this period serves simply to ensure that people are comfortable and are taking the full dose of the medication by the time of quit day.

The most effective medication for supporting smoking cessation is varenicline.<sup>6</sup> One trial<sup>7</sup> examined the mechanisms of action of smoking cessation medications, comparing varenicline, bupropion and placebo. Varenicline reduced the intensity of urges and reduced the satisfaction obtained from a lapse (temporary smoking episode during a quit attempt) to a greater extent than bupropion. Most other mood symptoms occurred with a similar intensity. This suggests that reducing urge intensity and reducing satisfaction with smoking are key mechanisms of action. Varenicline is usually started 1 week before quit day and it could be that its use prior to quit day undermines the rewarding value of cigarettes and underlies its greater effectiveness. This raises the possibility that NRT, which is usually started on the quit day, may be effective if used in this way, as it too reduces satisfaction from smoking when used concurrently with cigarettes.<sup>8</sup> Using nicotine in this way is termed 'nicotine preloading'. The reason that this may help achieve smoking cessation is because nicotine from NRT desensitises the nicotinic receptors and blocks the effects of further nicotine from cigarettes. This, in turn, undermines the learnt association between smoking and brain reward, making extinction of the reinforced behaviour more likely.<sup>9</sup>

## Nicotine preloading effectiveness

Two previous reviews<sup>10,11</sup> have examined the effectiveness of nicotine preloading and provided evidence that it approximately doubles the chance of achieving abstinence. However, our own review<sup>12</sup> showed no strong evidence that preloading was effective, principally because some larger trials showing no benefit had been published since the earlier reviews were conducted. The relative risk (RR) for short-term abstinence was 1.05 [95% confidence interval (CI) 0.92 to 1.19;  $p = 0.49$ ], with a high level of heterogeneity ( $I^2 = 69%$ ;  $p = 0.002$ ). The RR for long-term abstinence was 1.16 (95% CI 0.97 to 1.38), with a lower level of heterogeneity ( $I^2 = 36%$ ;  $p = 0.14$ ). The principal aim of this review was to pool all forms of NRT, although we hypothesised that nicotine patches may be more effective in the context of preloading. There is a plausible reason why patches may be more effective for preloading than other forms of NRT. Smoking

while using a short-acting NRT tends not to raise the concentration of nicotine in the blood, whereas smoking and using a patch does.<sup>8</sup> It may be this higher concentration of nicotine that undermines the reward from cigarettes. Indeed, there was some evidence of this, with patches having a RR of 1.26 (95% CI 1.03 to 1.55) for longer-term abstinence.


## Mechanisms of action of preloading

We can understand the potential mechanism of preloading by understanding the development of tobacco addiction (*Figure 1*).

Tobacco smoking creates a positive reward, such as feelings of pleasure, which leads to the reinforcement of subsequent smoking. After a period of regular smoking, neuroadaptation to regular doses of nicotine means that people who smoke experience negative moods when nicotine concentrations in the brain drop; these feelings are relieved by smoking and, thus, smoking is negatively reinforced. Independently of any reward that people may experience, mechanisms in the nucleus accumbens set up associative learning that results in the drive to smoke. These mechanisms create an acquired drive to smoke and tobacco dependence, manifested by the regular consumption of cigarettes, the occurrence of tobacco withdrawal symptoms when unable to smoke and difficulty in stopping smoking if a person were to choose to do so.

Preloading may reduce the drive to smoke and both positive and negative reinforcement. By keeping the concentration of nicotine in the blood high, the nicotine patch can mitigate the need for nicotine and also reduce the impact of further exogenous nicotine from cigarettes, thus reducing the positive reinforcement of smoking. Likewise, if the need for nicotine is low, this may lower any impact of smoking on reducing withdrawal discomfort (negative reinforcement). All three actions, especially the reduced drive to smoke, would reduce smoke intake during the pre-quit period. The net effect of the changes in the drive to smoke mean that a person will not smoke when he or she normally would, usually when cued by the environment to do so. Not smoking when cued to smoke will begin to extinguish the learnt association between the action of smoking a cigarette and reinforcement in the brain. Alternatively, smoking when cued to smoke but receiving no reinforcement from the nicotine may also undermine the drive to smoke by weakening the association. Consequently, after cessation, urges to smoke should be lower and this makes cessation more likely to be successful.<sup>13</sup>

Aside from this addiction-based mechanism, three other mediational hypotheses have been advanced for the mechanism of action of preloading. The first relates to medication adherence, which some evidence suggests is poor in smoking cessation.<sup>14</sup> The hypothesis here is that preloading enables the person to become used to using medication at a time when failure to use it does not undermine the success of the quit attempt. After quit day, when failure to use medication does undermine abstinence,<sup>15</sup> adherence will be superior in people using preloading than in people who did not use preloading.



**FIGURE 1** Development of tobacco addiction.

The second hypothesis is that the reduced level of smoking that occurs when people preload increases a person's confidence that they can abstain from smoking after quit day; the confidence that one can achieve abstinence is associated with achieving abstinence.<sup>16</sup>

A third hypothesis was developed from a recent trial<sup>17</sup> in which participants were interviewed about their experiences using preloading. A large proportion reported feeling nauseous and having an aversion to cigarettes during preloading. Aversive smoking is a process in which people smoke excessively to the point of nausea and vomiting. Although it is rarely used as a treatment to enhance cessation, it is effective at increasing the rate of cessation.<sup>18</sup> It is, therefore, plausible that nausea and aversion to smoking mediate the effect of preloading, and we tested this in the Preloading trial.

In our review,<sup>12</sup> we examined the putative mechanisms of action of preloading to find evidence to support or refute these possibilities. We examined the effects on both positive and negative reward, urge intensity and markers of consumption and addiction. There was scanty and mixed evidence on whether or not preloading reduced the positive reward from smoking. There was more evidence that preloading did not reduce the negative rewarding effects of smoking, that is, preloading did not appear to remove the ability of smoking to relieve tobacco withdrawal symptoms. Overall, four studies examined the effect on pre-quit urge intensity and two showed evidence of a modest reduction. There was clear evidence that preloading reduced cigarette consumption without instruction to do so. The mechanism of reduced intensity of urges suggests that we might expect reduced tobacco withdrawal symptoms after quit day, but there was reasonable evidence that this does not occur.

## Cost-effectiveness

Interventions are approved by the National Institute for Health and Care Excellence (NICE) for use in the NHS only if they are cost-effective, defined as achieving a cost per quality-adjusted life-year (QALY) of < £20,000. Interventions for smoking cessation are typically highly cost-effective. This is because smoking is particularly harmful to health and cessation is remarkably effective at ameliorating the effects of many years of smoking.<sup>19</sup> In fact, West<sup>20</sup> calculates that increments of as little as 1% in 6-month prolonged abstinence rates are highly likely to be cost-effective according to the NICE standard.

Arguably, the most reasonable way to plan a trial is to define a limit at which the intervention is cost-effective enough to change the decision on an intervention from non-use to use. In this case, the question would be: what increment in 6-month prolonged abstinence would produce a cost per QALY of < £20,000? The answer, argued by West,<sup>20</sup> is around a 1% increment. The problem with using this to calculate a trial sample size is that it is impractically small. Any trial that would detect an effect of this size would be one or two orders of magnitude larger than most 'large' smoking cessation trials today. Such a trial would never be funded and would not be able to recruit to target. Therefore, cost-effectiveness, although providing a logical rationale for calculating a sample size, is not useful in this regard.

One compelling rationale for the cost-effectiveness analysis in this trial is the political realities of the health economy today. The NHS is under severe financial pressure. Preloading will inevitably cost more than the comparator, usual care, which, at this point in a quit attempt, provides no intervention. In the current NHS, additional investment in a treatment such as smoking cessation therapy is likely to be made only if the intervention is cost saving. As there are no data on the cost-effectiveness from previous trials of preloading, we set out to assess the cost-effectiveness of preloading in this trial.

## Aims of the trial

It is clear, therefore, that an adequately powered trial of nicotine preloading is required to address the uncertainty about the effectiveness and cost-effectiveness of treatment and could usefully explore potential

mechanisms of action, which could be practically as well as theoretically useful. A trial of varenicline preloading showed that people who spontaneously suppressed their smoking in response to varenicline were much more likely to achieve abstinence than those who did not.<sup>21</sup> Other trials have reported similar associations with NRT.<sup>21-24</sup> In clinical use, therefore, one could suggest stopping preloading in those who do not suppress their smoking and bringing forward the quit day. However, subsequent planned replication found evidence that the effect was much less strongly predictive of the ability to quit smoking during nicotine preloading.<sup>25</sup> We, therefore, planned to examine the effectiveness of preloading in a trial powered to detect modest effects on long-term abstinence and investigate potential mediators that could allow therapists to judge whether to continue or abandon preloading. The objectives were to:

- examine the relative efficacy of a nicotine patch worn for 4 weeks prior to quitting plus standard NHS care post quit compared with standard NHS care only in smokers undergoing NHS treatment for tobacco dependence (addressed in *Chapter 3*)
- examine the adverse effects and safety of nicotine preloading (addressed in *Chapter 3*)
- examine the incremental cost-effectiveness of nicotine preloading (addressed in *Chapters 6 and 7*)
- examine possible mediating pathways between nicotine preloading and outcomes (addressed in *Chapter 4*)
- examine moderators of the effects of preloading, including the use of varenicline and baseline levels of dependence (addressed in this chapter and in *Chapter 4*)
- investigate opinions of the preloading intervention (addressed in *Chapter 5*)
- assess adherence to preloading treatment and subsequent standard smoking cessation pharmacotherapy (addressed in *Chapter 3*).

## Chapter 2 Methods

### Design

This was an open-label, multicentre, pragmatic superiority trial in which participants were randomised 1 : 1 to non-use or use of a nicotine patch for 4 weeks prior to quit day. Participants used standard pharmacotherapy and behavioural support for stopping smoking thereafter. The primary outcome was prolonged biochemically validated abstinence, measured 6 months after quitting. The protocol was published<sup>26</sup> and implemented with one change, which related to participants who had moved from the area during follow-up and were not available to attend in person for carbon monoxide (CO) measurement to confirm abstinence. We, therefore, asked such participants to provide a saliva sample and measured cotinine or anabasine concentrations to confirm abstinence from smoking. Anabasine is a tobacco-specific alkaloid that will indicate smoking abstinence in a person who is using NRT or e-cigarettes. Cotinine is a metabolite of nicotine with a much longer half-life, making it a good indicator of nicotine consumption within the last week, and will be in low concentrations in people who do not smoke or use nicotine.

In the original proposal to the National Institute for Health Research (NIHR), we did not suggest collecting genetic samples or assessing the impact of quitting on weight gain. However, these additional non-trial-related hypotheses were added to the published protocol.<sup>26</sup> In the event, it turned out to be impractical to collect genetic samples and this ambition was abandoned. The observational analyses of the impact of quitting and failed quit attempts on weight gain will be reported separately.

### Participants and settings

In three recruitment centres, Birmingham, Bristol and Nottingham, general practitioners (GPs) spoke to, wrote to, e-mailed or texted patients listed as smokers on the electronic health record. GPs encouraged their patients who wished to quit smoking with the help of pharmacotherapy and behavioural support to enrol in the trial. The final centre, London, was an existing NHS smoking cessation clinic, which asked participants seeking treatment if they would also like to take part in the trial. Thus, in all centres, patients were recruited from those who sought treatment at their own instigation, by referral from their GP or by advertising in various online and print media.

Potential participants telephoned the research team to learn more about the trial and were screened for eligibility and entered into our online trial database. If a potential participant appeared to be eligible and wanted to participate, we made an appointment and sent out the participant information sheet. At this initial appointment, we again described the trial and obtained witnessed consent with a signature and confirmed eligibility. The researcher, typically a research nurse, saw participants at their own general practice or at the London centre. We included people who were:

- regular smokers of cigarettes, cigars and/or roll-up tobacco cigarettes, with or without marijuana, aged  $\geq 18$  years
- suitable for preloading in the judgement of the researcher (see below)
- seeking support to stop smoking from the NHS Stop Smoking Service
- willing to set a quit day in 4 weeks
- able to understand and willing to adhere to study procedures.

We excluded:

- pregnant or breastfeeding women
- people with extensive dermatitis or another skin disorder that precluded patch use
- people who had acute coronary syndrome or who had had a stroke in the past 3 weeks
- people with an active pheochromocytoma or uncontrolled hyperthyroidism that would increase the risk of arrhythmias from the nicotine patch.

We judged if people would be suitable for preloading by assessing whether or not they were addicted to smoking. This was based on a clinical judgement of the following factors, with no specific cut-off points used:

- time to first cigarette in the morning, with earlier use reflecting a higher level of addiction
- number of cigarettes smoked per day, with a greater number reflecting a higher level of addiction
- higher levels of exhaled CO, which reflect a higher level of addiction
- failure of previous quit attempts despite use of appropriate pharmacotherapy.

## Interventions

### *Intervention group*

In the intervention group, participants wore a 21-mg nicotine patch daily for an intended 4 weeks prior to quit day. The intention was that this would be worn for 24 hours per day. However, any participants who had experienced previous AEs at night from 24-hour patch use were advised to wear the patch during waking hours only.

We asked participants to smoke as normal and not reduce nicotine consumption. Reducing consumption would probably lower the nicotine concentration in the blood, which could have resulted in cigarettes being more rewarding and, thus, have undermined the supposed benefits of preloading.<sup>27</sup>

We referred patients to the NHS Stop Smoking Service to set a quit day, obtain behavioural support and receive a prescription of pharmacotherapy to support cessation. Although we aimed for this quit day to be 4 weeks from the start of preloading, in keeping with the pragmatic design, we asked participants and NHS clinics to set this date within a window from 3 to 5 weeks after starting preloading. Preloading was allowed to continue for up to 8 weeks in exceptional circumstances. Preloading was also allowed to restart once, if necessary, for example if this was interrupted because a participant was admitted to hospital. In such cases, participants aimed to complete 3–5 weeks of preloading from the date of recommencement. We dispensed NRT in two lots, one of 2 weeks and a second, 1 week later, of 3 weeks. We made arrangements to dispense additional lots of NRT if preloading was extended.

The researchers explained the rationale of preloading and prompted action planning to maximise adherence to the patches, that is, they talked through participants' daily routine and assisted them to use it and environmental cues to minimise the chance of forgetting to use the patches. They provided reassurance about concerns that participants may have about side effects and how to manage them. A booklet containing this information was supplied to participants. We aimed to see participants 1 week after commencing preloading. At this visit, we asked participants about their experiences and their understanding of the necessity of preloading and again addressed these beliefs as well as concerns about preloading.

We offered participants lower-strength patches from the beginning if they reported experiencing adverse reactions to the 21-mg patch or if, during the treatment course, they experienced symptoms of nicotine overdose such as nausea, salivation and/or pounding heartbeat or other symptoms that they believed were due to the patch strength. We stopped preloading if a participant requested it, if it was not possible to alleviate AEs by reducing the dose or if an intervening health state or contraindication to preloading emerged.

### Control group

The research team were keen to offer participants in the control group a placebo, but the NIHR Health Technology Assessment (HTA) Board would not allow this. We were concerned that offering no treatment would lead to disengagement and, to counteract this, we developed a behavioural intervention that could seem plausible to participants but had no evidence that it would increase abstinence. We asked participants to consider their smoking pattern and the triggers for particular cigarettes (e.g. the first cigarette of the day, the first after dinner) and to plan ways to reduce these cues. Such a process is standard in smoking cessation support, so participants in the intervention group were likely to engage in this after preloading and in preparation for quitting. The control group received a booklet outlining this process, which was designed to be comparable to the booklet supplied to the intervention group. As in the intervention group, participants in the control group were referred to the NHS Stop Smoking Service to commence a quit attempt between 3 and 5 weeks after enrolment.

### Standard smoking cessation treatment common to both arms

In both arms, at the first and second contacts, we facilitated contact between participants and the local NHS Stop Smoking Service and wrote a referral letter to encourage the NHS Stop Smoking Service to work with us on encouraging participants to continue preloading. In particular, we asked the NHS Stop Smoking Service advisors to ignore the presence or absence of preloading when discussing and recommending the use of pharmacotherapy to support the quit attempt. We especially asked advisors to feel free to use varenicline, which starts prior to quit day and, hence, would be used concurrently with nicotine preloading. This is because we were keen that the treatment provided by the NHS Stop Smoking Services did not differ between trial arms. NICE guidance has specifically recommended against this combination of NRT and varenicline,<sup>28</sup> which advisors wrongly assumed was because of safety concerns about concurrent use. We therefore addressed this in the referral letter, by telephone and in face-to-face discussions with the NHS Stop Smoking Service.

The NHS trains Stop Smoking Service advisors to give weekly behavioural support starting 1–2 weeks prior to quit day and continuing until at least 4 weeks after quit day. This support addresses issues such as planning for the quit day, the 'not a puff' rule and how to deal with difficult situations, such as others smoking around the person who has quit. It also provides monitoring of behaviour and validation of abstinence through CO testing. The support is largely withdrawal-orientated therapy.<sup>29</sup>

Our protocol<sup>26</sup> allowed all other medication to be used concurrently with preloading.

### Outcomes

We followed up participants on five occasions for outcome assessment. These were named in relation to quit day and are shown in *Table 1*.

The first follow-up appointment was a face-to-face appointment, when possible, and occurred 1 week after baseline and 3 weeks before quit day. One week after quit day we telephoned participants to collect data on AEs, adherence to preloading and use of, and adherence to, other smoking cessation pharmacotherapy. We obtained data on smoking cessation from the NHS Stop Smoking Service at 4 weeks or, failing this, from a telephone call to the participant. At 6 and 12 months, we telephoned participants to obtain data on smoking status and health service use. We invited participants who claimed to be abstinent for at least 1 week to a meeting where we asked them to provide an exhaled CO concentration reading. Participants were compensated £15 for their time for attending this meeting. Therefore, if they attended a meeting at both 6 and 12 months' follow-up, participants were compensated a total of £30.

**TABLE 1** Schedule of contacts with participants

Visit name	Timing in relation to baseline	Main purpose
-3 weeks	1 week after baseline	AE assessment
		Data on mediators
		Data on adherence
+1 week	≈5 weeks after baseline	AE assessment
		Data on mediators
		Data on adherence
+4 weeks	≈9 weeks after baseline	Data from NHS Stop Smoking Service on abstinence
+6 months	≈7 months after baseline	Abstinence
+12 months	≈13 months after baseline	Abstinence

### Primary outcome

The primary outcome was 6-month prolonged abstinence, defined according to the Russell Standard criteria.<sup>30</sup> This allows a grace period of 2 weeks following quit day when lapses do not count against abstinence. Thereafter, we counted a person as abstinent if they smoked fewer than five cigarettes or cigars up to the 6-month assessment and were biochemically confirmed abstinent by an exhaled CO concentration of < 10 parts per million (p.p.m.).

### Secondary outcomes

The secondary outcomes were 12-month Russell Standard abstinence and biochemically confirmed 7-day point prevalence abstinence at 4 weeks, 6 months and 12 months.

### Adverse events

We defined AEs as those that occurred after baseline and until 1 week after quit day, thereby covering the period of preloading and an additional week for AEs to emerge. This excluded planned events, such as scheduled surgery. In the protocol,<sup>26</sup> we deemed that we would report only AEs of moderate severity or above, that is, those events that hindered or prevented the person going about their normal activities. This is because these events matter more to patients and because NRT has been used for many years and so many common minor AEs are known already.

We assessed the AEs arising from preloading in two ways. First, we elicited AEs from participants in both arms at the contacts at -3 weeks (1 week after baseline) and +1 week (5 weeks after baseline and 1 week after quit day). Spontaneously occurring AEs were coded at the level of preferred term and system organ class using the MedDRA (Medical Dictionary for Regulatory Activities) coding system.<sup>31</sup> However, spontaneously occurring reports may introduce bias. It seemed illogical to participants in the control group and to treating staff to discuss AEs when the participant was taking no medication at all. Therefore, second, at 1 week after baseline we also gave all participants a questionnaire concerning symptoms of nicotine overdose in the previous 24 hours (such as nausea and excessive salivation).

We defined serious adverse events (SAEs) as those leading to hospitalisation, death, permanent disability or congenital abnormality and reported these separately. We obtained the medical history of participants experiencing SAEs and these were classified by an independent assessment panel blinded to allocation as unrelated or unlikely to be, possibly, probably or definitely related to the use of nicotine patches.

## Sample size

We determined the sample size from plausible estimates of 6-month abstinence. We estimated that 15% of participants in the control group would attain 6-month abstinence based on data from similar trials.<sup>17,32,33</sup> We felt that a RR of 1.4 was plausible based on our meta-analysis<sup>12</sup> and would make preloading valuable to NHS Stop Smoking Service commissioners.<sup>12</sup> This gave us a sample size of 893 per group, or 1786 in total, to achieve 90% power (Table 2).

## Randomisation

The research team randomised participants at the baseline visit following consent, assessment of eligibility and enrolment. An independent statistician used Stata® 14.2 (StataCorp LP, College Station, TX, USA) to generate a randomisation list, stratified by treatment centre and using randomly permuted blocks of varying sizes, using a 1 : 1 ratio. This sequence was incorporated into an online database and the sequence remained concealed from all research staff.

**TABLE 2** Sample size required for 80% and 90% power for different combinations of control and intervention group prolonged abstinence rates<sup>a</sup>

Prolonged abstinence in control group, %	Prolonged abstinence in intervention group, %	Trial with 80% power, number per group	Trial with 90% power, number per group
<b>RR = 1.3</b>			
14	18.2	1249	1655
15	19.5	1150	1524
16	20.8	1064	1409
20	26.0	805	1065
<b>RR = 1.4</b>			
14	19.6	734	970
15	21.0	676	893
16	22.4	625	825
20	28.0	471	622
<b>RR = 1.5</b>			
14	21.0	490	646
15	22.5	451	594
16	24.0	416	549
20	30.0	313	412

<sup>a</sup> Calculated with Yates correction using nQuery Advisor (Statistical Solutions, Saugus, MA, USA).

### Notes

Shaded row indicates the figures used to set sample size.

Reproduced from Lindson-Hawley *et al.*<sup>26</sup> This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The text includes minor additions and formatting changes to the original text.

## Blinding

This was an open-label trial so participants, research staff and NHS Stop Smoking Service personnel knew to which group participants were assigned. Blinded follow-up was impossible as all staff had been involved in recruitment.

## Statistical analysis


The analysis of all cessation outcomes was performed using the intention-to-treat (ITT) principle as outlined in the Russell Standard.<sup>30</sup> Thus, everyone was included in the denominator and presumed to be smoking if this information remained unknown. This presumption was shown to be true in one trial that went to extraordinary lengths to establish the true status of those who did not respond to standard follow-up.<sup>30</sup> For the primary analysis, we calculated adjusted odds ratios (ORs) using multivariable logistic regression in Stata 14.2. We also calculated the percentage achieving abstinence, the risk difference (RD), RRs and 95% CIs using the post-estimation *adjrr* procedure in Stata 14.2. As the randomisation was stratified by centre, we adjusted for this covariate in the analysis and this was considered the primary analysis. In sensitivity analyses, we adjusted for two well-known predictors of abstinence to improve precision: the longest previous abstinence and the degree of addiction measured by the strength of urges to smoke at baseline.<sup>34–36</sup> Finally, because we envisaged that the use of NRT would deter NHS Stop Smoking advisors from prescribing varenicline, which is more effective than other pharmacotherapy,<sup>6</sup> we also adjusted for varenicline use.

We had pre-planned subgroup analyses that were assessed by including multiplicative interaction terms in the calculations described in the previous paragraph. The presumed mechanism of action of preloading suggests that preloading could be more effective in people who are more addicted to nicotine. This was assessed by investigating whether or not outcomes varied with baseline Fagerström Test for Cigarette Dependence (FTCD) score or exhaled CO concentration readings and is reported in *Chapter 3*. In another analysis, we examined whether or not the effect of preloading was less pronounced in people who used varenicline in the pre-quit period. This is because varenicline includes a period of use of at least 1 week prior to quit day and this appears to have similar effects to preloading.<sup>21</sup>

The population in whom we analysed the occurrence of AEs was all those who provided data on such events. The analysis of spontaneously elicited AEs was confined to events of moderate severity and above. We anticipated that most minor AEs would relate to well-established adverse reactions to nicotine patches; confining the analysis to AEs of moderate severity and above may identify novel adverse reactions to preloading specifically that were of more concern to patients. The analysis used analogous statistical models to those applied for the primary and secondary outcomes.

## Design features classified by PRECIS-2

Trials vary on an explanatory to pragmatic continuum; this can be assessed and represented by a tool called PRECIS-2 (PRagmatic EXplanatory Continuum Indicator Summary).<sup>37</sup> The aim of this trial was to examine the effectiveness of preloading in everyday clinical practice. In the UK, this was in the context of the NHS Stop Smoking Service. However, the aim was also to examine AEs and safety, which meant that these were assessed by researchers trained to assess these outcomes appropriately. Furthermore, NHS Stop Smoking Services do not routinely follow up people who try to stop smoking beyond 4 weeks, which meant that we instituted special follow-up measures to assess smoking abstinence. It was because of these aims that the trial design scored less than the maximum for pragmatic design features on the PRECIS-2 wheel (*Figure 2*).



**FIGURE 2** The PRECIS-2 domains. Created using <http://precis-2.org>.<sup>38</sup>



## Chapter 3 Results of the trial

### Participant flow

Between 13 August 2012 and 10 March 2015, 3837 people telephoned about enrolment. Of these, 1805 (47.0%) attended the initial appointment and 1792 (99.3%) of those were eligible and were enrolled in the study. Overall, 490 (12.8%) people who had telephoned were ineligible; the most common reasons for ineligibility were skin problems and an objection to using preloading patches (*Figure 3*).

One week after baseline, we followed up 1702 (95.0%) participants; and 5 weeks after baseline, 1 week after quit day, we obtained data from 1456 (81.3%) participants. These assessments provided data on AEs.

In total, 312 (17.4%) participants never made a quit attempt, 157 (17.5%) in the intervention group and 155 (17.4%) in the control group. We obtained data on 1585 (88.5%) participants at 4 weeks, 1461 (81.5%) at 6 months and 1389 (77.5%) at 12 months after quit day. The proportion successfully followed was similar in each group. Although 331 (18.5%) participants did not provide data at 6 months, we knew that 97 of these participants were smoking at 4 weeks post quit day and could not, therefore, be classified as abstinent at 6 months and that 54 of these participants never made a quit attempt and likewise could not be classified as abstinent at 6 months. Thus, altogether, we were certain of the primary outcome in 1612 (90.0%) participants.


### Baseline characteristics

The baseline characteristics were well balanced between the trial arms (*Table 3*). The mean age of participants was 48.9 [standard deviation (SD) 13.4] years. Men constituted 52.6% of the participants and 75.6% identified as white British. The proportion of participants with an advanced level of education was lower than the UK average.<sup>40</sup> Fifty-two per cent were in employment. Participants smoked a mean of 18.9 (SD 9.3) cigarettes per day at baseline, had a mean nicotine dependence score of 5.2 (SD 2.2), indicating moderate addiction, and a mean exhaled CO concentration of 23.7 (SD 12.5) p.p.m. One-third (32.5%) had used behavioural support or pharmacotherapy to try to quit in the previous 6 months.

### Medication adherence

One week after baseline, nearly three-quarters of participants in the active group reported using the patch daily; in the subsequent 3 weeks of preloading, > 80% of participants in the active group reported using the patch daily (*Table 4*). In total, 49 (5.5%) participants discontinued preloading prematurely. The majority who ceased preloading did so during the first week of treatment.

Post-quit day medication in those who made a quit attempt after preloading was also assessed. At 1 week after quit day, 11.8% of the control group and 8.2% of the intervention group were not using any medication. It is possible that these participants made a quit attempt without medication or that they made a quit attempt but had abandoned the attempt, and, hence, the medication to support the attempt, by the time of the assessment at 1 week after quit day (*Table 5*).



**FIGURE 3** Consolidated Standards of Reporting Trials (CONSORT) flow diagram. MI, myocardial infarction. Adapted from the Preloading Investigators.<sup>39</sup> This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See <http://creativecommons.org/licenses/by/4.0/>.

TABLE 3 Participant characteristics by trial group

Characteristic	Trial group		
	Control (N = 893)	Intervention (N = 899)	Total (N = 1792)
Age (years), mean (SD)	48.8 (13.4)	49.1 (13.3)	48.9 (13.4)
Gender, n (%)			
Male	469 (52.6)	473 (52.6)	942 (52.6)
Female	422 (47.3)	426 (47.4)	848 (47.4)
Ethnicity, n (%)			
White: British	675 (75.6)	680 (75.6)	1355 (75.6)
White: Irish	36 (4.0)	25 (2.8)	61 (3.4)
White: other	57 (6.4)	55 (6.1)	112 (6.3)
White and black Caribbean	17(1.9)	15 (1.7)	32 (1.8)
White and black African	3 (0.3)	5 (0.6)	8 (0.5)
White and Asian	8 (0.9)	6 (0.7)	14 (0.8)
Mixed other	7 (0.8)	8 (0.9)	15 (1.8)
Indian	11 (1.2)	10 (1.1)	21 (1.2)
Pakistani	9 (1.0)	6 (0.7)	15 (0.8)
Bangladeshi	2 (0.2)	13 (1.5)	15 (0.8)
Asian: other	3 (0.3)	3 (0.3)	6 (0.3)
Black: Caribbean	29 (3.3)	34 (3.8)	63 (3.5)
Black: African	8 (0.9)	13 (1.5)	21 (1.2)
Black: other	4 (0.5)	3 (0.3)	7 (0.4)
Chinese	3 (0.3)	2 (0.2)	5 (0.3)
Other	12 (1.3)	14 (1.6)	26 (1.5)
More than one option	0	4 (0.4)	4 (0.2)
Missing	9 (1.0)	7 (0.8)	16 (0.9)
Educational qualifications, n (%)			
Degree or equivalent and above	201 (22.5)	218 (24.3)	419 (23.4)
A levels or vocational level 3 and above	198 (22.2)	207 (23.0)	405 (22.6)
Other qualifications below A level or vocational level 3	230 (25.8)	212 (23.6)	442 (24.7)
Other qualifications (e.g. foreign)	52 (5.8)	52 (5.8)	104 (5.8)
No formal qualifications	204 (22.8)	199 (22.1)	403 (22.5)
Missing	8 (0.9)	11 (1.2)	19 (1.06)
Occupation, n (%)			
Employed	467 (52.3)	468 (52.1)	935 (52.3)
Unemployed	126 (14.1)	116 (12.9)	242 (13.5)
Looking after home and family	33 (3.7)	44 (4.9)	77 (4.3)

continued

TABLE 3 Participant characteristics by trial group (continued)

Characteristic	Trial group		
	Control (N = 893)	Intervention (N = 899)	Total (N = 1792)
Student	17 (1.9)	22 (2.5)	39 (2.2)
Retired	153 (17.1)	152 (16.9)	305 (17.1)
Long-term sick or disabled	26 (2.9)	26 (2.9)	52 (2.9)
Missing	4 (0.5)	8 (0.9)	12 (0.7)
<b>Smoking history</b>			
Type of cigarette smoked, n (%)			
Manufactured cigarettes	615 (68.9)	607 (67.5)	1222 (68.2)
Tobacco roll-ups	272 (30.5)	284 (31.6)	556 (31.0)
Cigars	6 (0.7)	8 (0.9)	14 (0.8)
Cigarettes per day (continuous)			
Mean (SD)	18.7 (9.0)	19.1 (9.6)	18.9 (9.3)
Median	19	18	18
Range	0–60	0–80	0–80
IQR	12–30	14–20	13–20
Dependence (FTCD), mean (SD)	5.2 (2.2)	5.2 (2.2)	5.2 (2.2)
CO concentration reading (contact 1)			
Mean (SD)	23.8 (12.8)	23.5 (12.3)	23.7 (12.5)
Median	21	21	21
Range	0–100	0–100	0–100
IQR	15–30	15–30	15–30
Longest previous abstinence (continuous, days)			
Mean	358.4	442.3	400.3
SD	750.7	993.7	881.4
Median	90	90	90
IQR	21–330	14–365.3	21–330
Smoking cessation support in last 6 months, n (%)			
Yes	304 (34.0)	279 (31.0)	583 (32.5)
No	588 (65.9)	619 (68.9)	1207 (67.4)
Missing	1 (0.1)	1 (0.1)	2 (0.1)

A level, Advanced level; IQR, interquartile range.

Adapted from the Preloading Investigators.<sup>39</sup> This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See <http://creativecommons.org/licenses/by/4.0/>.

**TABLE 4** Participant self-reported patch use during preloading

Variable, <i>n</i>	Number (% <sup>a</sup> ) of participants
<b>Week -3 (N = 866)</b>	
How many days was the patch worn over the last week?	
0 (0%)	5 (0.6)
1-3	34 (3.9)
4-6	177 (20.4)
7 (100%)	645 (74.5)
Missing	5 (0.6)
How many patches were used over the last week? (Median 7; range 0-14)	
0	4 (0.5)
1-6	179 (20.7)
7	510 (58.9)
> 7	168 (19.4)
Missing	5 (0.6)
<b>Week +1 (N = 727)</b>	
How many days was the patch worn over the last 3 weeks?	
0-7	41 (5.6)
8-14	47 (6.5)
15-21	617 (84.9)
Missing	22 (3.0)
How many patches were used over the last 3 weeks? (Median 21; range 0-42)	
0-7	40 (5.5)
8-14	46 (6.3)
15-21	513 (70.6)
> 21	102 (14.0)
Missing	26 (3.6)

a Percentage expressed as a proportion of all those who provided data.

**TABLE 5** Medication used to support cessation among those who made a quit attempt<sup>a</sup>

Medication used	Trial group, <i>n</i> (%)		
	Control ( <i>N</i> = 738) <sup>a</sup>	Intervention ( <i>N</i> = 742) <sup>a</sup>	Total ( <i>N</i> = 1480) <sup>a</sup>
None	87 (11.8)	61 (8.2)	148 (10.0)
Varenicline	218 (29.5)	164 (22.1)	382 (25.8)
Bupropion	6 (0.8)	12 (1.6)	18 (1.2)
Nicotine patches only	99 (13.4)	169 (22.8)	268 (18.1)
Acute nicotine only <sup>b</sup>	74 (10.0)	44 (5.9)	118 (8.0)
Combined nicotine	156 (21.1)	170 (22.9)	326 (22.0)
Missing	113 (15.3)	135 (18.2)	248 (16.8)

a Percentages add to slightly more than 100% because some participants used multiple medications.

b Acute nicotine means oral or nasal forms.

Adapted from the Preloading Investigators.<sup>39</sup> This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See <http://creativecommons.org/licenses/by/4.0/>.

## Primary and secondary outcomes

The primary outcome, biochemically validated 6-month abstinence, was achieved by 157 (17.5%) participants in the intervention group and 129 (14.5%) participants in the control group, a difference of 3.02 (95% CI -0.37 to 6.41).

The secondary outcomes showed similar modest differences. At 4 weeks, 319 (35.5%) participants in the intervention group achieved 7-day point prevalence abstinence, whereas 288 (32.3%) participants in the control group did so. At 12 months, 126 (14.0%) participants in the intervention group achieved validated prolonged abstinence, whereas 101 (11.3%) participants in the control group achieved it (*Tables 6 and 7*).

Adjustment for predictors of abstinence left the results essentially unchanged, except for adjustment for the use of post-quit day varenicline use, which changed the results noticeably. The effect of preloading was larger than in the unadjusted results and was statistically significant.

**TABLE 6** Primary and secondary smoking cessation outcomes presented as ORs for the primary analysis

Outcome	Analysis							
	Unadjusted		Adjusted <sup>a</sup>		Adjusted <sup>b</sup>		Adjusted <sup>c</sup>	
	OR (95% CI)	p-value	OR (95% CI)	p-value	OR (95% CI)	p-value	OR (95% CI)	p-value
<b>Primary outcome: 6-month Russell Standard abstinence</b>								
Intervention	1.25 (0.97 to 1.62)	0.081	1.25 (0.97 to 1.62)	0.081	1.26 (0.97 to 1.62)	0.081	1.34 (1.03 to 1.73)	0.028
<b>Secondary outcomes</b>								
4 weeks, Russell Standard abstinence								
Intervention	1.21 (1.00 to 1.48)	0.052	1.21 (1.00 to 1.48)	0.053	1.22 (1.00 to 1.48)	0.051	1.32 (1.08 to 1.62)	0.007
4 weeks, 7-day point prevalence abstinence								
Intervention	1.16 (0.95 to 1.41)	0.148	1.16 (0.95 to 1.41)	0.149	1.16 (0.95 to 1.41)	0.150	1.26 (1.03 to 1.54)	0.027
6 months, 7-day point prevalence abstinence								
Intervention	1.13 (0.90 to 1.41)	0.306	1.13 (0.90 to 1.41)	0.306	1.14 (0.90 to 1.43)	0.275	1.20 (0.95 to 1.51)	0.129
12 months, Russell Standard abstinence								
Intervention	1.28 (0.97 to 1.69)	0.085	1.28 (0.97 to 1.69)	0.085	1.27 (0.96 to 1.69)	0.091	1.36 (1.02 to 1.80)	0.036
12 months, 7-day point prevalence abstinence								
Intervention	1.22 (0.97 to 1.54)	0.083	1.23 (0.97 to 1.54)	0.082	1.22 (0.97 to 1.54)	0.087	1.28 (1.01 to 1.62)	0.038

a Adjusted for research centre: the primary analysis.

b Adjusted for research centre, previous longest abstinence (days, continuous) and baseline strength of urges to smoke (continuous, as per analysis plan).

c Adjusted for research centre, previous longest abstinence (days, continuous), baseline strength of urges to smoke (continuous, as per analysis plan) and varenicline prescribed at +1 week.

Adapted from the Preloading Investigators.<sup>39</sup> This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See <http://creativecommons.org/licenses/by/4.0/>.

TABLE 7 Primary and secondary outcomes expressed as RRs and RDs

Outcome	Analysis							
	Unadjusted		Adjusted <sup>a</sup>		Adjusted <sup>b</sup>		Adjusted <sup>c</sup>	
	RD/RR (95% CI)	p-value	RD/RR (95% CI)	p-value	RD/RR (95% CI)	p-value	RD/RR (95% CI)	p-value
<b>Primary outcome: 6-month Russell Standard abstinence</b>								
Estimated risks	17.5 and 14.5							
RR	1.25 (0.97 to 1.62)	0.081	1.21 (0.98 to 1.50)	0.081	1.21 (0.98 to 1.50)	0.082	1.27 (1.03 to 1.57)	0.029
RD	3.02 (-0.37 to 6.41)	0.081	3.02 (-0.37 to 6.41)	0.081	3.03 (-0.37 to 6.43)	0.080	3.80 (0.41 to 7.18)	0.029
<b>Secondary outcomes</b>								
4 weeks, Russell Standard abstinence								
Estimated risks	36.3 and 31.9							
RR	1.14 (1.00 to 1.29)	0.053	1.14 (1.00 to 1.29)	0.053	1.14 (1.00 to 1.29)	0.051	1.19 (1.05 to 1.35)	0.007
RD	4.35 (-0.04 to 8.73)	0.052	4.33 (-0.04 to 8.70)	0.052	4.37 (-0.01 to 8.75)	0.050	5.89 (1.60 to 10.19)	0.007
4 weeks, 7-day point prevalence abstinence								
Estimated risks	35.5 and 32.3							
RR	1.10 (0.97 to 1.25)	0.149	1.10 (0.97 to 1.25)	0.149	1.10 (0.97 to 1.25)	0.151	1.15 (1.02 to 1.31)	0.027
RD	3.23 (-1.15 to 7.61)	0.148	3.22 (-1.15 to 7.59)	0.149	3.22 (-1.17 to 7.60)	0.150	4.86 (0.58 to 9.14)	0.026
6 months, 7-day point prevalence abstinence								
Estimated risks	22.3 and 20.3							
RR	1.10 (0.92 to 1.31)	0.306	1.10 (0.92 to 1.31)	0.306	1.10 (0.92 to 1.32)	0.276	1.15 (0.96 to 1.37)	0.129
RD	1.98 (-1.81 to 5.77)	0.306	1.98 (-1.81 to 5.76)	0.306	2.11 (-1.68 to 5.91)	0.275	2.93 (-0.85 to 6.71)	0.129
12 months, Russell Standard abstinence								
Estimated risks	14.0 and 11.3							
RR	1.24 (0.97 to 1.58)	0.086	1.24 (0.97 to 1.58)	0.086	1.24 (0.97 to 1.58)	0.093	1.30 (1.02 to 1.66)	0.036
RD	2.71 (-0.37 to 5.78)	0.085	2.71 (-0.37 to 5.78)	0.085	2.66 (-0.43 to 5.75)	0.091	3.31 (0.22 to 6.39)	0.036

continued

**TABLE 7** Primary and secondary outcomes expressed as RRs and RDs (*continued*)

Outcome	Analysis							
	Unadjusted		Adjusted <sup>a</sup>		Adjusted <sup>b</sup>		Adjusted <sup>c</sup>	
	RD/RR (95% CI)	<i>p</i> -value	RD/RR (95% CI)	<i>p</i> -value	RD/RR (95% CI)	<i>p</i> -value	RD/RR (95% CI)	<i>p</i> -value
12 months, 7-day point prevalence abstinence								
Estimated risks	22.4 and 19.0							
RR	1.17 (0.98 to 1.41)	0.083	1.17 (0.98 to 1.41)	0.083	1.17 (0.98 to 1.41)	0.088	1.21 (1.01 to 1.45)	0.038
RD	3.32 (-0.43 to 7.07)	0.082	3.32 (-0.42 to 7.06)	0.082	3.28 (-0.48 to 7.04)	0.087	3.98 (0.23 to 7.73)	0.037

a Adjusted for research centre.

b Adjusted for research centre, previous longest abstinence (days, continuous) and baseline strength of urges to smoke (continuous, as per analysis plan).

c Adjusted for research centre, previous longest abstinence (days, continuous), baseline strength of urges to smoke (continuous, as per analysis plan) and varenicline prescribed at +1 week.

Adapted from the Preloading Investigators.<sup>39</sup> This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See <http://creativecommons.org/licenses/by/4.0/>.

## Subgroup analysis

There was no evidence that people who used varenicline as their post-cessation medication received less benefit from nicotine preloading than people using other cessation medication. For the effect of preloading compared with control for participants using varenicline, the OR was 1.42 (95% CI 0.90 to 2.26). For participants not using varenicline, the OR was 1.30 (95% CI 0.95 to 1.77;  $p = 0.740$ ) for the interaction.

## Adverse events

Adverse events that were moderate or severe in intensity were uncommon in both arms. Therefore, the absolute difference between arms was small with an absolute difference in the percentage of participants suffering an AE in the intervention group compared with the control group of up to 4% (*Table 8*).

One week after baseline, 394 (45.5%) participants in the intervention group and 271 (32.4%) participants in the control group reported at least one symptom from the checklist of symptoms of nicotine excess ( $p < 0.001$  for the difference). The only three symptoms for which there was statistically significant evidence that they were more common in the intervention group were dizziness, palpitations and nausea. Of these symptoms, 5.6% and 3.0% were somewhat or very dizzy in the intervention and control groups, 3.9% and 1.9% had palpitations and 8.1% and 3.1% experienced nausea, respectively (*Figure 4*).

There were 17 SAEs during the 5-week period, nine in the intervention group and eight in the control group, giving an OR of 1.12 (95% CI 0.42 to 3.03). Of these, one was judged to be possibly caused by preloading: acute coronary syndrome in a 64-year-old woman. The SAEs reported are summarised in *Table 9*.


**TABLE 8** Reported AEs of moderate or severe intensity in the trial groups

Event	Trial group		Percentage point difference (95% CI)
	Control (N = 860)	Intervention (N = 880)	
Gastrointestinal disorders	19 (2.2)	55 (6.2)	4.0 (2.2 to 5.9)
Abdominal pain	3 (0.3)	6 (0.7)	0.3 (-0.3 to 1.0)
Diarrhoea	3 (0.3)	8 (0.9)	0.6 (-0.2 to 1.3)
Nausea	8 (0.9)	30 (3.4)	2.5 (1.1 to 3.8)
Vomiting	3 (0.3)	14 (1.6)	1.2 (0.3 to 2.2)
General disorders	11 (1.2)	30 (3.3)	2.1 (0.7 to 3.5)
Asthenia	5 (0.6)	10 (1.1)	0.6 (-0.3 to 1.4)
Fatigue	0 (0.0)	6 (0.7)	0.7 (0.1 to 1.2)
Injuries, poisoning and procedural complications	8 (0.9)	4 (0.5)	-0.5 (-1.2 to 0.3)
Musculoskeletal and connective disorders	7 (0.8)	10 (1.1)	0.3 (-0.6 to 1.2)
Nervous system	16 (1.9)	56 (6.4)	4.5 (2.7 to 6.4)
Abnormal dreams	1 (0.1)	9 (1.0)	0.9 (0.2 to 1.6)
Dizziness	6 (0.7)	15 (1.7)	1.0 (0.0 to 2.0)
Headache	3 (0.3)	14 (1.6)	1.2 (0.3 to 2.2)
Poor-quality sleep	3 (0.3)	20 (2.3)	1.9 (0.9 to 3.0)
Psychiatric	7 (0.8)	17 (1.9)	1.1 (0.0 to 2.2)
Depressed mood	4 (0.5)	5 (0.6)	0.1 (-0.6 to 0.8)
Respiratory	21 (2.4)	15 (1.7)	-0.7 (-2.1 to 0.6)
Chest infection	4 (0.5)	1 (0.1)	-0.3 (-0.8 to 0.2)
Influenza-like illness	3 (0.3)	7 (0.8)	0.4 (-0.3 to 1.2)
Nasopharyngitis	7 (0.8)	4 (0.5)	-0.4 (-1.1 to 0.4)
Skin and subcutaneous tissue disorders	4 (0.5)	7 (0.8)	0.3 (-0.4 to 1.1)
Skin irritation	2 (0.2)	5 (0.6)	0.3 (-0.3 to 0.9)


**Note**

This table shows the proportion of people reporting an AE for any system or organ class term that had  $\geq 10$  participants reporting it and any preferred term that had at least five participants reporting it. The denominator includes all those who participated either at -3 weeks or +1 week.


Adapted from the Preloading Investigators<sup>39</sup> supplementary material. This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See <http://creativecommons.org/licenses/by/4.0/>.



**FIGURE 4** Prevalence and severity of symptoms experienced in the last 24 hours, reported after having been in the preloading group or control group for 1 week. (a) Stomach pain; (b) cold sweat; (c) diarrhoea; (d) palpitations; (e) dizziness; (f) nausea; (g) vomiting; (h) headaches; (i) watery mouth; (j) weakness; (k) tremor; and (l) pallor. (continued)



**FIGURE 4** Prevalence and severity of symptoms experienced in the last 24 hours, reported after having been in the preloading group or control group for 1 week. (a) Stomach pain; (b) cold sweat; (c) diarrhoea; (d) palpitations; (e) dizziness; (f) nausea; (g) vomiting; (h) headaches; (i) watery mouth; (j) weakness; (k) tremor; and (l) pallor. (continued)



**FIGURE 4** Prevalence and severity of symptoms experienced in the last 24 hours, reported after having been in the preloading group or control group for 1 week. (a) Stomach pain; (b) cold sweat; (c) diarrhoea; (d) palpitations; (e) dizziness; (f) nausea; (g) vomiting; (h) headaches; (i) watery mouth; (j) weakness; (k) tremor; and (l) pallor.

TABLE 9 Serious adverse events

Age and gender	Trial group	Relevant medical history	Event
68-year-old man	Intervention	Chronic myeloid leukaemia	Hospitalised with chest infection
85-year-old woman	Intervention	Osteoporosis	Hospitalised with pelvic fracture following accidental fall
72-year-old woman	Intervention	None	Hospitalised for aspiration of malignant pleural effusion
65-year old woman	Intervention	Cardiovascular disease, hypertension, pacemaker and history of blackouts	Hospitalised for a blackout
27-year-old woman	Intervention	Psychotic illness, illicit drug use	Psychotic episode following period of illicit drug use leading to anxiety attacks
64-year-old woman	Intervention	None	Acute coronary syndrome
54-year-old woman	Intervention	Angina	Hospitalised with acute coronary syndrome or non-cardiac chest pain
45-year-old woman	Intervention	Self-harming	Hospitalised for increased self-harming and suicidal ideation
68-year-old man	Control	Reflux oesophagitis	Hospitalised with cancer of the oesophagus
55-year-old woman	Control	COPD and type 2 diabetes mellitus	Death due to COPD
59-year-old man	Control	Alcohol dependence	Death as a result of an accidental house fire
52-year-old man	Control	Two previous hernia repairs	Hospitalised for hernia repair
47-year-old woman	Control	None	Hospitalised for pyelonephritis
38-year-old woman	Control	Asthma	Hospitalised with chest infection
64-year-old woman	Control	COPD	Exacerbation of COPD
25-year-old man	Control	None	Pneumonia

COPD, chronic obstructive pulmonary disease.

Adapted from the Preloading Investigators<sup>39</sup> supplementary material. This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See <http://creativecommons.org/licenses/by/4.0/>.



# Chapter 4 Moderators and mediators of the effect of nicotine preloading

## Introduction

*Chapter 3* showed no evidence that, in the primary analysis, preloading was an effective strategy for promoting smoking cessation in the current NHS setting. This is because preloading deterred the use of varenicline, the most effective smoking cessation medication, as a post-quit day medication.<sup>6</sup> However, when adjusted for the use of varenicline, there was evidence of an independent effect of preloading as an effective strategy for promoting smoking cessation. However, in the future, it is plausible that this deterrent effect could be overcome by changing the guidelines or the everyday customs and practices of smoking cessation therapists. Therefore, it is appropriate to understand better how preloading may work and the people for whom it may work best. This may allow us to maximise the benefit for patients and, in those who choose preloading, to monitor the effectiveness of the strategy and discontinue preloading if benefits are unlikely.

## Effect modification

This chapter addresses two questions. The first examines effect modification or moderation of the possible treatment effect of preloading. It is possible that preloading was effective only for a subgroup of the population of smokers seeking help to quit. Given its proposed mechanism of action on undermining the reward from smoking and the drive to smoke, we hypothesised that preloading would be more effective for people who showed evidence of higher dependence on cigarettes. This might be evidenced by a higher cigarette consumption at baseline (shown by cigarettes per day or exhaled CO concentration at baseline) or a higher dependence score (FTCD). Understanding this may help us target preloading to the group who stand to gain a greater than average benefit from preloading, thereby maximising the cost-effectiveness of the treatment approach.

## Mechanism of action of preloading

The second question addresses the question of how preloading may work.

As discussed in *Chapter 1, Mechanisms of action of preloading*, our review of the mechanisms of action of preloading revealed scant evidence for any of these mechanisms explaining the possible effectiveness of this strategy. This is important for clinical practice. Nicotine preloading may not help everyone who is trying to stop smoking. Therapists could monitor whether or not preloading is achieving its intermediate effects and, if not, abandon the strategy early, saving resources on behalf of the NHS. In this chapter, we examine the possible mediating pathways between nicotine preloading and outcomes.

## Method

### Design

The trial protocol and main outcomes are described in *Chapters 2 and 3*. For the moderation analysis, we followed the same analysis strategy as outlined in *Chapter 2, Statistical analysis*, but added multiplicative interaction terms to the equation between two markers of dependence assessed at baseline and trial group. As markers of dependence we used FTCD, the standard measure of baseline dependence, and exhaled CO concentration. The latter is a measure of smoke intake in the preceding hours; more dependent smokers draw more heavily on their cigarettes or smoke more cigarettes per day and, hence, tend to have higher CO measurements.

For the mediation analysis, we followed the regression framework described by Kenny.<sup>41</sup> The steps are as follows:

1. show that the preloading variable causes smoking cessation (*Chapter 3*)
2. show that preloading causes change in the mediator
3. show that change in the mediator is associated with smoking cessation
4. to establish complete mediation, show that controlling for change in the mediator abolishes the association between preloading and cessation.

Given that *Chapter 3* showed that, on adjustment for the effect of post-cessation varenicline, there was evidence for the efficacy of preloading, this chapter deals with steps 2–4.

### Outcomes

For the moderation analyses, the outcome was the primary outcome: Russell Standard 6-month abstinence.

We assessed the impact of preloading on potential mediators of effect outlined in *Figure 5*. These were measured 1 week after starting preloading or the control condition (3 weeks prior to quit day) and were:


- positive reinforcement – modified Cigarette Evaluation Questionnaire (mCEQ) satisfaction subscale<sup>42</sup> and noticing whether cigarettes were more or less enjoyable than previously
- negative reinforcement – mCEQ reward subscale
- drive to smoke – self-reported change in urge strength and change in frequency of the urge to smoke combined, assessed using the Mood and Physical Symptoms Scale – Craving (MPSS-C) subscale,<sup>43</sup> smoking stereotypy taken from the Nicotine Dependence Syndrome Scale;<sup>44</sup> the mCEQ craving question; and a question used by Hajek *et al.*<sup>21</sup> in a similar trial that asked participants to rate their urge to smoke compared with usual
- cigarette consumption – cigarettes per day and exhaled CO concentration
- symptoms of addiction – modified score on the FTCD,<sup>45</sup> modified by removing cigarette consumption from the scale to ensure that symptoms of addiction were distinct from cigarette consumption.

The hypothesis is that, by undermining the learned addiction to cigarettes during the pre-quitting period, preloading reduces the intensity of craving and withdrawal during the post-quit period. For this, we examined the effect of preloading on the intensity of urges and mood symptoms at the end of the first week of abstinence. We used the MPSS-C and the Mood and Physical Symptoms Scale – Mood (MPSS-M) subscales to measure these. The results of assessments of craving and withdrawal symptoms in those who are smoking can be hard to interpret,<sup>46</sup> so we analysed these once in those who had been perfectly abstinent and once in those who were continuing to try to be abstinent.

For our other three mediational hypotheses, we assessed the impact of the possible mediators measured at 1 week after commencement. These were as follows:

1. Medication adherence: days of use of post-quit day medication measured at the +1-week visit.
2. Confidence question: ‘How high would you rate your chances of giving up smoking for good at this attempt?’, measured on a five-point scale (with 1 being ‘not at all’ and 5 being ‘extremely good’).
3. Nausea and aversion: we assessed nausea using the mean scores for two questions derived from themes from participant interviews in a previous trial.<sup>47</sup> These were ‘Over the past week how nauseous have you felt when you have seen cigarettes or lighters?’ and ‘Over the past week how nauseous have you felt when you have smelt cigarette smoke?’ and were measured on five-point scales from not at all to extremely. Aversion was measured using the aversion subscale of the mCEQ.

To maximise the sensitivity to detect mediation in the mediator analyses, our outcomes were Russell Standard 4-week and 6-month abstinence. Given that 4-week abstinence is more proximate to the mediators, it should have a stronger association with the mediators than 6-month abstinence.



**FIGURE 5** Effect of preloading compared with control on the primary outcome, depending on baseline tobacco dependence. (a) FTCD score (0–3, 4–6 and 7–10); and (b) baseline exhaled CO concentration in p.p.m.

### Statistical analysis

The moderator analysis used the same model as for the primary analysis outlined in *Chapter 2, Statistical analysis*, but added, in turn, our two markers of dependence (FTCD and exhaled CO concentration) and the multiplicative term representing the baseline marker of dependence multiplied by the trial group indicator variable.

In all of the mediator analyses, we excluded people who had missing data on the mediator. In the analyses, we examined for evidence of mediation on variables assessed at –3 weeks (1 week after baseline) and at +1 week (5 weeks after baseline, 1 week after quit day).

For the second step of the mediation analysis, we assessed the effect of treatment group on mediators descriptively by comparing means between treatment groups and then by analysis of covariance, with adjustment for centre and for the baseline value of the mediator when applicable; thus, effectively examining the effect of preloading on change in the mediator. We checked the residuals to ensure that there was no marked deviation from normality.

We proceeded to the third step of mediation analysis only for those variables for which there was reasonable statistical evidence that preloading influenced the change in the mediator. We assessed the effect of mediators on abstinence outcomes at 4 weeks and 6 months using logistic regression. We looked

at this first in unadjusted analysis and then with adjustment for treatment group, as advocated for mediation analysis by Kenny.<sup>41</sup> As previously, these analyses were adjusted for stratification by centre.

In the fourth step of mediation, we examined whether or not potential mediators (i.e. those correlated with both the treatment group and the outcome) did indeed mediate the relationship between treatment group and each outcome; this was done by adding each to a logistic regression model including the mediator and the treatment group. Given that there was strong statistical evidence for the efficacy of preloading only when adjusted for use of varenicline, we used the model adjusted for varenicline as the primary model in this analysis. We added each potential mediator singly and then all of the mediators in the same model.

## Results

### ***Modification of the effect of preloading on abstinence by baseline tobacco dependence***

There was no evidence that people who were more dependent on smoking received a greater benefit from preloading. The *p*-values for multiplicative interaction terms for the effect of preloading in those with higher dependence scores and a higher exhaled CO concentration were 0.831 and 0.171, respectively. Per unit increase in each variable, the ORs were 1.01 (95% CI 0.90 to 1.14) and 1.01 (95% CI 0.99 to 1.04), respectively (see *Figure 5*).

### ***Effect of preloading on potential mediators***

#### **Mediators measured at –3 weeks**

This assessment took place 1 week after baseline and 3 weeks before quit day.

There was evidence that preloading reduced both positive and negative reward (*Table 10*). Preloading should reduce the drive to smoke and the reduction of reward should also reduce the drive to smoke. There was evidence that three of the four measures of drive to smoke reduced because of preloading. The exception was withdrawal mood symptoms, but measures of drive to smoke specifically all reduced. If this model is correct, then consumption of cigarettes should decrease and this was indeed observed, with a mean modest reduction of 2.6 cigarettes per day (from a baseline mean of 18.9 cigarettes per day) and a reduction in exhaled CO concentration of 3.2 p.p.m. (from a baseline mean of 23.7 p.p.m.). Likewise, perhaps reflecting a decreased drive to smoke, symptoms of addiction (FTCD, excluding daily cigarette consumption) were also shown to have decreased.

Two alternative hypotheses were that preloading improves confidence in quitting and that preloading works through creating an aversion to smoking. There was no evidence that confidence in quitting improved because of preloading but there was strong evidence that both markers of aversion to smoking increased because of preloading (see *Table 10*). The medication adherence hypothesis could be tested only after quit day.

#### **Mediators measured at +1 week**

This assessment took place 1 week after quit day, and potentially after stopping preloading treatment, and 5 weeks after baseline.

As participants were trying to achieve abstinence and many were abstaining, we did not measure positive or negative reward from smoking cigarettes at this assessment. In the main hypothesis, reduced urges to smoke during preloading and a reduced level of smoking mean that people are experiencing cues to smoke that do not prompt smoking, thus beginning the process of extinguishing the learnt drive to smoke. This would manifest as reduced urges to smoke or craving experienced after quit day and there was evidence that this did occur, although there was no evidence that withdrawal mood symptoms were reduced. At this assessment, when participants were abstinent, it was not sensible to ask about any other potential mediators on this pathway.

TABLE 10 Effect of the intervention on potential mediators

Potential mediator	Trial group, mean (SD)		Difference between intervention and control <sup>a</sup> (95% CI)	p-value
	Control	Intervention		
<b>At -3 weeks</b>				
Positive reinforcement				
mCEQ satisfaction subscale	4.132 (1.425)	3.584 (1.351)	-0.547 (-0.651 to -0.443)	< 0.001
Enjoyment more or less than usual	2.673 (0.650)	2.149 (0.725)	-0.524 (-0.590 to -0.459)	< 0.001
Negative reinforcement				
mCEQ reward subscale	2.945 (1.473)	2.608 (1.338)	-0.354 (-0.459 to -0.249)	< 0.001
Drive to smoke				
MPSS-C	2.613 (0.941)	2.141 (0.797)	-0.485 (-0.555 to -0.415)	< 0.001
MPSS-M	1.893 (0.726)	1.904 (0.724)	0.009 (-0.043 to 0.062)	0.724
Smoking stereotypy	2.185 (0.761)	2.285 (0.762)	0.102 (0.036 to 0.168)	0.003
Urges stronger or weaker than usual	2.911 (0.657)	2.160 (0.722)	-0.752 (-0.818 to -0.686)	< 0.001
Cigarette consumption				
Cigarettes per day	15.7 (8.7)	13.4 (8.3)	-2.6 (-3.2 to -2.1)	< 0.001
Exhaled CO concentration	23.58 (12.8)	20.41 (11.7)	-3.17 (-4.0 to -2.3)	< 0.001
Symptoms of addiction				
FTCD excluding cigarettes per day	3.938 (1.789)	3.636 (1.790)	-0.2997 (-0.403 to -0.196)	< 0.001
Confidence in quitting				
How do you rate your chances?	3.811 (0.788)	3.853 (0.824)	0.028 (-0.036 to 0.092)	0.384
Aversion				
Nausea	1.334 (0.594)	1.533 (0.736)	0.186 (0.129 to 0.242)	< 0.001
mCEQ aversion subscale	1.339 (0.717)	1.589 (0.954)	0.241 (0.168 to 0.314)	< 0.001
<b>At +1 week</b>				
Drive to smoke				
MPSS-C (in those abstinent)	1.279 (1.046)	1.0231 (0.958)	-0.285 (-0.438 to -0.132)	< 0.001
MPSS-C (in those still trying to quit)	1.504 (1.082)	1.311 (1.053)	-0.214 (-0.335 to -0.093)	0.001
MPSS-M (in those abstinent)	1.751 (0.634)	1.719 (0.636)	-0.035 (-0.126 to 0.056)	0.454
MPSS-M (in those still trying to quit)	1.789 (0.687)	1.770 (0.682)	-0.007 (-0.079 to 0.065)	0.848
Confidence in quitting				
How do you rate your chances? (in those abstinent)	4.371 (0.746)	4.360 (0.658)	-0.010 (-0.117 to 0.097)	0.858
How do you rate your chances? (in those abstinent or still trying to quit)	4.102 (0.916)	4.190 (0.787)	0.092 (-0.006 to 0.189)	0.066
Aversion (in those trying to quit)				
Nausea (in those abstinent)	1.831 (1.199)	1.976 (1.392)	0.203 (-0.018 to 0.424)	0.072
Nausea (in those abstinent or trying to quit)	0.683 (0.333)	0.679 (0.319)	-0.011 (-0.060 to 0.038)	0.649
Nausea (in those abstinent or trying to quit)	0.676 (0.317)	0.695 (0.331)	0.017 (-0.019 to 0.053)	0.365

continued

**TABLE 10** Effect of the intervention on potential mediators (*continued*)

Potential mediator	Trial group, mean (SD)		Difference between intervention and control <sup>a</sup> (95% CI)	p-value
	Control	Intervention		
Medication adherence				
Number of days of medication use in the last week (in those who are still trying to quit), n (%)				
0	82 (14.2)	68 (11.7)		0.333
1–6	78 (13.5)	72 (12.3)		
7	419 (72.4)	443 (76.0)		

a Adjusted for baseline (where appropriate) and centre.

**Note**

Data represent the mean across items for all scales apart from FTCD, for which the total score is used.

As in the pre-quit period, there was no evidence that preloading increased participants’ confidence in their ability to quit smoking. Unlike in the pre-quit period, there was no evidence of a difference in aversion to cigarettes after the quit day (see *Table 10*).

The final mediating hypothesis is that preloading improves adherence to post-cessation medication but there was no evidence to support this (see *Table 10*).

**Association between mediators and outcome (smoking abstinence)**

We analysed the association between mediators and outcome for those variables for which there was evidence that preloading influenced the mediator (*Table 11*).

In the analyses assessing the main hypothesis for the mechanism of action, at –3 weeks, there was no evidence of an association between change in either positive or negative reinforcement from smoking and subsequent abstinence from smoking at 4 weeks or 6 months. Although two of the three measures of drive to smoke were not associated with smoking abstinence, one of these, noticing a change in the strength of urges, was associated with abstinence. Objective reduction in consumption, measured by a reduced CO concentration over the week, was associated with later abstinence, but self-reported reduction in cigarettes smoked per day was not associated with later abstinence. There was no evidence that change in symptoms of addiction was associated with later abstinence (see *Table 11*). At +1 week, during the abstinence period, reduction in urge strength was associated with later abstinence.

After the second step in the mediation analysis, the only surviving competing hypothesis to our main hypothesis was that the effect of preloading was mediated by creating an aversion to smoking. However, in this third step, there was no evidence that a change in aversion (measured by nausea and the mCEQ aversion subscale at –3 weeks) predicted abstinence.

**Effect of preloading on the outcome, controlled for mediators**

In the final step of the mediation analysis, we considered whether or not the strength of association between use of preloading and abstinence was diminished after adding three potential mediators. These mediators, all of which showed evidence of potential mediation in the previous steps, were (1) noticing that urges were weaker than usual while still smoking, (2) reduced exhaled CO concentration while still smoking and (3) reduced urge strength after abstinence. As the clear evidence of efficacy of preloading emerged only in the analyses adjusting for post-cessation varenicline use, we used this as the primary comparison for this final stage of mediation analysis. In the data on abstinence, we included all participants in the analysis with the presumption that people who dropped out were smoking. However, where people were not followed up, the value of their mediator was not imputed and so

**TABLE 11** Association of mediators with abstinence at 4 weeks and 6 months

Potential mediator	Abstinence			
	At 4 weeks, OR (95% CI); <i>p</i> -value		At 6 months, OR (95% CI); <i>p</i> -value	
	Unadjusted for treatment group	Adjusted for treatment group	Unadjusted for treatment group	Adjusted for treatment group
<b>Change from baseline at –3 weeks</b>				
Positive reinforcement				
mCEQ satisfaction subscale	0.974 (0.901 to 1.054); 0.521	0.987 (0.910 to 1.070); 0.746	0.915 (0.828 to 1.012); 0.083	0.928 (0.837 to 1.028); 0.153
Enjoyment more or less than usual	0.864 (0.761 to 0.981); 0.024	0.880 (0.761 to 1.017); 0.082	0.818 (0.695 to 0.963); 0.016	0.832 (0.691 to 1.003); 0.053
Negative reinforcement				
mCEQ reward subscale	0.996 (0.919 to 1.080); 0.932	1.006 (0.927 to 1.091); 0.885	1.073 (0.967 to 1.191); 0.182	1.089 (0.980 to 1.209); 0.112
Drive to smoke				
MPSS-C	0.959 (0.860 to 1.069); 0.445	0.980 (0.876 to 1.097); 0.727	1.060 (0.921 to 1.219); 0.416	1.099 (0.951 to 1.270); 0.202
Smoking stereotypy	1.021 (0.903 to 1.155); 0.741	1.015 (0.897 to 1.148); 0.819	1.080 (0.923 to 1.264); 0.338	1.072 (0.915 to 1.255); 0.390
Urges stronger or weaker than usual	0.864 (0.761 to 0.981); 0.024	0.880 (0.761 to 1.017); 0.082	0.818 (0.695 to 0.963); 0.016	0.832 (0.691 to 1.003); 0.053
Cigarette consumption				
Cigarettes per day	1.008 (0.993 to 1.023); 0.311	1.011 (0.995 to 1.027); 0.173	1.002 (0.983 to 1.022); 0.825	1.006 (0.986 to 1.026); 0.582
CO concentration	0.986 (0.976 to 0.996); 0.007	0.987 (0.977 to 0.997); 0.012	0.988 (0.975 to 1.001); 0.062	0.989 (0.976 to 1.002); 0.094
Symptoms of addiction				
FTCD	1.003 (0.918 to 1.095); 0.954	1.012 (0.925 to 1.106); 0.799	1.016 (0.907 to 1.138); 0.780	1.029 (0.918 to 1.153); 0.625
Aversion				
Nausea	0.888 (0.763 to 1.035); 0.128	0.872 (0.748 to 1.017); 0.082	1.072 (0.884 to 1.300); 0.481	1.052 (0.866 to 1.277); 0.611
mCEQ aversion subscale	1.001 (0.898 to 1.115); 0.989	0.990 (0.888 to 1.103); 0.856	1.012 (0.882 to 1.162); 0.863	1.000 (0.871 to 1.147); 0.992
<b>Change from baseline at +1 week</b>				
MPSS-C	0.750 (0.690 to 0.817); <0.001	0.754 (0.692 to 0.820); <0.001	0.774 (0.699 to 0.858); <0.001	0.779 (0.703 to 0.863); <0.001
<b>Note</b>				
Odds ratios relate to a 1-point (or unit) change in the potential mediator from baseline to the particular assessment point.				

these participants were dropped from the analysis. To ensure that the ORs were comparable across analyses, the number with valid data was used on the mediator in all analyses, including those analyses that did not include the mediator.

There was evidence that each of the mediators explained the effect of preloading to some extent (*Table 12*). Controlling for a reduction in urge strength reduced the effect of preloading on abstinence by 47% for 4-week abstinence and 59% for 6-month abstinence. Controlling for a reduction in exhaled CO concentration during the pre-quit period reduced the effect of preloading on abstinence by 23% for 4-week abstinence and 14% for 6-month abstinence. Controlling for a reduction in craving after quitting reduced the effect of preloading on abstinence by 28% for 4-week abstinence and 21% for 6-month abstinence. Controlling for all three potential mediators reduced the effect of preloading on abstinence by 71% for 4-week abstinence and 78% for 6-month abstinence.

**TABLE 12** Effect of preloading on smoking abstinence at 4 weeks and 6 months, controlling for potential mediators

Potential mediator	OR (95% CI) for effect of treatment on smoking status at 4 weeks; <i>p</i> -value			OR (95% CI) for effect of treatment on smoking status at 6 months; <i>p</i> -value		
	In model adjusted for centre and varenicline use only <sup>a</sup> ( <i>n</i> = 1792)	In model adjusted for centre and varenicline use only ( <i>n</i> as available for the mediator)	In model adjusted for centre and varenicline use and mediator ( <i>n</i> as available for the mediator)	In model adjusted for centre and varenicline use only <sup>a</sup> ( <i>n</i> = 1792)	In model adjusted for centre and varenicline use only ( <i>n</i> as available for the mediator)	In model adjusted for centre and varenicline use and mediator ( <i>n</i> as available for the mediator)
Urges stronger or weaker than usual ( <i>n</i> = 1696)	1.32 (1.08 to 1.61); 0.007	1.26 (1.03 to 1.55); 0.026	1.13 (0.90 to 1.43); 0.303)	1.33 (1.03 to 1.73); 0.028	1.29 (0.99 to 1.67) 0.056	1.11 (0.82 to 1.49); 0.501
Change in exhaled CO concentration at -3 weeks ( <i>n</i> = 1642)	1.32 (1.08 to 1.61); 0.007	1.24 (1.01 to 1.53); 0.042	1.18 (0.96 to 1.46); 0.118	1.33 (1.03 to 1.73); 0.028	1.26 (0.97 to 1.64); 0.08	1.22 (0.93 to 1.59); 0.14
Change in MPSS-C at +1 week ( <i>n</i> = 1408)	1.32 (1.08 to 1.61); 0.007	1.29, (1.03 to 1.60); 0.024	1.20 (0.96 to 1.50); 0.103	1.33 (1.03 to 1.73); 0.028	1.30 (0.99 to 1.70); 0.056	1.23 (0.94 to 1.61); 0.14
All of the above ( <i>n</i> = 1327)	1.32 (1.08 to 1.61); 0.007	1.22 (0.98 to 1.53); 0.079	1.06 (0.82 to 1.38); 0.661	1.33 (1.03 to 1.73); 0.028	1.25 (0.95 to 1.64); 0.108	1.05 (0.77 to 1.44); 0.757

<sup>a</sup> These analyses include only participants with data on mediator and, therefore, differ from those presented in *Chapter 3*. This allows direct comparison with the results of analyses including the mediator.

**Note**

As there are missing data on some mediators, the models without the mediator have been fitted in those with all data and in those without missing data on the mediator, so that they are comparable. Numbers used for different mediators are shown.



# Chapter 5 People's reactions to nicotine preloading

## Introduction

It is important to understand how people feel about medical interventions, particularly in the case of behavioural issues, such as smoking cessation. People believe that they have direct insight into behavioural issues and behaviour change by virtue of their past and current experience and, therefore, need to feel that the treatment they are receiving is appropriate or they will not take it.

## Methods

At week +1 (1 week after quit day) we asked participants to tell us their views on nicotine preloading. We did not ask similar questions to the control group. We used an open-ended question to ask participants for their views. However, to aid categorisation, the researcher collecting the data ticked one or more statements on a list of beliefs, attitudes and experiences that we had prepared and added to the case report form (CRF). This list was taken from qualitative interviews carried out in a previous study of preloading.<sup>17</sup> In addition, we asked participants to rate the helpfulness of preloading and whether or not they would recommend this strategy to another person trying to quit smoking.

## Results

The results are shown in *Table 13*. Overall, 87.2% found preloading to be helpful and 90.5% would recommend preloading to others. A mixed set of beliefs and experiences was reported, most of which reflected a generally positive view of the intervention.

## Discussion

Participants in this trial were generally happy to preload, reported it as a positive experience and would recommend the strategy to others.

This evaluation was only ever meant to give some overall sense of participants' reactions to preloading and clearly this lacks depth. In particular, we did not record or note the verbatim thoughts of participants and, for practical reasons, the research team interpreted what participants said and ticked one or more boxes that they felt captured their thoughts. This process is likely to be somewhat inaccurate, depending on the interpretation in the moment of the conversation, as well as not capturing the full extent of participants' thoughts. Nevertheless, in the absence of a full qualitative analysis, which was not planned nor funded, we believe that it reinforces data presented in *Chapters 1* and *2*. In particular, it suggests that preloading was well tolerated and that most participants perceived changes in their smoking as a result of preloading. In the preloading trial group, 65% of participants perceived the reduction in consumption and 35% felt that smoking was less enjoyable. These spontaneously reported effects reinforce what we captured quantitatively in the mediation analysis.

## Conclusion

These limited reflections on participants' feelings about preloading suggest that most participants found it helpful and that the large majority would recommend preloading.

**TABLE 13** Perceived helpfulness of the intervention in those randomised to preloading (of those contacted at +1 weeks)

Question	Number (%) of participants ( <i>N</i> = 727)
How helpful was the preloading intervention?	
Very helpful	488 (67.13)
Slightly helpful	146 (20.08)
Not very helpful	76 (10.45)
Missing	17 (2.34)
Would you recommend the preloading intervention to someone else?	
Yes	658 (92.8)
No	51 (7.02)
Unprompted responses to thoughts on preloading	Number (%) of participants mentioning response
Experience of smoking	
Did not feel urge to smoke	225 (30.95)
Reduced smoking to control nausea	41 (5.64)
Experienced nausea	87 (11.97)
Felt no effect of preloading	66 (9.08)
Lack of enjoyment when smoking	253 (34.80)
Smoking rate reduced	473 (65.06)
Smoking rate stayed the same	69 (9.49)
Smoking rate increased	16 (2.20)
Relief to stop smoking	107 (14.72)
Smoking intolerable	31 (4.26)
Ready to quit on quit day	254 (34.94)
Nausea aided quit attempt	50 (6.88)
Overall evaluation	
Helpful	495 (68.09)
Disappointed with preloading	38 (5.23)
Surprised asked to preload	93 (12.79)
Continued patch use until quit day	314 (43.19)
Discontinued patch use	64 (8.80)
Belief nicotine not harmful	4 (0.55)
Preloading is aversion therapy	31 (4.26)
Worried about preloading	62 (8.53)
Trusted guidance of research team	198 (27.24)
Preloading dangerous	14 (1.93)
Did not accept reason for preloading	19 (2.61)
Aware of previous warnings not to preload	41 (5.64)
Patch AEs	
Skin irritation	122 (16.78)
Sleep disturbance	125 (17.19)
Trouble getting patches to stay on	86 (11.83)

# Chapter 6 A within-trial cost-effectiveness analysis of nicotine preloading

## Introduction

The Preloading trial tested the effectiveness of a smoking cessation intervention. Such interventions typically have a very low cost per QALY and are among the most cost-effective in health care.<sup>48,49</sup> This is because continued smoking is dangerous but cessation is surprisingly effective at reducing the effects of many previous years of smoking.<sup>19,50</sup> As a consequence, one analysis suggests that, at any reasonable cost, improving the 6-month prolonged abstinence percentage by 1% should be cost-effective.<sup>20</sup> In this chapter, we examine the cost-effectiveness of preloading relative to the control condition.

## Methods

Cost-effectiveness analysis was conducted alongside the Preloading trial. Following NICE guidance, the analysis was performed from the NHS and Personal Social Services perspective, to reflect the NHS England decision-making framework, and on a ITT basis.<sup>51</sup> All costs were presented in 2014/15 Great British pounds (£).

### Costs

Total costs comprised the intervention costs, NHS Stop Smoking Services costs, AE costs, health resource use costs and medication costs.

#### Intervention costs

The intervention consisted of 4 weeks of NRT preloading (i.e. the use of NRT before quit day) and two sessions of behavioural support for the preloading group. For the control group, only two sessions of similar-intensity behavioural support were provided. For both arms, the participants were also given a four-page booklet containing information on smoking cessation pertinent to each group.

The NRT used in the intervention was a 21-mg patch every 24 hours provided by GlaxoSmithKline plc (GSK House, Middlesex, UK) at no cost, but, for the purposes of this analysis, we costed this as if it had been purchased by the NHS. The number of patches dispensed was extracted from the trial dispensing form. The cost of NRT for the intervention was calculated by multiplying the amount dispensed to the participants by the weighted average cost per patch. We assumed that the few participants with no record of dispensing had not been given any patches.

The behavioural support sessions were provided as part of the intervention at baseline and at -3 weeks. We included costs only for sessions that were attended so that not everyone incurred the cost of attending a second appointment. The behavioural support sessions were costed by adapting the existing cost template of NHS Stop Smoking Services according to the length of the sessions delivered in the trial.<sup>52</sup>

#### NHS Stop Smoking Services costs

After the intervention period, the participants were referred to NHS Stop Smoking Services for standard behavioural support and pharmacotherapies. NHS Stop Smoking Services were unable to supply participants' attendance data at the NHS Stop Smoking Services behavioural support sessions, so several assumptions were made to estimate the NHS Stop Smoking Services behavioural support cost. We assumed that people had received support if they had an appointment date and a service provider noted on the CRF. People who had no appointment date were assumed not to have attended. If provider data

were missing or an appointment was missing, participants' attendance at NHS Stop Smoking Services was considered missing. Based on the NHS Stop Smoking Services costing report,<sup>52</sup> the average number of sessions was multiplied by the inflated cost per session (£16) to calculate the cost of NHS Stop Smoking Services behavioural support sessions for those who attended.

Data on the use of post-quit date pharmacotherapy were collected through self-report at +1 week (1 week after quit date), with respondents reporting the type of medication or could record a response of 'none'. If no response was recorded, these data on pharmacotherapy were considered missing. The pharmacotherapies were costed using the weighted average cost per prescribed item for the form specified.<sup>53</sup> *Table 14* lists the weighted average cost per prescription item for each type of pharmacotherapy used in the trial. Because this information was collected only at one time point and no other details were recorded, only one prescription item in the analysis was taken into account.

### Adverse event costs

Adverse events resulting in hospitalisation were recorded according to the protocol.<sup>26</sup> For the purpose of costing, only the AEs that were determined to be at least possibly related to the intervention were included. The cost of an AE was estimated using the weighted average cost of all Healthcare Resource Groups (HRGs) related to the cause of the hospitalisation.

### Health resource use costs

Information on health resource use was collected through a self-reported questionnaire at baseline and 6 and 12 months' follow-up, covering the 6-month period prior to each time point. The health resources reported included help for smoking cessation outside of the study, hospital visits and use of primary and community services. If an entire section was left blank, the data were coded as missing. If some of the questions were answered and others were left blank, these blanks were assumed to represent nil use of those services. A set of national average costs were applied to the quantities reported by the participants (*Table 15*). For home visits from all professionals, travel time and expenses were not available. We assumed that the consultation time was the same as that in a general practice; 12 minutes of travel time was added in addition to account for the time spent by the professional travelling to the appointment. However, travel expenses or any other reimbursement were not included. Overheads were included when applicable.

**TABLE 14** Weighted average cost per prescription item for pharmacotherapies for smoking cessation

Type of pharmacotherapy	Cost per prescription item (£)
Gum	13
Patch	25
Lozenge	15
Inhaler	32
Mist (mouth spray)	25
Nasal spray	39
Strips	15
Microtab	17
Unidentified spray <sup>a</sup>	27
Acute NRT <sup>b</sup>	24
Varenicline	34
Bupropion	38

a Weighted average of nasal and mouth spray.

b All forms of NRT that were not specified, excluding patches.

Source: extracted from *Prescription Cost Analysis, England 2015*.<sup>53</sup>

**TABLE 15** National average costs of health resource use

Cost item	Unit cost (£)	Source(s)
Help for smoking cessation		
GP (per consultation)	36	Curtis and Burns <sup>54</sup>
Practice nurse (per consultation)	7	Curtis and Burns <sup>54</sup>
Pharmacist (per consultation)	10	Curtis and Burns <sup>54</sup>
NHS Stop Smoking Services cessation class (per session)	16	NICE <sup>52</sup> and Curtis and Burns <sup>54</sup>
NHS smoking helpline (per call)	6	Curtis and Burns <sup>54</sup> and Parrott <i>et al.</i> <sup>55</sup>
Prescription for nicotine patches (per item)	25	Prescribing and Medicines Team <sup>53</sup>
Prescription of acute NRT (per item)	24	Prescribing and Medicines Team <sup>53</sup>
Prescription of bupropion (per item)	38	Prescribing and Medicines Team <sup>53</sup>
Prescription of varenicline (per item)	34	Prescribing and Medicines Team <sup>53</sup>
Hospital visits		
Accident and emergency department (per visit)	132	DHSC <sup>56</sup>
Emergency ambulance (per use)	231	Curtis and Burns <sup>54</sup>
Outpatient (per attendance)	113	Curtis and Burns <sup>54</sup>
Day case (per case)	710	Curtis and Burns <sup>54</sup>
Non-emergency ambulance (per use)	180	DHSC <sup>56</sup>
Patient transport services (per journey)	35	Curtis and Burns <sup>54</sup> and DHSC <sup>56</sup>
Hospital inpatient stay (per night)	734	DHSC <sup>56</sup>
Primary and community services		
GP, in practice (per consultation)	37	Curtis and Burns <sup>54</sup>
Practice nurse, in practice (per consultation)	12	Curtis and Burns <sup>54</sup>
GP, home visit (per visit)	75	Curtis and Burns <sup>54</sup>
Practice/district nurse or health visitor, home visit (per visit)	26	Curtis and Burns <sup>54</sup>
Community psychiatric nurse, home visit (per visit)	27	Curtis and Burns <sup>54</sup>
Other health-care professionals, home visit (per visit)	29	DHSC <sup>56</sup>
NHS walk-in centre (per visit)	54	Curtis and Burns <sup>54</sup>

DHSC, Department of Health and Social Care.

## Medication costs

Medication data, excluding smoking cessation medication, were collected alongside the trial by self-report, including medication name, start date and end date. If participants were still taking the medication at the 12-month follow-up, an option of 'ongoing' was provided. Owing to the extreme complexity of the records, several simplifying assumptions were made. All medication usage was assigned to the corresponding period based on the following assumptions.

- All medicines recorded, unless they were specified as not prescribed, were assumed to be on prescription.
- Because the number of prescriptions and the amount taken were not recorded, it was assumed that one prescription would last a maximum of 1 month.
- If the start date was missing, there was no reasonable way to make assumptions about usage. The cost of the medicine was, therefore, considered missing.

- If the start date of a medicine was earlier than the quit date, we assumed that the patient had had one prescription of the medicine during the intervention period.
- If a person was recorded as using a medicine at the 12-month follow-up, the cost of this was calculated for the period starting from the recorded start date to the 12-month follow-up date. Depending on the start date, it was then allocated to the intervention period, 6 months post quit date and 12 months post quit date. Otherwise:
  - If the end date was missing, the cost of the medicine was assumed to be missing at 6 months post quit date and 12 months post quit date, because there was no reasonable way to make assumptions about usage.
  - If the end date was not missing, the cost was calculated according to the start and end dates and then allocated to the corresponding period.

As smoking cessation medications specifically were recorded, we excluded these from this medication list. It was also assumed that the participants with no medication recorded, but who had been followed up, had not taken any medication during the trial period.

The costs of medications were estimated by matching their generic name to that in the *Prescription Cost Analysis, England 2015*<sup>53</sup> and extracting a weighted average cost per item for that generic medicine. The form and dosage were used when available, but most records did not contain this information and so average costs were used.

### Outcome

The outcome used in the cost-effectiveness analysis was 6-month prolonged Russell Standard abstinence, which was the primary outcome of the trial. The 4-week quit rate and 12-month prolonged abstinence, measured according to the Russell Standard, were also used for the secondary analysis to provide comparison with national statistics. The methods of calculation were the same as for the primary statistical analysis.

### Analysis

#### Handling missing data

Following the Russell Standard, it was assumed that people who were missing from follow-up were smoking. Missing data for health resource use costs were handled by multiple imputation using chained equations as the primary method. A set of imputation models was specified, one for each variable with missing data. Each variable was then regressed on to all other variables, including completely recorded variables, and stratified by randomised group. Imputations were performed using predictive mean matching with 10 nearest neighbours for all cost variables on an aggregated level instead of individual usage. For continuous variables, imputations were performed using linear regression. Logistic regression was used for binary variables. Ordered logistic regression was used for categorical variables when the order was meaningful. The analysis models were fitted to each imputed data set separately and the results were estimated using Rubin's rules.<sup>57</sup>

#### Base-case analysis

Combining the costs and outcomes, a cost-effectiveness analysis was performed at 6 months post quit date, producing an incremental cost-effectiveness ratio (ICER) in the form of the incremental cost per additional 6-month abstinence, comparing the intervention group with the control group.

Similar analyses were performed at the 4-week and 12-month follow-ups. The ICER measuring cost per participant who quit for 4 weeks could be used to compare the results of the intervention with national statistics on NHS Stop Smoking Services.

## Sensitivity analyses

A non-parametric bootstrap resampling technique was adopted to assess the uncertainty around the primary analysis at 6 months post quit date. Bootstrapping has been proposed as an efficient approach for calculating the confidence limits for the ICER as its validity does not depend on any specific form of underlying distribution.<sup>58-61</sup> A cost-effectiveness acceptability curve (CEAC) was plotted based on the outcomes of the 5000 bootstrap iterations.<sup>62</sup>

A complete-case analysis was performed on the participants who had complete data on costs at both baseline and 6 months' follow-up, as well as on other baseline characteristics (age, gender, research centre, medical history). This was to examine the impact of multiple imputation.

## Results

### Costs

#### Intervention costs

The weighted average cost per patch for all 21-mg nicotine patches was £1.40, extracted from *Prescription Cost Analysis, England 2015*.<sup>53</sup> During the trial, some participants received lower-dosage (14-mg) patches at a later stage of the intervention period. The extracted weighted average cost per unit for all 14-mg nicotine patches was the same as for 21-mg patches. Hence, all nicotine patches dispensed were costed at the same price (£1.40), regardless of the dosage.

Behavioural support sessions, provided by the trial team at baseline and at -3 weeks, were estimated to last 10 minutes per session for both arms. Based on the NHS Stop Smoking Services' costing report,<sup>52</sup> a 30-minute individual session, delivered by a band 5 or 6 smoking cessation adviser, was estimated to cost £14.82. By inflating this cost to 2014/15 prices<sup>54</sup> and allocating the cost to a 10-minute session, we estimated the cost per session in the trial at £5.42.

Booklets used in the trial were printed in house and no precise costs were recorded. For the NHS, printing services are either included in overheads or outsourced to professional printing companies. The cost per booklet was estimated to be £0.15, based on an academic institution's print services price list.<sup>63</sup> However, the marginal cost of printing is likely to reduce as the amount of printing increases, so this estimate is probably higher than the cost that would be incurred by the NHS.

In total, the intervention cost amounted to £59 per participant in the intervention group and £11 per participant in the control group (*Table 16*).

**TABLE 16** Breakdown of the trial intervention cost in both trial groups

Cost item	Trial group, cost (£)	
	Intervention (n = 899)	Control (n = 893)
Booklet	0.15	0.15
Behavioural support (SD)	11 (1)	11 (1)
Nicotine patches (SD)	48 (14)	0 (2)
Total (SD)	59 (14)	11 (2)

## NHS Stop Smoking Services costs

Table 17 shows the utilisation and mean cost of standard NHS Stop Smoking Services behavioural support and pharmacotherapies before the quit date. Of the 813 responding participants in the intervention group, 98.4% indicated that they had received standard NHS Stop Smoking Services behavioural support. In the control group, 97.6% of 798 responding participants indicated that they had received standard NHS Stop Smoking Services behavioural support. A slightly higher proportion of responding participants in the intervention group than in the control group had taken some form of pharmacotherapy as a smoking cessation aid (83.8% of 717 vs. 80.3% of 722). Costs were similar between arms.

## Adverse event costs

During the trial, there was one SAE that was identified as possibly being related to the intervention, which occurred in the intervention group. The SAE was a heart attack that required hospitalisation, with the number of bed-days not recorded. The weighted average cost of all HRGs related to myocardial infarction (all complication and comorbidity scores) was included in the analysis to account for the adverse effect of the intervention. This cost was estimated to be £1469 per episode.<sup>56</sup>

## Health resource use costs

Health resource use was recorded in three sections of the CRF: (1) help for smoking cessation, (2) hospital visits and (3) primary and community services. The completeness of these three sections did not vary much at the same time point within arms, indicating that the missing values were probably the result of loss to follow-up. Tables 18–20 summarise the usage of each service and the mean cost of each cost item. The low mean usage and large SDs suggested the uneven use of services among participants in both arms. Although a small group of participants used these services frequently, the majority used them only a little. For instance, at baseline, the maximum number of visits to a GP in the previous 6 months was 26 in both arms. However, over half of the participants visited a GP only once or not at all (54% in the intervention group and 51% in the control group).

The unadjusted mean cost of services among the available cases did not appear to be different between arms at the same time point, except for hospital-related services. The consistently higher mean cost of hospital-related services in the control group was likely to be driven by the longer hospital stays.

## Medication costs

Based on the assumptions described earlier in *Methods*, over half of the participants were prescribed medication during the intervention period. Among the participants providing data, the majority were on medication at each time point (Table 21). The mean cost of medication did not differ much between arms.

**TABLE 17** Use of NHS Stop Smoking Services, including behavioural support and pharmacotherapies, by trial group

Standard services of NHS Stop Smoking Services	Trial group	
	Intervention	Control
Behavioural support, <i>n</i>	813	798
Participants receiving support, % ( <i>n</i> )	98.4 (800)	97.6 (779)
Mean cost (£) (SD)	94 (12)	94 (15)
Pharmacotherapies, <i>n</i>	717	722
Participants using pharmacotherapy, % ( <i>n</i> )	83.8 (601)	80.3 (580)
Mean cost (£) (SD)	30 (18)	30 (19)

**TABLE 18** Usage and cost of smoking cessation help during the 6-month period prior to baseline and the 6-month and 12-month follow-ups, by trial group

Help sources	Time point, mean number of uses or cost (SD)					
	Baseline		6 months		12 months	
	Intervention (n = 897)	Control (n = 889)	Intervention (n = 692)	Control (n = 700)	Intervention (n = 644)	Control (n = 643)
GP	0.08 (0.43)	0.10 (0.53)	0.06 (0.39)	0.09 (0.50)	0.06 (0.35)	0.10 (0.60)
Practice nurse	0.11 (0.75)	0.07 (0.42)	0.45 (1.42)	0.40 (1.31)	0.09 (0.65)	0.10 (0.70)
Pharmacist	0.07 (0.59)	0.09 (0.64)	0.14 (0.90)	0.20 (1.11)	0.09 (0.83)	0.06 (0.51)
NHS smoking cessation support	0.07 (0.57)	0.07 (0.49)	1.75 (3.11)	1.60 (2.78)	0.24 (1.42)	0.21 (1.24)
NHS smoking helpline	0.01 (0.09)	0.01 (0.09)	0.04 (0.34)	0.01 (0.09)	0.01 (0.12)	0.00 (0.04)
Prescription of nicotine patches	0.07 (0.45)	0.10 (0.54)	0.66 (1.60)	0.63 (1.68)	0.18 (1.08)	0.13 (0.80)
Prescription of acute forms of NRT	0.14 (0.72)	0.13 (0.71)	0.98 (1.98)	0.76 (1.88)	0.22 (1.17)	0.13 (0.83)
Prescription of bupropion	0.00 (0.03)	–	0.01 (0.18)	0.02 (0.23)	0.00 (0.08)	–
Prescription of varenicline	0.06 (0.42)	0.06 (0.40)	0.60 (1.48)	0.62 (1.43)	0.11 (0.66)	0.09 (0.54)
Cost (£) of smoking cessation help	13 (47)	14 (45)	96 (122)	89 (122)	21 (81)	18 (70)

**TABLE 19** Usage and cost of hospital-related services during the 6-month period prior to baseline and the 6-month and 12-month follow-ups, by trial group

Hospital visits	Time point, mean number of use per cost (SD)					
	Baseline		6 months		12 months	
	Intervention (n = 896)	Control (n = 890)	Intervention (n = 690)	Control (n = 703)	Intervention (n = 647)	Control (n = 649)
Accident and emergency visit	0.11 (0.39)	0.15 (0.47)	0.17 (0.54)	0.13 (0.42)	0.09 (0.34)	0.14 (0.63)
Emergency ambulance	0.04 (0.24)	0.07 (0.34)	0.06 (0.31)	0.05 (0.28)	0.03 (0.19)	0.08 (0.54)
Outpatient	0.77 (2.84)	0.92 (3.91)	0.75 (2.44)	0.80 (4.46)	0.67 (2.42)	1.09 (4.69)
Day case	0.11 (1.02)	0.09 (0.40)	0.08 (0.51)	0.10 (0.43)	0.10 (0.44)	0.11 (0.61)
Non-emergency ambulance	0.00 (0.05)	0.01 (0.16)	0.01 (0.15)	0.00 (0.08)	0.01 (0.08)	0.02 (0.27)
Patient transport services	0.00 (0.09)	0.10 (2.62)	0.01 (0.09)	0.16 (3.63)	0.01 (0.19)	0.11 (2.59)
Hospital stay (nights)	0.23 (1.74)	0.38 (2.58)	0.36 (3.64)	0.47 (3.32)	0.18 (1.37)	0.65 (7.40)
Cost (£) of hospital-related services	359 (1645)	489 (2097)	446 (2782)	544 (2700)	296 (1170)	722 (5570)

**TABLE 20** Usage and cost of primary and community services during the 6-month period prior to baseline and the 6-month and 12-month follow-ups, by trial group

Services	Trial group, mean number of use per cost (SD)					
	Baseline		6 months		12 months	
	Intervention (n = 894)	Control (n = 891)	Intervention (n = 689)	Control (n = 701)	Intervention (n = 645)	Control (n = 647)
GP (in practice)	2.18 (2.95)	2.37 (3.08)	1.99 (2.77)	2.06 (3.34)	1.95 (3.86)	2.34 (3.88)
Practice nurse (in practice)	0.86 (2.45)	0.84 (1.54)	0.98 (3.29)	0.93 (2.50)	0.69 (1.95)	0.86 (2.60)
GP (home visit)	0.01 (0.13)	0.03 (0.40)	0.01 (0.16)	0.02 (0.19)	0.01 (0.08)	0.02 (0.31)
Practice/district nurse or health visitor (home visit)	0.02 (0.37)	0.14 (2.03)	0.02 (0.61)	0.20 (1.52)	0.11 (2.49)	0.29 (5.23)
Community psychiatric nurse (home visit)	0.02 (0.33)	0.07 (1.15)	0.02 (0.35)	0.03 (0.58)	0.08 (1.24)	0.01 (0.17)
Other health-care professionals (home visit)	0.09 (1.22)	0.10 (1.26)	0.05 (0.67)	0.07 (1.18)	0.02 (0.22)	0.05 (0.52)
NHS walk-in centre	0.08 (0.40)	0.09 (0.45)	0.09 (0.36)	0.08 (0.33)	0.08 (0.31)	0.11 (0.72)
Cost (£) of primary and community services	100 (134)	113 (164)	94 (130)	101 (154)	91 (204)	114 (221)

**TABLE 21** Proportion of participants on medication and mean cost of medication during the 4-week intervention period and months 1–6 and 7–12 post quit date, by trial group

Variable	Time period					
	Within intervention period (4 weeks)		Months 1–6		Months 7–12	
	Intervention (N = 855)	Control (N = 835)	Intervention (N = 611)	Control (N = 570)	Intervention (N = 594)	Control (N = 565)
Participants taking medication, % (n)	62.3 (533)	66.6 (556)	56.5 (345)	55.3 (315)	54.2 (322)	52.4 (296)
Mean cost (£) of medication (SD)	30 (142)	35 (111)	140 (404)			

## Analysis

### Multiple imputation

Table 22 shows the missing data percentages for the variables included in the imputation model. Although the primary outcome time point was 6 months, in order to provide as much information as possible some baseline covariates and the 12-month variables are also included. As the highest percentage of missing data was 35.32%, the number of imputations was set to be 35.<sup>64</sup>

### Base-case analysis

At 6 months post quit date, the intervention group had a higher proportion of participants remaining abstinent than the control group (17.5% vs. 14.4%). The difference between arms was 3.1 percentage points (95% CI –0.3 to 6.4 percentage points). The total costs at 6 months post quit date included the intervention costs, NHS smoking cessation support during the intervention period, health resource use costs and medication costs in the 6 months after the quit date. The breakdown of the results is shown in Table 23. Although the unadjusted mean total costs in the intervention group were lower than in the control group, after adjusting for health resource use costs at baseline, age, gender, research centre and

**TABLE 22** Number and percentage of missing data for variables included in the multiple imputation (total number of sample  $N = 1792$ )

Variable	Number of missing values, $n$	Proportion of missing values, %
Gender	2	0.11
Age	12	0.67
Research centre	0	0
Medical condition at baseline	4	0.22
Longest abstinence in days	0	0
Strength of urge to smoke at baseline	8	0.45
Cigarettes smoked per day at baseline	0	0
Cigarettes smoked per day at 6 months	460	25.67
Cigarettes smoked per day at 12 months	583	32.53
Cost of standard NHS Stop Smoking Services behavioural support	181	10.10
Cost of standard NHS Stop Smoking Services pharmacotherapy	353	19.70
Cost of help for smoking cessation at baseline	6	0.33
Cost of help for smoking cessation at 6 months	400	22.32
Cost of help for smoking cessation at 12 months	505	28.18
Cost of hospital-related services at baseline	6	0.33
Cost of hospital-related services at 6 months	399	22.27
Cost of hospital-related services at 12 months	496	27.68
Cost of primary and community services at baseline	7	0.39
Cost of primary and community services at 6 months	402	22.43
Cost of primary and community services at 12 months	500	27.90
Cost of intervention	0	0
Cost of medication within intervention period	102	5.69
Cost of medication in months 1–6 post quit date	611	34.10
Cost of medication in months 7–12 post quit date	633	35.32
Smoking status according to Russell Standard at 4 weeks post quit date	0	0
Smoking status according to Russell Standard at 6 months post quit date	0	0
Smoking status according to Russell Standard at 12 months post quit date	0	0
Experience of SAEs resulting in hospitalisation	0	0
Cost of possibly related SAEs	0	0

**TABLE 23** Summary of results based on the imputed data set

Variable	Trial group	
	Intervention (n = 899)	Control (n = 893)
Quit rate at 4 weeks post quit date according to Russell Standard, mean (95% CI), %	36.3 (33.1 to 39.4)	31.9 (28.9 to 35.0)
Difference in quit rate at 4 weeks post quit date according to Russell Standard, mean (95% CI), percentage points	4.4 (-0.1 to 8.6)	
Abstinence rate at 6 months post quit date according to Russell Standard, mean (95% CI), %	17.5 (15.0 to 20.0)	14.4 (12.1 to 16.8)
Difference in abstinence rate at 6 months post quit date, mean (95% CI), percentage points	3.1 (-0.3 to 6.4)	
Abstinence rate at 12 months post quit date, mean (95% CI), %	14.0 (11.7 to 16.3)	11.3 (9.2 to 13.4)
Difference in abstinence rate at 12 months post quit date, mean (95% CI), percentage points	2.7 (-0.3 to 5.8)	
Health resource use cost in the 6 months prior to baseline, mean (SE), £	471 (56)	615 (72)
Intervention cost (£), mean (SE)	58 (0)	11 (0)
NHS Stop Smoking Services cost (£) during the intervention period, mean (SE)	124 (1)	122 (1)
Smoking cessation cost (£) before quit date, mean (SE)	182 (1)	133 (1)
Difference in smoking cessation cost (£) before quit date, adjusted for age, gender, research centre and urge to smoke at baseline, mean (95% CI)	49 (47 to 51)	
Health resource use cost (£) in the 6 months post quit date, mean (SE)	640 (104)	770 (106)
Medication cost (£) in the 6 months post quit date, mean (SE)	154 (14)	186 (19)
Cost (£) of possibly related SAEs, mean (SE)	2 (2)	0 (0)
Total costs (£) at 6 months' follow-up, mean (SE)	978 (105)	1090 (110)
Adjusted difference in total costs (£) at 6 months, <sup>a</sup> mean (95% CI)	4 (-188 to 222)	
Health resource use cost (£) from 6 months to 12 months post quit date, mean (SE)	414 (46)	804 (186)
Medication cost (£) from 6 months to 12 months post quit date, mean (SE)	165 (22)	188 (22)
Total costs (£) at 12 months' follow-up, mean (SE)	1557 (125)	2082 (231)
Adjusted difference in total costs (£) at 12 months, <sup>a</sup> mean (95% CI)	-233 (-747 to 42)	
ICER (£) at 4 weeks post quit date, mean (95% CI)	1114 (-2259 to 7439) per additional person who quits	
ICER (£) at 6 months post quit date, mean (95% CI)	129 (-16,527 to 17,782) per additional abstinence	
ICER (£) at 12 months post quit date	Intervention dominates control (preloading being more effective and less costly) (-95,487 to 37,133)	

SE, standard error.

<sup>a</sup> Adjusted for baseline health-care services cost, age, gender, research centre and presence of medical conditions.

**Note**

Costs shown as per-person costs.


presence of medical conditions at baseline, the mean total costs were £4 higher in the intervention group than in the control group (95% CI –£188 to £222). Combining the adjusted difference in mean total costs and difference in abstinence rate at 6 months post quit date, the ICER was calculated as £129 per additional 6-month abstinence. The bootstrapped CI for both the adjusted difference in mean total costs and the ICER showed a wide uncertainty.

In the national statistics for the NHS Stop Smoking Services,<sup>65</sup> only the smoking cessation costs per person who quit were reported, including for behavioural support and pharmacotherapy if applicable. For the purpose of comparison, a smoking cessation cost was also calculated by adding the cost of the nicotine patches and/or the behavioural support cost to the NHS Stop Smoking Services cost incurred before the quit date. As expected, owing to the additional cost of the intervention, the intervention group had a higher mean cost than the control group (£182 vs. £133). The cost per participant who was proven to have quit at 4 weeks was £501 in the intervention group and £417 in the control group. The adjusted difference was almost the same as the unadjusted difference, with the intervention group costing £49 more than the control group. The incremental cost per additional participant who was proven to have quit at 4 weeks was, therefore, £1114.

At the 12-month follow-up, the difference between total costs was greater than at the 6-month follow-up, with the costs in the intervention group being much lower than those in the control group (£1557 vs. £2082). The intervention group had lower total costs, by £233, even after adjusting for baseline health resource use costs and other covariates. As abstinence was higher in the intervention group than in the control group (14.0% vs. 11.3%), the results demonstrated a dominance condition, in which the intervention group was less costly and more effective than the control group. Similar to the results at the 6-month follow-up, the bootstrapped CIs showed a wide range of uncertainty.

### Sensitivity analyses

To explore the uncertainty surrounding the results, 5000 bootstrap iterations were used to plot the cost-effectiveness plane and CEAC. *Figure 6* presents the cost-effectiveness plane, which shows a cluster of ICERs scattering across all four quadrants. Although the overall majority fell to the right side of the zero incremental abstinence rate line, indicating a more effective intervention, over half of those concentrated in the north-east quadrant, indicating a more expensive intervention.



**FIGURE 6** Cost-effectiveness plane of incremental costs and incremental abstinence rate at 6 months post quit date, comparing the preloading group with the control group.


Figure 7 presents the CEAC to illustrate the bootstrapping iterations. The CEAC shows that the probability of preloading being cost-effective, compared with the control group, increased with the increase in costs (i.e. uncertainty of the results reduced). When the costs reached £3600, the probability of preloading being cost-effective was approximately 80%. For the probability to reach 90%, another £3300 would be required. Soon after this point, the curve became flat, stabilising at about 96%.

### Complete-case analysis

To assess the impact of multiple imputation on the results, an analysis of the outcomes at the primary outcome time point (6 months post quit date) was conducted on complete cases only. In this analysis, only the participants who had complete data on costs both at baseline and at 6 months' follow-up, as well as other baseline covariates, were included. Therefore, 462 participants in the intervention group and 426 participants in the control group were not included in the complete-case analysis.

Among the complete cases, the 6-month prolonged abstinence rate was 25.3% in the intervention group and 23.0% in the control group. The difference between arms was slightly smaller than in the imputed data set (2.3 vs. 3.1 percentage points). Although the health resource use cost in the 6 months prior to baseline was similar to that in the imputed data set, the health resource use cost in the 6 months post quit date was much lower than in the imputed data set. In the intervention group, it was £507 among the complete cases, compared with £640 in the imputed data set. The difference was more prominent in the control group, with a cost of £458 among the complete cases and £770 in the imputed data set. This led to a reverse of the relative position. In the imputed data set, the health resource use cost in the 6 months post quit date was higher in the control group, whereas among the complete cases it was higher in the intervention group. The only SAE was excluded in the complete case analysis because of missing data following that event. There was, therefore, no cost for the SAE incurred among complete cases. As a result, the adjusted difference in total costs at 6 months' follow-up was estimated as £138, which is larger than in the imputed data set. The ICER was calculated as £6000 per additional 6-month prolonged abstinence, with a much wider CI (Table 24).

As the smoking cessation costs before quit date did not differ much between the base case and complete cases, a comparison was made of health resource use costs. In addition, the health resource use cost among the available cases (i.e. the cost variable at the single time point is not missing) was also provided for reference (Table 25). It is apparent that the mean cost drawn from imputed data is closer to that of the available cases. This suggests that the complete-case analysis was likely to have underestimated the mean health resource use cost because of the requirement of completeness on multiple variables, especially for the control group at 6 months' follow-up.



**FIGURE 7** Cost-effectiveness acceptability curve of the probability of preloading being cost-effective compared with the control group.

**TABLE 24** Summary of results based on complete cases only

Variable	Trial group	
	Intervention (N = 462)	Control (N = 426)
Number of 6-month prolonged abstinence cases	117	98
Abstinence rate (%) at 6 months post quit date, mean (95% CI)	25.3 (21.4 to 29.5)	23.0 (19.1 to 27.3)
Difference in abstinence rate (percentage points) at 6 months post quit date, mean (95% CI)	2.3 (-3.3 to 8.0)	
Health resource use cost (£) in the 6 months prior to baseline, mean (SD)	454 (1486)	627 (2551)
Intervention cost (£), mean (SD)	59 (12)	11 (1)
NHS Stop Smoking Services cost (£) during the intervention period, mean (SD)	126 (21)	124 (23)
Health resource use cost (£) in the 6 months post quit date, mean (SD)	507 (1432)	458 (1430)
Medication cost (£) in the 6 months post quit date, mean (SD)	153 (445)	165 (608)
Cost (£) of possibly related SAEs	–	–
Total costs (£) at 6 months' follow-up, mean (SD)	844 (1548)	758 (1641)
Difference in total costs (£), adjusted for baseline health-care services cost, age, gender, research centre and presence of medical conditions at baseline, mean (95% CI)	138 (-13 to 323)	
ICER (£) at 6 months follow-up, mean (95% CI)	6000 (-2440 to 1,276,267) per additional 6-month prolonged abstinence	

**TABLE 25** Comparison of mean health resource use costs between the base-case (imputed) data, complete cases and available cases

Analysis	n	Intervention (£)	n	Control (£)
6 months prior to baseline				
Complete	462	454	426	627
Available	892	471	886	617
Imputed	899	471	893	615
6 months post quit date				
Complete	462	507	426	458
Available	688	637	696	738
Imputed	899	640	893	770



# Chapter 7 The modelled cost-effectiveness of nicotine preloading

## Introduction

The objective of the current analysis was to compare the long-term cost-effectiveness of pharmacotherapy for 4 weeks prior to setting a smoking quit date with no pharmacotherapy before the quit date through extrapolation of the results of the clinical trial. The analysis was conducted using a modified version of the European-study on Quantifying Utility of Investment in Protection from Tobacco (EQUIPT) return on investment (ROI) tool.<sup>66</sup> At the core of the EQUIPT ROI tool is a validated economic model, which forecasts the short- and long-term outcomes for smokers who cease smoking within the next calendar year or who continue smoking.<sup>67</sup> The model allows the estimation of the impact of smoking cessation interventions based on these outcomes. As detailed below, the economic model has been modified slightly to allow the estimation of the comparative costs and effectiveness of the interventions within the current clinical trial, which compared the use of nicotine patches for 4 weeks prior to an attempt to quit smoking with no use of pharmacotherapy prior to the quit attempt.

## Methods

### Clinical trial

The clinical trial compared treatment with nicotine patches for 4 weeks prior to a planned quit date (intervention) with no pre-treatment prior to a planned quit date (control). Both the intervention and control groups also received standard behavioural counselling prior to the quit date. Biochemically validated 12-month abstinence was achieved by 14.0% of the intervention group and 11.3% of the control group. In the primary analysis, this gave an unadjusted OR of 1.24 (95% CI 0.97 to 1.58;  $p = 0.086$ ) and a RD of 2.71 (95% CI  $-0.37$  to 5.78;  $p = 0.085$ ). As expected, there was an imbalance between arms in the frequency of use of varenicline for post-cessation medication; adjustment for this gave an OR of 1.30 (95% CI 1.02 to 1.66;  $p = 0.036$ ) and a RD of 3.31 (95% CI 0.22 to 6.39;  $p = 0.036$ ) between the intervention and control groups.

### Economic model

A Markov model (EQUIPTMOD), developed as part of EQUIPT, was used to estimate the long-term costs and effects of using NRT pre-treatment compared with no pre-treatment in a hypothetical cohort of smokers with the same age and sex distribution as in the trial, who make a one-time attempt at quitting smoking. EQUIPTMOD allows the determination of the impact of either continuing or stopping smoking on both morbidity and mortality outcomes and costs. In this chapter, we estimate the lifetime costs, QALYs and life-years associated with NRT pre-treatment compared with no pre-treatment.

## Methods

### Design of the model

There are three primary states within the model: (1) current smoker, (2) former smoker and (3) dead (*Figure 8*).

With each 1-year cycle, the cohort is subjected to a set of transition probabilities that allow them to either stay within their current state or move to one of the other two states. Death is an absorbing state, meaning that those who enter this state remain within the state. We ran the model until participants reached the age of 100 years or died.




FIGURE 8 Model schematic.

The model is replicated for different population cohorts based on the age and sex distribution of patients within the clinical trial. To obtain trial population-level estimates, these cohort-level estimates are weighted by the percentage of the trial population falling into each age and sex cohort.

To estimate the impact of the intervention on costs and smoking-related outcomes, two separate models were created: one that simulates a cohort of smokers who quit in the first year and one that simulates a cohort of smokers who do not quit in the first year. The results of the two models are combined by weighting the outputs by the trial population and the effectiveness of the intervention and the control.

### Transition probabilities

Transition probabilities incorporated within the model include:

- the probability of quitting smoking in the first cycle (year) based on the effectiveness of the intervention and the control within the trial
- the age- and sex-specific annual probability of mortality associated with current smoking and being a former smoker
- the probability of smoking cessation and relapse over the long term in current and former smokers.

The probabilities of smokers successfully quitting in the first year after the intervention were based on the biochemically validated 12-month abstinence rates from the clinical trial. Based on this measure, 14.0% of those in the intervention group and 11.3% of those in the control group were abstinent at 12 months. In the base-case analysis, the 12-month abstinence rate was assumed to be predictive of long-term cessation. This was tested within sensitivity analyses through applying a rate of relapse of 30% in the second year after the intervention.<sup>68</sup> Smokers who did not quit smoking, or who relapsed, were subjected to the same background quit rate in all subsequent years, which is reflective of the balance of quitting and relapsing over a lifetime.<sup>69</sup>

The probability of death by age, sex and smoking status was calculated using the attributable risk of death based on smoking status. The following was required for this calculation: age- and sex-specific probabilities of death in the general population; the age- and sex-specific prevalences of smoking status (current, former or never smokers); and the RR of death by smoking status. Mortality rates were based on actuarial life tables and the age- and sex-specific prevalences of smoking were derived from the survey data.<sup>70,71</sup> The RRs of death for former and current smokers compared with never smokers were derived from published data<sup>19</sup> (see *Appendix 1, Table 29*).

Long-term cessation and relapse were modelled through the application of an underlying quit rate, which applies to all age- and sex-specific cohorts after the first year. This was estimated at a value of 2% per annum and represents the balance between those quitting smoking each year and those who start smoking or relapse.<sup>69</sup>

### Prevalence of smoking-related diseases

The smoking-related population attributable fraction relating to current and former smokers for smoking-related diseases was estimated based on epidemiological data. The model estimates, for each cycle, the prevalence of smoking-related diseases based on the proportion of the cohort who are either current smokers or former smokers.

Four diseases, lung cancer, coronary heart disease (CHD), chronic obstructive pulmonary disease (COPD) and stroke, were found to be responsible for the majority of the smoking-related disease burden and were, therefore, incorporated within the model.<sup>72,73</sup> The number of cases each year of these diseases was derived through calculation of the attributable fraction based on the prevalence of smoking-related diseases in England, the prevalence of smoking status in England (current, former or never smokers) and the relative effect of smoking on the prevalence of each disease<sup>49,74–78</sup> (see *Appendix 1, Tables 30–36*).

### Costs

Within the model, costs comprised both the smoking cessation costs of the intervention and control arms of the clinical trial and the health-care costs associated with smoking-related diseases.

Prior to the planned quit date, both the control group and the intervention group received standard behavioural counselling. In addition, those in the intervention group also received 4 weeks of NRT. Based on the within-trial analysis, this resulted in a mean cost per person of £58 [standard error (SE) £0] in the intervention group and £11 (SE £0) in the control group. Furthermore, prior to the quit date, both treatment arms received NHS Stop Smoking Services, with a mean cost per person of £124 (SE £1) in the intervention group and £122 (SE £1) in the control group. The cost of the NHS Stop Smoking Services accessed over the 12 months after the quit date was also included in the analysis: £133 (SE £6) for the intervention group and £103 (SE £5) for the control group, based on the within-trial analysis. This resulted in total costs overall for smoking cessation of £295 (SE £6) for the intervention group and £236 (SE £6) for the control group.

The annual costs for an individual with each of the diseases were estimated based on a systematic literature review. Costs relate to prevalent cases of disease. The annual cost for COPD is £1042.57, for lung cancer is £7002.65, for CHD is £1247.79 and for stroke is £5886.66<sup>79–82</sup> (see *Appendix 1, Table 36*).

All costs were inflated to the year 2016 using the Hospital and Community Health Services Index<sup>83</sup> (see *Appendix 1, Table 37*).

### Utility values

Utility decrements associated with smoking-related diseases were derived from the US Medical Expenditure Panel Survey.<sup>84</sup> Utility values based on current smoking status (current or former smoker) were derived from the Health Survey for England adjusted for relevant covariates including disease prevalence.<sup>85</sup> The EuroQol-5 Dimensions, a validated instrument for measuring health-related quality of life, was used for both sets of utility values and UK tariffs were used for calculating utility scores<sup>86</sup> (see *Appendix 1, Table 38*).

### Outcomes

The costs, life-years and QALYs associated with both the intervention and the control groups were estimated over the lifetime of the cohort. In the base case, both costs and effects were discounted at a rate of 3.5% per annum as per NICE guidance.<sup>87</sup> A 1.5% per annum discount rate for costs and outcomes was tested in the sensitivity analyses. The analysis was conducted from the perspective of the NHS.

The incremental cost–utility ratio, expressed as the incremental cost per QALY gained, was reported to assess the cost-effectiveness of the intervention group compared with the control group.

### Key assumptions

As is the case with all models, a number of assumptions were required to estimate the economic impact of tobacco-control interventions; these have been detailed in a previous publication<sup>67</sup> and are summarised in *Box 1*.

**BOX 1** Assumptions in the EQUIPTMOD model

The population-based mortality rates are adjusted using the RRs of death in smokers and former smokers, which are derived from the literature.<sup>19</sup> Although the reference is dated and absolute mortality may have changed, the assumption that the relative effect was likely to be maintained, and the choice of study, was justified based on the prospective nature of the study, the sample size ( $n = 34,439$ ) and the years of follow-up (40 years).

The current model does not explicitly adjust for the time since quitting because of the absence of distributional data regarding time since quitting; duration of smoking; and the risk of smoking-related disease and mortality. Rather, an average risk of smoking-related disease and mortality is applied to former smokers. As this is a cohort rather than an individual patient simulation model, the impact of this assumption may be limited.

Given the lack of data to support an alternative assumption, the prevalence of each disease is assumed to be independent of the prevalence of other diseases. Also, the model assumes that, in the case of multiple diseases, the disutility associated with the disease with the greatest disutility is applied. This is a conservative approach in that it provides a lesser estimate of the QALY gains from smoking cessation than either a multiplicative or an additive approach.

For all diseases, in people aged  $< 35$  years, the risk of smoking-related disease was assumed to be equal across smoking groups. This was deemed to be the most appropriate assumption given that data regarding the differential rate of all diseases by smoking status were not available for this age group. This assumption is both conservative and, given the very low prevalence of disease in this group, unlikely to have a significant impact on the results.

The underlying quit rate, which applies to all cohorts after the first year, represents the balance between those who quit smoking each year and those who start smoking or relapse. This assumption is supported by a meta-analysis, which showed that there was no difference in relapse rates after 12 months, regardless of whether the patients used or did not use an intervention to quit smoking.<sup>68</sup>

**Handling uncertainty**

The effect of parameter uncertainty on the calculated outcomes was assessed through probabilistic sensitivity analyses involving Monte Carlo simulation.<sup>88</sup> Standard probability distributions were included for the natural history parameters, RRs and ORs, costs and utilities. Beta distributions were used for transition probabilities and utility values by smoking status, normal distributions were used for utility decrements due to disease, log-normal distributions were used for RRs and ORs and gamma distributions were used for costs. Population-level data were assumed to be fixed. Distribution parameters can be found in *Appendix 1, Tables 35–38*. The background quit rate was parameterised using a beta distribution. As distributional data were not available we assumed a conservative sample size of 50 for the parameterisation.

A set of 5000 outcome estimates were obtained, with the results displayed using a scatterplot of incremental costs versus QALYs and a CEAC that graphically presents the probability that the intervention is cost-effective as a function of the willingness of decision-makers to pay for an outcome (QALY).<sup>88</sup>

**Results****Base-case analysis**

The total lifetime costs within the intervention group were £13,111 and within the control group were £13,177 (a difference of £66). The costs associated with smoking cessation, which included both behavioural and pharmacological interventions, were higher in the intervention group (£295) than in the control group (£236; a difference of £59). Health-care costs associated with smoking-related diseases over a lifetime, however, were lower in the intervention group (£12,816) than in the control group (£12,941; a difference of £125) (*Table 26*).

**TABLE 26** Cost-effectiveness results for the base-case analysis comparing the intervention group with the control group

Variable	Trial group		Difference (intervention – control)
	Intervention	Control	
Costs (£) per smoker			
Smoking cessation costs	295	236	59
Health-care costs	12,816	12,941	–125
Total costs	13,111	13,177	–66
Effectiveness			
Quitters per 1000 smokers	139	112	27
Life-years per smoker	17.977	17.957	0.020
QALYs per smoker	14.300	14.267	0.033
Cost-effectiveness			
ICER	Intervention is dominant		

A greater number of individuals quit smoking in the intervention group than in the control group (139 per 1000 smokers vs. 112 per 1000 smokers, a difference of 27 individuals). The greater number of individuals quitting smoking in the intervention group resulted in more discounted life-years lived in the intervention group than in the control group (17.977 life-years vs. 17.957 life-years) and more QALYs (14.300 vs. 14.267). The intervention is dominant over the control as the intervention was both more effective, producing both more QALYs and more life-years, and less costly.

### Additional analysis

An analysis was conducted adjusting for an imbalance in the use of varenicline post quit date within the two groups (Table 27). The adjusted RD for cessation at 12 months was 3.31 (95% CI 0.22 to 6.39), compared with a RD of 2.71 (95% CI –0.37 to 5.78) for the base case. The adjusted difference in smoking cessation costs was £63 (95% CI £52 to £78), compared with £59 (95% CI £44 to £74) in the base case.

After adjustment for varenicline imbalance, there were 33 more people who quit in the intervention group than in the control group; this is six more people who quit than in the unadjusted analysis. The difference in total costs was also greater, with the intervention costs being £90 lower than the control costs.

**TABLE 27** Cost-effectiveness results comparing the intervention group with the control group after adjustment for varenicline imbalance

Variable	Trial group		Difference (intervention – control)
	Intervention	Control	
Costs (£) per smoker			
Smoking cessation costs	299	236	63
Health-care costs	12,787	12,941	–153
Total costs	13,086	13,177	–90
Effectiveness			
Quitters per 1000 smokers	145	112	33
Life-years per smoker	17.982	17.957	0.025
QALYs per smoker	14.307	14.267	0.040
Cost-effectiveness			
ICER	Intervention is dominant		

The intervention also resulted in more QALYs (a difference of 0.040) and life-years (a difference of 0.025) than the control. As in the base-case analysis, the intervention is dominant over the control as it is both less costly and more effective.

**Deterministic sensitivity analysis**

The cost-effectiveness results were robust to an alternative discount rate of 1.5% per annum for costs and outcomes, with the intervention remaining cost saving (£19,273 for the intervention group vs. £19,384 for the control group) and resulting in more QALYs (19.091 for the intervention group vs. 19.043 for the control group) (*Table 28*).


With a relapse rate of 30% after the first year, the cost difference between the intervention group and the control group was reduced, as were the QALY and life-year differences. However, the intervention remained less costly and more effective than the control and is, therefore, still dominant over the control (*Table 28*).

**Probabilistic sensitivity analysis**


As can be seen from the scatterplot of incremental costs compared with incremental QALYs (*Figure 9*), the majority of the estimates (80%) are within the lower right quadrant, indicating that the intervention is dominant over the control. As is evident from the CEAC (*Figure 10*), at a willingness-to-pay (WTP) threshold of £20,000 per QALY there is a 94% probability that the intervention is cost-effective. There is a 95% probability that the intervention is cost-effective at a WTP threshold of £30,000 per QALY.

**TABLE 28** Results of the deterministic sensitivity analyses

Scenario	Trial group	Costs (£)	QALYs	Incremental costs (£)	Incremental QALYs	ICER
1.5% discount rate	Control	19,385	19.043	Reference	Reference	
	Intervention	19,273	19.091	-111.72	0.049	Intervention is dominant
30% relapse	Control	13,333	14.226	Reference	Reference	
	Intervention	13,303	14.250	-29.02	0.023	Intervention is dominant




**FIGURE 9** Scatterplot of incremental costs vs. incremental QALYs for the intervention group vs. the control group.



**FIGURE 10** Cost-effectiveness acceptability curve for the probability that the intervention is cost-effective with a relapse rate of 0% after year 1.

If 30% of smokers who quit in the first year are assumed to relapse, there is a 93% probability that the intervention is cost-effective at a WTP threshold of £20,000 per QALY and a 94% probability that the intervention is cost-effective at a WTP threshold of £30,000 per QALY (Figure 11).



**FIGURE 11** Cost-effectiveness acceptability curve for the probability that the intervention is cost-effective with a relapse rate of 30% after year 1.



## Chapter 8 Discussion and conclusions

### Effectiveness of preloading

#### Summary of main findings

In this pragmatic open-label trial testing the effect of nicotine preloading for 4 weeks prior to a quit day, there was no evidence that preloading increased the proportion of people achieving smoking abstinence. Adherence to the nicotine patch used for preloading was good, with the large majority using treatment as prescribed. Preloading was tested in a clinical setting where smokers could opt to use either NRT or non-nicotine pharmacotherapies for continued cessation treatment after preloading had ended. Preloading encouraged the use of NRT for cessation treatment or deterred the use of varenicline as post-quit day medication. Varenicline is more effective than other medications, so in a planned analysis we adjusted for its use after quit day. This led to clear evidence that preloading itself did increase the likelihood of achieving abstinence. There was no evidence that use of varenicline undermined the effect of preloading. Most people continued with the preloading treatment, implying that it is well tolerated. Around 1 in 20 people suffered AEs of moderate severity and above as a consequence of the treatment, principally nausea. There was no evidence of an excess of SAEs.

#### Public involvement

The study was run under the auspices of the UK Centre for Tobacco and Alcohol Studies (UKCTAS).<sup>89</sup> UKCTAS has a standing panel of public members who guide the research programme, helping select topics that matter to people who smoke and shaping the way that research is carried out. Before the study started, we discussed the study and the methods with the panel. One member of the panel joined the trial steering committee that provided oversight to the trial.

In the early days of the study, we encountered a much slower rate of recruitment than we had anticipated. We used the method of recruitment that we had employed in three of the four centres in previous trials.<sup>17,32,36</sup> In the past, around 5–10% of people who received an invitation letter from their GP had enrolled in our studies. As in this trial, in the previous trials the invitation letter invited people wanting to stop smoking to seek support, rather than emphasising the novel treatment. We know from discussions with previous participants that it is the opportunity to receive support to quit that is the main draw for potential participants. In the Preloading trial, only around 1% of people who were invited enrolled in the trial. We asked GPs to write to batches of participants, 100 at a time, to ensure that we had a reasonable number of initial appointments to fill the clinic but did not generate a waiting list. However, initial recruitment was much slower than anticipated and, therefore, accrual into the study was much slower than planned.

As a consequence, we consulted with eight members of the UKCTAS panel to review our recruitment material and two other members of the public from the Clinical Research Network. They commented on the documents and answered questions about our material. Our recruitment material in the Preloading trial, as in previous trials, was very brief, which is probably important in attracting people who smoke. Consequently, only a few minor amendments were suggested, which we implemented after approval from the ethics committee. However, the response to the recruitment letter remained as poor as it had been. In fact, the Preloading trial coincided with a downturn in interest in NHS Stop Smoking Services and a rise in the use of e-cigarettes; it is thought that these two factors may be linked. We enhanced our recruitment rate by sending more letters per practice in larger batches and using Docmail® (CFH Docmail Ltd, Radstock, UK) to send the invitations, easing the burden on general practices. We also added other means of recruitment including text messages from practices and advertising.

At the time of writing, the results of this trial have only just become available. We plan to return to the UKCTAS panel with the results and discuss them with the members. To help guide implementation into policy and practice, it will be important to obtain the public's views on what the results mean and what would make a person who wants to stop smoking take up preloading.

### **Strengths and limitations**

This trial has several strengths. The trial had power to detect the modest benefits that may have been expected, given the previous meta-analyses.<sup>12</sup> It was conducted with rigour, with a prespecified protocol and analysis plan; it followed standards set out in CONSORT (Consolidated Standards of Reporting Trials) guidelines<sup>90</sup> and achieved high follow-up rates compared with many trials of smoking cessation interventions, increasing confidence in the findings. It is the first trial of preloading to assess AEs to standards set out in Good Clinical Practice. In an open-label trial such as this, it is non-intuitive, both to participants and to trial staff, to report and enquire about AEs occurring in people on no medication. We trained our staff to enquire in the same way regardless of trial group, but it remains possible that the open-label design may have led to over-reporting of AEs in the preloading group. By also actively soliciting reports of likely AEs by questionnaire in all participants, we may have removed some of this bias. However, both methods revealed a somewhat similar profile, with nausea being the most common adverse consequence of preloading specifically. Patients also reported other well-established AEs of using a nicotine patch relating to its stimulant (poor sleep and dreaming) and adhesive (skin irritation) properties, but these were uncommon. However, taken together, both methods showed that severe AEs are rare and that the medication is well tolerated. A further strength of the study is that we collected data on potential mechanisms of action of preloading; these are addressed in *Chapter 4*.

The open-label design could be viewed as a limitation. Most notably, the open-label design led to 29.5% of participants in the control group choosing to use varenicline for post-quit day medication compared with 22.1% in the preloading group. This is a modest absolute difference, but, in this study, use of varenicline more than doubled the odds of achieving the primary outcome compared with the use of an alternative pharmacotherapy (chiefly NRT) and, in our pre-stated analysis, adjustment for this difference led to a statistically significant effect of preloading on the primary and secondary outcomes. There were also more people in the preloading group who used nicotine patches only, possibly because they received 5 weeks' supply of the medication. The two study arms also had different expectations, which may have affected their smoking behaviour and their responses to various subjective ratings meant to assess the effects of preloading on smoking reward, enjoyment and urges to smoke. A blinded design would probably have shown more clearly an effect of preloading on smoking abstinence and would allow an unbiased analysis of mediators.

The open-label design could be seen as a strength because it produced an outcome that would not have been detected in a blinded design. If patch preloading reduces the use of varenicline, this would suggest that, within the NHS Stop Smoking Services, preloading is an efficacious strategy, but not an effective one, because preloading would be used in an open-label manner in that context. It is unclear, however, whether the difference in varenicline use arose because patients who were happy on NRT opted to continue it or because smoking cessation therapists or prescribers (mainly GPs) were unhappy to prescribe varenicline to someone already using NRT. We sought to counter the latter effect in discussions and with a letter of referral from the research team to the NHS Stop Smoking Services, which took on the pre- and post-quit support and prescribing. However, we know of several instances where prescribers could not be persuaded that co-prescribing the medications was safe, as NICE guidance was viewed as 'trumping' this. Revised NICE guidance could easily remove the apparent prohibition on concurrent use. If the difference was due to patients feeling content with patches and disinclined to add another medication, informing patients that adding varenicline improves outcomes would be another potential remedy.

Thus, the open-label design may be viewed as a weakness because it clouded the answer to the scientific question of efficacy and mechanisms of action of preloading, and as a strength because it revealed the effect of preloading as it would play out in the current UK NHS or similar health systems. That said, it is likely that we would be able to overcome the effect on use of varenicline subsequently through changes to guidelines and discussion with patients.

### Comparison with other literature

Our previous meta-analysis yielded a RR of 1.16 (95% CI 0.97 to 1.38) for prolonged abstinence, but a RR of 1.26 (95% CI 1.03 to 1.55) for nicotine patches.<sup>12</sup> In this trial, the RR for the primary outcome (also prolonged abstinence) was very similar, at 1.27 (95% CI 1.03 to 1.57), in the analysis adjusted for the use of varenicline. The previous meta-analysis of nicotine patches alone was from an exploratory subgroup analysis and the main analysis showed no evidence of effectiveness, with a RR of 1.16 (95% CI 0.97 to 1.38). Thus, compared with the current literature, the trial has strengthened the evidence for the efficacy of preloading. However, our trial is the only trial to be carried out in a context in which the therapists who prescribed the preloading (our trial team) were different from those who prescribed the post-cessation support (the NHS Stop Smoking Service). Arguably, the context of this trial is more likely to reflect that of most health systems, where there is less behavioural support and dedicated smoking cessation expertise available to people who want to stop smoking than has been the case in the previous efficacy trials, thus revealing an effect that could negatively affect the impact of preloading.

One other factor also deserves attention. In this trial, we asked centres to record the proportion of people who did not make a quit attempt. We were concerned that deferring a quit attempt may mean that a person loses motivation to make one, thereby undermining the effect of preloading. This variable was incompletely recorded by centres, and it was clear that practice with respect to recording also differed in a way that makes relying on this variable unwise. From cross-tabulating other relevant data recorded, it appears that 112 (6.3%) people did not make a quit attempt: 60 (6.7%) of these were in the preloading group and 52 (5.8%) were in the control group. As the proportion was similar in both arms, this is not an effect of preloading per se, but it could reflect the fact that participants waited 4 weeks to quit smoking and we know that plans to quit smoking change quickly.<sup>91</sup> Not many smoking-related trials record the proportion of participants who do not make attempts to quit smoking. However, some of our previous trials have recruited in largely similar ways to this trial and, in these trials, 3% and 12% made no attempt to quit smoking, with a much shorter delay (1–2 weeks and 1 day) between trial enrolment and the target quit day.<sup>33,36</sup> A more recent trial reported that 17% of people who had undertaken 2 weeks of preloading failed to make a quit attempt, but this was defined as not achieving 24 hours of abstinence after quit day.<sup>17</sup> Evidence suggests that around half of all quit attempts do not achieve this milestone, meaning that perhaps only 8–9% failed to make a quit attempt.<sup>92</sup> Taken with these other trials, it appears that preloading and the necessary delay in making a quit attempt is not deterring people from following through with that attempt.

### Interpretation

This trial has clarified the role of preloading in the treatment of tobacco dependence. Preloading is an efficacious strategy that could lead to around 3% of people who are seeking help to quit smoking achieving 12-month prolonged abstinence, who might not otherwise have done so. This effect may seem small, but the current 12-month abstinence rate in the UK specialist Stop Smoking Services is 8%<sup>93</sup> and so an additional 3% would represent a worthwhile improvement. A failed quit attempt is likely to cost a person about 3–5 years of life expectancy.<sup>34</sup> Thus, around 12 people need to use preloading to gain around 1 year of life. However, within the specific setting of the NHS Stop Smoking Services, without changing NICE guidelines and informing advisors, the efficacy of preloading could be undermined by the effect it has on deterring use of the most effective cessation medication (varenicline) and, possibly, by delaying quit attempts in those motivated to quit immediately. Thus, it seems sensible to confine it as a strategy for use in highly controlled circumstances. If used in NHS Stop Smoking Services, we would recommend that NHS advisors discuss the choice of post-cessation treatment at the start of any period of preloading so that experience of preloading does not deter the use of varenicline.

Our study is not the only study that has produced observational evidence of the superiority of varenicline in routine NHS practice. The recent HTA-funded ELONS (Evaluating Long-term Outcomes of NHS Stop Smoking Services) study showed that the OR for use of varenicline compared with non-use of varenicline was 1.7 (95% CI 1.3 to 2.3),<sup>93</sup> very similar to the OR of 2.2 in this study. A Cochrane network meta-analysis of trials gave an OR of 1.57 (95% credible interval 1.29 to 1.91) for varenicline compared with single-form NRT and an OR of 1.59 (95% credible interval 1.29 to 1.96) for varenicline compared with bupropion.<sup>6</sup> A subsequent very large trial produced ORs of 1.68 (95% CI 1.46 to 1.93) for varenicline compared with the NRT patch and 1.75 (95% CI 1.52 to 2.01) for varenicline compared with bupropion.<sup>94</sup> The randomised trials suggest that the superiority of varenicline in these observational data is probably because varenicline is more effective both within and outside the context of a clinical trial. This suggests that a way to improve the outcome of the NHS Stop Smoking Services is to increase the proportion of patients who use varenicline. The ORs of 1.7 and 2.2 for use of varenicline compared with non-use of varenicline compare favourably with those for preloading (1.25 for the primary analysis and 1.34 for the varenicline-adjusted analysis); the use of varenicline seems simpler, and requires less service change, than implementing a new strategy of preloading.

It is important to note that these conclusions relate to preloading as we implemented it in this trial. It remains possible that preloading performed in other ways or in contexts other than the UK NHS Stop Smoking Services, which provide a range of medications and behaviour support free of charge, may improve outcomes to a greater extent. We used a 4-week period of preloading, which, theoretically, ought to be more effective than the 2 weeks used in several previous studies. However, there is no clear evidence that this is so; therefore, limiting preloading to a shorter period could overcome the possible disadvantages that significantly delaying a quit attempt may entail. Theoretically, it is also possible that higher doses of nicotine could lead to greater effectiveness.<sup>95</sup> The additional 21 mg of nicotine per 24 hours preceding quit day was generally well tolerated and other research shows that 63 mg of nicotine per day appears to be well tolerated too.<sup>91</sup> In addition, the higher-dose NRT reduced consumption to a greater extent than the 21-mg patch that was used, suggesting that higher doses may be effective.

It is also possible that varenicline preloading may be effective. One small trial showed that varenicline preloading more than doubled the number achieving 12-week abstinence.<sup>21</sup> A further trial produced somewhat less positive results, but the trial was too small to offer a precise estimate of effect.<sup>96</sup> Consequently, there is no evidence that varenicline preloading improves long-term abstinence, but, given that the RR of achieving abstinence through use of a smoking cessation medication appears to be constant, whether measured early or late in a quit attempt,<sup>97</sup> we might expect that it does. Thus, future trials of preloading might want to examine whether or not this promising effect of varenicline holds in a larger trial and manifests in an increased proportion of participants achieving long-term abstinence.

## Mediation

### *Summary of findings*

There was no evidence that preloading was more effective for those showing a greater dependence on smoking. Participants allocated to preloading compared with the control condition showed a reduced reward from smoking, a reduced urge to smoke and reduced smoke inhalation prior to quitting and lowered their cigarette consumption. After attempting abstinence, participants using preloading experienced a reduced craving for cigarettes. Of these possible mediators, only a reduced urge to smoke before and after quit day and reduced consumption while using preloading were associated with abstinence. Together, these changes appeared to mediate most of the effect of preloading on abstinence. Although preloading increased feelings of aversion to smoking, these feelings were not associated with an increased likelihood of achieving abstinence and, thus, there is no evidence that this was an important mediating mechanism. There is also no evidence that the effect of preloading on abstinence was explained by increased confidence in quitting or increased adherence to post-cessation medication.

### Strengths and limitations

This study has several strengths. Chief among these are that we planned a comprehensive evaluation of the mechanism of action, assessing all steps in the pathway, and we included analyses of competing hypotheses that were advanced to explain the preloading effect. Being the largest trial to date and the trial with the most comprehensive data on mediators means that the pathway of effect has been clarified. The trial also has some limitations. Our follow-up of participants to assess the effect of preloading on mediators while smoking was carried out only 1 week after commencing treatment. This follow-up was timed to maximise adherence to preloading and to allow the dose to be adjusted if needed. However, previous trials have suggested that the effect of preloading on smoking increases with duration;<sup>21,96</sup> therefore, we may have seen larger associations between preloading and change in mediators and between change in mediators and abstinence if this assessment had taken place later. Another issue is that our analysis does not account for the multistep nature of mediation. Our hypothesis was that preloading reduces the strength of urges to smoke while in the pre-quit phase and these reduced urges reduce cigarette consumption. However, we modelled these mediators as separate 'parallel' mediators rather than in a structural equation model. Finally, the open-label trial leaves open the possibility that some of these effects are subject to bias, such as participant expectations. Participants in the intervention group were told about the proposed mechanism of preloading to motivate them to adhere to the medication. Thus, the effect of preloading on the proposed mediators could at least partly be caused by this effect rather than by the pharmacological action of the additional nicotine. However, we might have seen an increase in confidence in the preloading group if this was driven by expectations of a positive outcome and this was not apparent. It, therefore, seems less likely that participants' expectations could explain the increase in abstinence and, therefore, this may be an unlikely explanation of the apparent mediation.

### Comparison with other studies

Our analysis of whether or not the effect of preloading depends on baseline tobacco dependence is unique. We used two markers of dependence, FTCD and exhaled CO concentration. In our study, as in previous studies, for example Aveyard *et al.*,<sup>36</sup> FTCD predicted the likelihood of achieving abstinence. The ORs were 0.85 (95% CI 0.62 to 1.17) for moderate dependence compared with low dependence and 0.61 (95% CI 0.42 to 0.90) for moderate dependence compared with high dependence. The *p*-value for trend through those categories is 0.013. Thus, in this population of people who seek help to stop smoking and who are more dependent than the average person who smokes, this marker functions as a predictor of abstinence and might, therefore, be expected to moderate the effect of preloading. However, exhaled CO concentration did not function as a useful predictor of the likelihood of abstinence; compared with a CO concentration of < 10 p.p.m. at baseline, for the categories in *Figure 5b*, the ORs were 0.67, 0.63, 0.79 and 0.74, with a *p*-value for trend of 0.84. This may, therefore, explain why exhaled CO concentration did not moderate the association.

Our mediation analysis is complemented by previous analyses in other trials of preloading that examined the effect of preloading on several potential mediators. Unlike previous analyses,<sup>12</sup> we found that preloading did reduce both positive and negative reward from smoking, but our study is much larger than the previous studies that have examined these mediators, so these trials may have missed this association. As two previous studies have also discovered,<sup>12</sup> we found a small reduction in pre-quit urges to smoke. Most previous trials examined changes in cigarette consumption caused by preloading and, as we found, noted reductions in the pre-quit period.<sup>12</sup> Those trials that examined reduction in dependence reported the same kind of reductions that we observed in this trial. Previously, we concluded that preloading did not appear to reduce craving after quit day,<sup>12</sup> but there was clear evidence in this trial that preloading did reduce craving. Although previous studies examined the effect of preloading on potential mediators, none undertook a full mediation analysis, as we have done here. Doing so revealed new insights. Although people's perception of reward may have changed, the main apparent mechanism seems to be through reduction in the urge to smoke. It is possible that this effect is indeed mediated by reward, but that people's perception of it may not be very sensitive. Alternatively, the drive to smoke may weaken in smokers saturated with nicotine from an alternative source without any effect on their subjective reactions when they do smoke. The main drive to smoke does not require conscious appreciation for it to be

experienced.<sup>98</sup> No previous studies have examined whether or not there is effect modification by strength of dependence on tobacco.

### **Interpretation**

This study and previous literature together have produced clear evidence that preloading reduces the intensity of urges to smoke and that it reduces the intensity of smoking during the pre-quit period. The reduced drive to smoke appears to be the best candidate mechanism for the effect of preloading, with reduced smoke intake being one of its consequences.

This has important implications for clinical practice. If preloading were to be used routinely in NHS Stop Smoking Services, then advisors could monitor its effect using markers of urge strength, asking users whether or not they have experienced reduced urge intensity, and also by measuring exhaled CO concentration, which is routine in NHS clinics. This could allow clinicians to advise their patients to abandon preloading if it appears to be having little effect, confident that the evidence now supports this.

Many trials of treatment for tobacco dependence enrol people who smoke a minimum of 10 cigarettes per day, but around one-third of the population who smoke consume fewer cigarettes than this per day. We enrolled such participants if they were seeking help to quit and smoked at least one cigarette per day, providing they manifested other features of dependence, including difficulty attaining abstinence. This may have contributed to including a greater range of participants than in some trials of pharmacotherapy. Including a wide range of participants should make it easier to detect effect modification between markers of dependence. Although there was no clear evidence of effect modification, both point estimates suggested a greater relative benefit in people with a higher level of dependence. As we did not plan for the study to have power to detect this interaction, it may be that we simply failed to find evidence for an effect, rather than this representing clear evidence against an effect. Given the mechanisms of action of preloading and this evidence together, it would seem appropriate for smoking cessation advisors to consider this strategy in anyone seeking treatment, but perhaps particularly for people with a higher level of dependence.

## **Within-trial cost-effectiveness**

### **Summary of main findings**

The primary outcome of the cost-effectiveness analysis was the incremental cost per additional case of 6-month prolonged abstinence. The prolonged abstinence rate at 6 months post quit date according to the Russell Standard was 17.5% in the intervention group and 14.4% in the control group, a difference of 3.1% (95% CI -0.3% to 6.4%). Mean total costs, from randomisation to 6 months post quit date, were £978 (SE £105) in the intervention group and £1090 (SE £110) in the control group. The adjusted incremental costs were £4 (95% CI -£188 to £222). The incremental costs per additional 6-month prolonged abstinence were, therefore, £129 (95% CI -£16,527 to £17,782). The wide CI crossed the zero point, which amounts to no clear evidence that the intervention was more cost-effective than the control condition. The analysis of data at 12 months' follow-up suggested a possible reduction in health service costs in the intervention group (-£233, 95% CI -£747 to £42). This pointed to a potential cost-saving scenario in the long run, given that the abstinence rate at 12 months was not significantly different between arms. Sensitivity analysis did not change the pattern of these results. There were indications that the costs might have been underestimated in the complete-case analysis.

### **Strengths and limitations**

The strength of this analysis lies in the comprehensive analysis of all health and social care costs, thus providing a clear picture for the NHS when deciding on treatment. As in all such studies, however, we suffered from missing data. In particular, people who try to quit smoking with support and fail to do so are always somewhat reluctant to return for follow-up. For the sake of the primary outcome, we maximised the return of data on smoking status among participants who were reluctant to be followed up.

This sometimes meant that we excused people from answering the health resource questions and, as a result, these data were more often missing than data on smoking status. As the data showed, people with complete data were more likely to be abstinent, but there is no reason to imagine that health service use differed between arms among people who were not abstinent and this is unlikely to bias the results.

With the complicated nature of health resource use data, it was inevitable that some assumptions had to be made before any analysis could be undertaken. The less than reliable approach of self-reporting only added to the uncertainties. However, short of accessing participants' usage directly from the providers, it was the best way to collect this information. The assumption that no response equates to no use is generally seen to be compatible with the way that people complete health resource use questionnaires. The assumptions made about monthly prescriptions are less certain. The prescribing patterns varied between GPs and, without more detailed information, it was not possible to estimate the cost of medication more accurately. Collecting these data from participants directly in a trial of this kind would add a considerable burden and probably increase withdrawal rates. Even if this burden could be disregarded, participants' reports of medication use are often less than satisfactory for the purpose of costing. In spite of these uncertainties, the assumptions were applied to both arms and, therefore, should not bias the results towards either group.

Participants with complete information on health resource use had much lower use than that suggested from the imputed data. This is not surprising: participants with greater health needs may find it more burdensome to complete questionnaires, be less likely to achieve abstinence and be more likely to drop out of follow-up. However, this effect is unlikely to differ between arms.

The data presented are a within-trial analysis of cost-effectiveness. The reason that people try to stop smoking, and the reason the NHS invests in smoking cessation services, is to support long-term abstinence and to avoid the costs of smoking-related illnesses in the future. It is not possible to collect such data in trials, but it is possible to model them and we present these data in *Chapter 7*. A second issue relates to the design of the trial itself and the constraints that this imposed on the cost-effectiveness analysis. To be able to assess AEs and the mechanism of action of preloading in an unbiased way, those in the control group delayed their quit attempt to the same extent as those in the preloading group. To ensure that people returned to give us these data, we gave behavioural support to those in the control group and set this group up to believe that this would be useful to them. There is no clear evidence that this is the case and, in any case, the support that we gave is commonly incorporated into standard NHS smoking cessation support, which both the intervention group and the control group received later. In this within-trial analysis, we included the cost of the behavioural support in the control group. The NHS decision problem, however, was to assess the difference between preloading and standard NHS smoking cessation support, with only a minimal period of preparation before quitting. Thus, the control group behavioural support sessions would not happen in any future NHS scenario. Assuming that the outcomes remain the same, the simple exclusion of two behavioural support sessions from the control group would result in an increase in the adjusted difference in costs between arms and an increase in the ICER in turn. For the complete-case analysis, the difference in costs between trial arms would increase from £138 to £155, resulting in a modest change in the ICER of around £700, whereas the change in the adjusted difference in costs between arms in the imputed data (from £4 to £17) would lead to an increase in the ICER of £550. However, the assumption that extra behavioural support in preparation to quit has no impact on outcomes cannot be easily made. These numbers are only estimates and further assessment is required to provide supporting or opposing evidence. In addition, the cost-effectiveness analysis appropriately focuses on the primary analysis of the primary outcome. However, this is a biased estimate of the efficacy of preloading because it is confounded by differences in the use of varenicline. Had we used the estimate for the difference in the effect of preloading adjusted for varenicline, then the cost-effectiveness might have more strongly favoured preloading over the control.

### Interpretation

This is the first assessment of the cost-effectiveness of nicotine preloading. Indeed, relatively few trials have conducted within-trial analyses of the cost-effectiveness of smoking cessation medication. One comparator is the NHS Stop Smoking Service, which collects data on the cost per person who has quit smoking and remained abstinent for 4 weeks. *Statistics on NHS Stop Smoking Services in England April 2014 to March 2015*<sup>65</sup> showed, among local authorities, a cost per person who quit smoking ranging from £98 to £1185, with a mean of £456. The cost per person who quit smoking at 4 weeks in this trial was £501 in the preloading group and £417 in the control group, somewhat in the middle of the distribution. That said, the NHS counts self-reported abstinence as abstinence, which we excluded; if we had included self-reported abstinence, it would reduce the cost per quitter by nearly one-third.

Interpreting the data here is harder because there is no available WTP threshold for 6-month prolonged abstinence; therefore, it is not possible to draw clear conclusions with regard to whether or not the intervention can be seen to be cost-effective. An incremental cost of £129 per additional 6-month abstinence might be considered cost-effective if the policy-makers judge the abstinence to be beneficial, given the impact of smoking cessation on long-term quality of life. What may encourage policy-makers to consider preloading are the data showing that, at 12 months, preloading reduced overall health service costs. In the short term at least, smoking cessation should reduce the demand for health services by reducing the incidence of both minor and major ill-health consequences of smoking. Future modelling may provide further data to support this.

## Modelling the long-term cost-effectiveness of preloading

### Summary of findings

The smoking cessation costs within the intervention group over the course of the first year were higher than those in the control group, with intervention group costs of £295, compared with control group costs of £265. However, more smokers quit smoking in the intervention group ( $n = 139$ ) than in the control group ( $n = 112$ ) and consequently health-care costs associated with smoking were lower in the intervention group over the course of the lifetime. Overall, the total costs were £29 lower in the intervention group. The intervention was also more effective than the control condition, resulting in 14.0% of smokers in the intervention group quitting at 1 year compared with 11.3% of smokers in the control group, and consequently produced more QALYs and life-years. The intervention would be considered cost-effective as it resulted in greater efficacy at a lower cost than the control condition. The results were robust to changes in assumptions regarding discount rates and relapse after the first year of follow-up.

### Strengths and limitations

The major strength of this approach is that it builds on the comprehensive within-trial cost-effectiveness assessment presented in *Chapter 6*. However, it takes the same perspective as people who are stopping smoking: that the main reason to stop smoking is to avoid future smoking-related disease.<sup>99</sup> As such, it better represents the views of possible service users of NHS Stop Smoking Services and of the community at large. The major weakness is that, as with practically all long-term cost-effectiveness studies, the results are modelled on the future likelihood of disease. Confidence in this modelling is supported by the robust epidemiological evidence available on the association between smoking and incidence of and mortality from disease and the difference in risk arising as a result of stopping smoking at different ages. The model has been extensively discussed and described elsewhere (forthcoming supplement in the journal *Addiction*) and is used by NICE to examine the cost-effectiveness of smoking cessation medications.<sup>67</sup> However, nobody has prospectively validated models of incidence, mortality and health-care expenditure of cohorts of people who continue or stop smoking, so ultimately the data should be regarded as somewhat conjectural. This emphasises the importance of sensitivity analyses and a strength of the findings here is that they appear largely unaltered by both deterministic and probabilistic sensitivity analyses; all answers converged to suggest that preloading is dominant over the comparator in the large majority of model runs.

## Research recommendations

1. Will changes to NICE guidance and interventions with clinicians and/or patients overcome the effect of preloading on the subsequent use of varenicline?
2. Are higher doses of nicotine preloading more effective, especially in those who do not seem to suppress the urge to smoke in response to the standard dose?
3. Are people who reduce their urge to smoke in response to preloading more likely to stop smoking than those who experience no reduction in the urge to smoke?
4. Is reduced urge to smoke translated into reduced consumption of cigarettes? Would this work as a marker of the effectiveness of nicotine preloading?
5. Is response to use of cessation pharmacotherapy while in the period prior to quit day an effective way of personalising treatment for people seeking help to stop smoking?
6. Does varenicline preloading increase the proportion of people achieving long-term abstinence? Is varenicline preloading cost-effective in the long term?

## Recommendations for practice

Using nicotine preloading requires a person to make a planned quit attempt. Our trial shows that, when there is dislocation between the person prescribing the NRT preloading and the subsequent smoking cessation service, the choice of subsequent pharmacotherapy undermines the benefit of preloading. The most likely scenario for implementation in the NHS is that a GP would refer a patient to NHS Stop Smoking Services, which replicates the scenario in our trial. In such a circumstance, preloading is unlikely to add greatly to the effectiveness of standard care and we would not recommend its use.

In other circumstances, it is possible that preloading would prove to be effective. A clinician looking to maximise the chances of successful cessation in a patient would prescribe varenicline as post-cessation medication. Both observational data from our trial, other observational data and trial data (discussed in *Modelling the long-term cost-effectiveness of preloading*) testify to the superiority of this medication. Suggesting this to a patient first and gaining commitment to its use before discussing the use of preloading may overcome the deterrent effect of preloading on the subsequent use of varenicline.

## Conclusion

Use of nicotine patch preloading for 4 weeks prior to attempting to stop smoking can increase the proportion of people who stop successfully, but its benefit is undermined because it reduces the use of varenicline after preloading. If this latter effect could be overcome, then nicotine preloading appears to reduce health service costs in the long term. Using the primary outcome of 6-month prolonged abstinence, there is no clear evidence that preloading is more cost-effective than the control condition, but there is a suggestion that over a 12-month period it may be more effective and it is very likely to be cost-effective over a lifetime perspective.

Nicotine preloading appears to work because it reduces the strength of urges to smoke during preloading and after preloading has finished. This seems to be the central mechanism underlying its effect. None of the other theories proposed for its mechanism of action have any support and are likely to be part of the mechanism of action.



# Acknowledgements

This trial was funded by the NIHR HTA programme (reference number 09/110/01). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.

The trial protocol is published in the journal *Trials*.<sup>26</sup>

## Trial Steering Committee

We are very grateful to the following members of the Trial Steering Committee:

- Professor Michael Ussher PhD (chairperson)
- Dr Lion Shahab MA MSc PhD CPsychol (expert in tobacco dependence)
- Dan Griffin (smokers panel representative/lay member)
- Jane Wright (NHS Stop Smoking Service manager)
- Dr Helen J Stokes-Lampard FRCGP PhD (academic GP)
- Dr Tess Harris (academic GP)
- Dr Rumana Omar PhD (statistician)
- Professor Paul Aveyard (chief investigator, non-voting member)
- Dr Nicola Lindson (trial manager, non-voting member).

## Contributions of authors

We agreed as a group that authorship would be corporate – the Preloading Investigators – and would prefer this to be how the report was described when published. The investigators were as follows:

**Paul Aveyard** (Professor of Behavioural Medicine) was the chief investigator and principal investigator of both the Bristol and the Birmingham centres.

**Nicola Lindson** (Cochrane Managing Editor) was a trial manager and co-applicant.

**Sarah Tearne** (Clinical Trial Manager) was a clinical trial manager.

**Rachel Adams** (Research Nurse) was responsible for recruitment and follow-up.

**Khaled Ahmed** (Data Entry Clerk) was responsible for data entry.

**Rhona Alekna** (Research Nurse) was responsible for recruitment and follow-up.

**Miriam Banting** (Research Nurse) was responsible for recruitment and follow-up.

**Mike Healy** (Administrator) was responsible for study administration.

**Shahnaz Khan** (Administrator) was responsible for study administration.

**Gurmail Rai** (Senior Analyst Programmer) was responsible for database design and maintenance.

**Carmen Wood** (Administrator) was responsible for study administration.

**Emma C Anderson** (Research Assistant) was responsible for recruitment and follow-up.

**Alia Ataya-Williams** (Administrator) was responsible for study management and interpretation of the data.

**Angela Attwood** (Research Fellow) was responsible for recruitment and follow-up.

**Kayleigh Easey** (Research Assistant) was responsible for recruitment and follow-up.

**Megan Fluharty** (Research Assistant) was responsible for recruitment and follow-up.

**Therese Freuler** (Research Assistant) was responsible for recruitment and follow-up.

**Megan Hurse** (Apprentice) was responsible for study administration, recruitment and follow-up.

**Jasmine Khouja** (Research Assistant) was responsible for recruitment and follow-up.

**Lindsey Lacey** (Data Entry Clerk), was responsible for data entry and also acted as a research assistant.

**Marcus Munafò** (Professor of Biological Psychology) was the lead researcher at the Bristol centre and a co-applicant.

**Deborah Lycett** (Reader in Nutrition, Dietetics and Spiritual Health) was a co-investigator and was responsible for study management and the interpretation of data.

**Andy McEwen** [National Centre for Smoking Cessation and Training (NCSCT) Executive Director] was responsible for study management and interpretation of the data.

**Tim Coleman** (Professor of Primary Care) was the principal investigator at the Nottingham centre.

**Anne Dickinson** (Research Assistant) was responsible for recruitment and follow-up.

**Sarah Lewis** (Professor of Medical Statistics) was the trial statistician with responsibility for the statistical analysis.

**Sophie Orton** (Research Fellow) was responsible for the statistical analysis.

**Johanna Perdue** (Administrator) was a trial administrator, with responsibility for study administration.

**Clare Randall** (Administrator) was a trial administrator, with responsibility for study administration.

**Rebecca Anderson** (Data Entry Clerk) was responsible for site set-up, recruitment, intervention delivery, data collection and data entry.

**Natalie Bisal** (Data Entry Clerk) was responsible for data collection, data cleaning and study closure.

**Peter Hajek** (Professor of Clinical Psychology and Director of the Wolfson Institute of Preventive Medicine's Tobacco Dependence Research Unit) was a co-applicant and a site principal investigator, responsible for study design, data analysis and write-up and supervision of site activities.

**Celine Homsey** (Data Entry Clerk) was responsible for site set up, recruitment, intervention delivery, data collection and data entry.

**Hayden J McRobbie** (Senior Clinical Researcher) was a co-applicant (study design) and was responsible for study management, design and interpretation of data.

**Katherine Myers-Smith** (Research Fellow) was responsible for site set up, recruitment, intervention delivery, data collection and data entry.

**Anna Phillips** (Data Entry Clerk) was responsible for recruitment, data collection and study closure.

**Dunja Przulj** (Data Entry Clerk) was responsible for recruitment, data collection and study closure.

**Jinshuo Li** (Health Economist) was responsible for the health economic analysis.

**Doug Coyle** (Health Economic Analyst) was responsible for the health economic analysis.

**Katherine Coyle** (Health Economic Analyst) was responsible for the health economic modelling.

**Subhash Pokhrel** (Health Economic Analyst) was responsible for the health economic analysis.

## Publications

The Preloading Investigators. Effects on abstinence of nicotine patch treatment before quitting smoking: parallel, two arm, pragmatic randomised trial. *BMJ* 2018;**361**:k2164. <https://doi.org/10.1136/bmj.k2164>

## Data-sharing statement

All data requests should be submitted to the corresponding author for consideration. Access to available anonymised data may be granted following review and if appropriate agreements are in place.

## Patient data

This work uses data provided by patients and collected by the NHS as part of their care and support. Using patient data is vital to improve health and care for everyone. There is huge potential to make better use of information from people's patient records, to understand more about disease, develop new treatments, monitor safety, and plan NHS services. Patient data should be kept safe and secure, to protect everyone's privacy, and it's important that there are safeguards to make sure that it is stored and used responsibly. Everyone should be able to find out about how patient data are used. #datasaveslives You can find out more about the background to this citation here: <https://understandingpatientdata.org.uk/data-citation>.



## References

1. Hughes JR, Keely J, Naud S. Shape of the relapse curve and long-term abstinence among untreated smokers. *Addiction* 2004;**99**:29–38. <https://doi.org/10.1111/j.1360-0443.2004.00540.x>
2. West R, Shiffman S. Effect of oral nicotine dosing forms on cigarette withdrawal symptoms and craving: a systematic review. *Psychopharmacology* 2001;**155**:115–22. <https://doi.org/10.1007/s002130100712>
3. Shiffman S, Shadel WG, Niaura R, Khayrallah MA, Jorenby DE, Ryan CF, Ferguson CL. Efficacy of acute administration of nicotine gum in relief of cue-provoked cigarette craving. *Psychopharmacology* 2003;**166**:343–50. <https://doi.org/10.1007/s00213-002-1338-1>
4. Hughes JR. Effects of abstinence from tobacco: valid symptoms and time course. *Nicotine Tob Res* 2007;**9**:315–27. <https://doi.org/10.1080/14622200701188919>
5. Hartmann-Boyce J, Aveyard P. Drugs for smoking cessation. *BMJ* 2016;**352**:i571. <https://doi.org/10.1136/bmj.i571>
6. Cahill K, Stevens S, Perera R, Lancaster T. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. *Cochrane Database Syst Rev* 2013;**10**:CD009329. <https://doi.org/10.1002/14651858.CD009329.pub2>
7. West R, Baker C, Cappelleri J, Bushmakin A. Effect of varenicline and bupropion SR on craving, nicotine withdrawal symptoms, and rewarding effects of smoking during a quit attempt. *Psychopharmacology (Berl)* 2008;**197**:371–7. <https://doi.org/10.1007/s00213-007-1041-3>
8. Fagerström KO, Hughes JR. Nicotine concentrations with concurrent use of cigarettes and nicotine replacement: a review. *Nicotine Tob Res* 2002;**4**(Suppl. 2):73–9. <https://doi.org/10.1080/1462220021000032753>
9. West R. Defining and Assessing Nicotine Dependence in Humans. In Corrigan WA, editor. *Understanding Nicotine and Tobacco Addiction*. Chichester: John Wiley & Sons, Ltd; 2006. pp. 36–63. <https://doi.org/10.1002/9780470029237.ch4>
10. Stead LF, Perera R, Bullen C, Mant D, Lancaster T. Nicotine replacement therapy for smoking cessation. *Cochrane Database Syst Rev* 2008;**1**:CD000146. <https://doi.org/10.1002/14651858.CD000146.pub3>
11. Shiffman S, Sweeney CT, Ferguson SG, Sembower MA, Gitchell JG. Relationship between adherence to daily nicotine patch use and treatment efficacy: secondary analysis of a 10-week randomized, double-blind, placebo-controlled clinical trial simulating over-the-counter use in adult smokers. *Clin Ther* 2008;**30**:1852–8. <https://doi.org/10.1016/j.clinthera.2008.09.016>
12. Lindson N, Aveyard P. An updated meta-analysis of nicotine preloading for smoking cessation: investigating mediators of the effect. *Psychopharmacology (Berl)* 2011;**214**:579–92. <https://doi.org/10.1007/s00213-010-2069-3>
13. West R, Brown J. *Theory of Addiction*. Chichester: John Wiley & Sons, Ltd; 2013. <https://doi.org/10.1002/9781118484890>
14. Foulds J, Hughes J, Hyland A, Le Houezec J, McNeill A, Melvin C, et al. *Barriers to Use of FDA-approved Smoking Cessation Medications: Implications for Policy Action*. Madison, WI: Society for Research on Nicotine and Tobacco; 2009.
15. Shiffman S. Use of more nicotine lozenges leads to better success in quitting smoking. *Addiction* 2007;**102**:809–14. <https://doi.org/10.1111/j.1360-0443.2007.01791.x>

16. Gwaltney CJ, Metrik J, Kahler CW, Shiffman S. Self-efficacy and smoking cessation: a meta-analysis. *Psychol Addict Behav* 2009;**23**:56–66. <https://doi.org/10.1037/a0013529>
17. Lindson-Hawley N, Banting M, West R, Michie S, Shinkins B, Aveyard P. Gradual versus abrupt smoking cessation: a randomized, controlled noninferiority trial. *Ann Intern Med* 2016;**164**:585–92. <https://doi.org/10.7326/M14-2805>
18. Hajek P, Stead LF. Aversive smoking for smoking cessation. *Cochrane Database Syst Rev* 2001;**3**:CD000546. <https://doi.org/10.1002/14651858.CD000546.pub2>
19. Doll R, Peto R, Boreham J, Sutherland I. Mortality in relation to smoking: 50 years' observations on male British doctors. *BMJ* 2004;**328**:1519. <https://doi.org/10.1136/bmj.38142.554479.AE>
20. West R. The clinical significance of 'small' effects of smoking cessation treatments. *Addiction* 2007;**102**:506–9. <https://doi.org/10.1111/j.1360-0443.2007.01750.x>
21. Hajek P, McRobbie HJ, Myers KE, Stapleton J, Dhanji AR. Use of varenicline for 4 weeks before quitting smoking: decrease in ad lib smoking and increase in smoking cessation rates. *Arch Intern Med* 2011;**171**:770–7. <https://doi.org/10.1001/archinternmed.2011.138>
22. Rose JE, Behm FM, Westman EC, Kukovich P. Precessation treatment with nicotine skin patch facilitates smoking cessation. *Nicotine Tob Res* 2006;**8**:89–101. <https://doi.org/10.1080/14622200500431866>
23. Rose JE, Herskovic JE, Behm FM, Westman EC. Precessation treatment with nicotine patch significantly increases abstinence rates relative to conventional treatment. *Nicotine Tob Res* 2009;**11**:1067–75. <https://doi.org/10.1093/ntr/ntp103>
24. Rose JE, Behm FM, Drgon T, Johnson C, Uhl GR. Personalized smoking cessation: interactions between nicotine dose, dependence and quit-success genotype score. *Mol Med* 2010;**16**:247. <https://doi.org/10.2119/molmed.2009.00159>
25. Lindson-Hawley N, Shinkins B, West R, Michie S, Aveyard P. Does cigarette reduction while using nicotine replacement therapy prior to a quit attempt predict abstinence following quit date? *Addiction* 2016;**111**:1275–82. <https://doi.org/10.1111/add.13330>
26. Lindson-Hawley N, Coleman T, Docherty G, Hajek P, Lewis S, Lycett D, et al. Nicotine patch preloading for smoking cessation (the preloading trial): study protocol for a randomized controlled trial. *Trials* 2014;**15**:296. <https://doi.org/10.1186/1745-6215-15-296>
27. Flaxman J. Quitting smoking now or later: gradual, abrupt, immediate, and delayed quitting. *Behav Ther* 1978;**9**:260–70. [https://doi.org/10.1016/S0005-7894\(78\)80111-7](https://doi.org/10.1016/S0005-7894(78)80111-7)
28. National Institute for Health and Care Excellence (NICE). *Guidance on Smoking Cessation*. London: NICE; 2008.
29. Hajek P. Withdrawal-oriented therapy for smokers. *Br J Addict* 1989;**84**:591–8. <https://doi.org/10.1111/j.1360-0443.1989.tb03474.x>
30. West R, Hajek P, Stead L, Stapleton J. Outcome criteria in smoking cessation trials: proposal for a common standard. *Addiction* 2005;**100**:299–303. <https://doi.org/10.1111/j.1360-0443.2004.00995.x>
31. Medical Dictionary for Regulatory Activities. *Welcome to MedDRA*. URL: [www.meddra.org](http://www.meddra.org) (accessed 23 January 2018).
32. Marteau TM, Aveyard P, Munafò MR, Prevost AT, Hollands GJ, Armstrong D, et al. Effect on adherence to nicotine replacement therapy of informing smokers their dose is determined by their genotype: a randomised controlled trial. *PLOS ONE* 2012;**7**:e35249. <https://doi.org/10.1371/journal.pone.0035249>

33. Aveyard P, Johnson C, Fillingham S, Parsons A, Murphy M. Nortriptyline plus nicotine replacement versus placebo plus nicotine replacement for smoking cessation: pragmatic randomised controlled trial. *BMJ* 2008;**336**:1223–7. <https://doi.org/10.1136/bmj.39545.852616.BE>
34. Fidler J, Ferguson SG, Brown J, Stapleton J, West R. How does rate of smoking cessation vary by age, gender and social grade? Findings from a population survey in England. *Addiction* 2013;**108**:1680–5. <https://doi.org/10.1111/add.12241>
35. West R, Ussher M. Is the ten-item Questionnaire of Smoking Urges (QSU-brief) more sensitive to abstinence than shorter craving measures? *Psychopharmacology* 2010;**208**:427–32. <https://doi.org/10.1007/s00213-009-1742-x>
36. Aveyard P, Brown K, Saunders C, Alexander A, Johnstone E, Munafò MR, Murphy M. Weekly versus basic smoking cessation support in primary care: a randomised controlled trial. *Thorax* 2007;**62**:898–903. <https://doi.org/10.1136/thx.2006.071837>
37. Loudon K, Treweek S, Sullivan F, Donnan P, Thorpe KE, Zwarenstein M. The PRECIS-2 tool: designing trials that are fit for purpose. *BMJ* 2015;**350**:h2147. <https://doi.org/10.1136/bmj.h2147>
38. PRagmatic Explanatory Continuum Indicator Summary (PRECIS)-2. *PRECIS-2*. URL: <http://precis-2.org> (accessed 23 January 2018).
39. The Preloading Investigators. Effects on abstinence of nicotine patch treatment before quitting smoking: parallel, two arm, pragmatic randomised trial. *BMJ* 2018;**361**:k2164. <https://doi.org/10.1136/bmj.k2164>
40. The Organisation for Economic Co-operation and Development (OECD). *Education at a Glance 2014*. France: OECD; 2014.
41. Kenny DA. *Mediation*. 2016. URL: <http://davidakenny.net/cm/mediate.htm> (accessed 3 January 2017).
42. Cappelleri JC, Bushmakin AG, Baker CL, Merikle E, Olufade AO, Gilbert DG. Confirmatory factor analyses and reliability of the modified cigarette evaluation questionnaire. *Addict Behav* 2007;**32**:912–23. <https://doi.org/10.1016/j.addbeh.2006.06.028>
43. West R, Hajek P. Evaluation of the mood and physical symptoms scale (MPSS) to assess cigarette withdrawal. *Psychopharmacology (Berl)* 2004;**177**:195–9. <https://doi.org/10.1007/s00213-004-1923-6>
44. Shiffman S, Waters AJ, Hickcox M. The Nicotine Dependence Syndrome Scale: a multidimensional measure of nicotine dependence. *Nicotine Tob Res* 2004;**6**:327–48. <https://doi.org/10.1080/1462220042000202481>
45. Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO. The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. *Br J Addict* 1991;**86**:1119–27. <https://doi.org/10.1111/j.1360-0443.1991.tb01879.x>
46. Shiffman S, West R, Gilbert D, SRNT Work Group on the Assessment of Craving and Withdrawal in Clinical Trials. Recommendation for the assessment of tobacco craving and withdrawal in smoking cessation trials. *Nicotine Tob Res* 2004;**6**:599–614. <https://doi.org/10.1080/14622200410001734067>
47. Lindson N, Aveyard P, Ingram JT, Inglis J, Beach J, West R, Michie S. Rapid reduction versus abrupt quitting for smokers who want to stop soon: a randomised controlled non-inferiority trial. *Trials* 2009;**10**:69. <https://doi.org/10.1186/1745-6215-10-69>
48. Aveyard P. The place of varenicline in smoking cessation treatment. *Thorax* 2008;**63**:666–8. <https://doi.org/10.1136/thx.2008.096081>

49. Parrott S, Godfrey C, Raw M, West R, McNeill A. Guidance for commissioners on the cost effectiveness of smoking cessation interventions. Health Educational Authority. *Thorax* 1998;**53**:S1–38.
50. US Department of Health and Human Services. *The Health Consequences of Smoking – 50 Years of Progress: A Report of the Surgeon General*. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2014.
51. National Institute for Health and Care Excellence (NICE). *Guide to the Methods of Technology Appraisal 2013*. London: NICE; 2013.
52. National Institute for Health and Care Excellence (NICE). *Smoking Cessation Services Costing Report – Implementing NICE Guidance*. London: NICE; 2008.
53. Prescribing and Medicines Team. *Prescription Cost Analysis, England 2015*. Leeds: NHS Digital (formerly the Health and Social Care Information Centre); 2016.
54. Curtis L, Burns A. *Unit Costs of Health and Social Care 2015*. Canterbury: Personal Social Services Research Unit, University of Kent; 2015.
55. Parrott S, Godfrey C, Kind P. *Cost-effectiveness of Brief Intervention and Referral for Smoking Cessation*. York: Centre for Health Economics, University of York; 2006.
56. Department of Health and Social Care. *Reference Costs 2014–15*. London: DHSC; 2015.
57. Rubin DB. Statistical matching using file concatenation with adjusted weights and multiple imputations. *J Bus Econ Stat* 1986;**4**:87–94. <https://doi.org/10.2307/1391390>
58. Efron B, Tibshirani R. *An Introduction to the Bootstrap*. New York, NY: Chapman & Hall; 1993. <https://doi.org/10.1007/978-1-4899-4541-9>
59. Chaudhary MA, Stearns SC. Estimating confidence intervals for cost-effectiveness ratios: an example from a randomized trial. *Stat Med* 1996;**15**:1447–58. [https://doi.org/10.1002/\(SICI\)1097-0258\(19960715\)15:13<1447::AID-SIM267>3.0.CO;2-V](https://doi.org/10.1002/(SICI)1097-0258(19960715)15:13<1447::AID-SIM267>3.0.CO;2-V)
60. Willan AR, O'Brien BJ. Confidence intervals for cost-effectiveness ratios: an application of Fieller's theorem. *Health Econ* 1996;**5**:297–305. [https://doi.org/10.1002/\(SICI\)1099-1050\(199607\)5:4<297::AID-HEC216>3.0.CO;2-T](https://doi.org/10.1002/(SICI)1099-1050(199607)5:4<297::AID-HEC216>3.0.CO;2-T)
61. Severens JL, De Boo TM, Konst EM. Uncertainty of incremental cost-effectiveness ratios. A comparison of Fieller and bootstrap confidence intervals. *Int J Technol Assess Health Care* 1999;**15**:608–14.
62. Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves. *Health Econ* 2001;**10**:779–87. <https://doi.org/10.1002/hec.635>
63. Design & Print Solutions. *Business Stationery*. 2017. URL: [www.york.ac.uk/media/design-and-print/print-solutions/pricing/price\\_list.pdf](http://www.york.ac.uk/media/design-and-print/print-solutions/pricing/price_list.pdf) (accessed 14 February 2017).
64. White IR, Royston P, Wood AM. Multiple imputation using chained equations: issues and guidance for practice. *Stat Med* 2011;**30**:377–99. <https://doi.org/10.1002/sim.4067>
65. Lifestyles Statistics Team. *Statistics on NHS Stop Smoking Services in England April 2014 to March 2015*. Leeds: NHS Digital; 2015.
66. Pokhrel S, Evers S, Leidl R, Traperro-Bertran M, Kalo Z, Vries H, et al. EQUIPT: protocol of a comparative effectiveness research study evaluating cross-context transferability of economic evidence on tobacco control. *BMJ Open* 2014;**4**:e006945-e. <https://doi.org/10.1136/bmjopen-2014-006945>

67. Coyle K, Coyle D, Lester-George A, West R, Nemeth B, Hiligsmann M, *et al.* Development and application of an economic model (EQUIPTMOD) to assess the impact of smoking cessation [published online ahead of print August 18 2017]. *Addiction* 2017. <https://doi.org/10.1111/add.14001>
68. Etter JF, Stapleton JA. Nicotine replacement therapy for long-term smoking cessation: a meta-analysis. *Tob Control* 2006;**15**:280–5. <https://doi.org/10.1136/tc.2005.015487>
69. West R. *Background Smoking Cessation Rates in England*. London: Smoking in England; 2006.
70. Office for National Statistics (ONS). *National Life Tables, United Kingdom: 2012–2014*. Newport: ONS; 2014.
71. Public Health England. *Local Tobacco Control Profiles for England*. 2014.
72. Thun MJ, Apicella LF, Henley SJ. Smoking vs. other risk factors as the cause of smoking-attributable deaths: confounding in the courtroom. *JAMA* 2000;**284**:706–12. <https://doi.org/10.1001/jama.284.6.706>
73. US Department of Health and Human Services. *The Health Consequences of Smoking: A Report of the Surgeon General*. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Centre for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2004.
74. Townsend N, Wickramasinghe K, Bhatnagar P, Smolina K, Nichols M, Leal J, *et al.* *Coronary Heart Disease Statistics: A Compendium of Health Statistics. 2012 Edition*. London: British Heart Foundation; 2012.
75. Association of Public Health Observatories (APHO). *Modelled Estimate of Prevalence of COPD in England*. APHO: 2011.
76. NHS Digital. *Health Survey for England – 2013*. Leeds: NHS Digital; 2013.
77. Maddams J, Brewster D, Gavin A, Steward J, Elliott J, Utley M, Møller H. Cancer prevalence in the United Kingdom: estimates for 2008. *Br J Cancer* 2009;**101**:541–7. <https://doi.org/10.1038/sj.bjc.6605148>
78. Thun MJ, Carter BD, Feskanich D, Freedman ND, Prentice R, Lopez AD, *et al.* 50-year trends in smoking-related mortality in the United States. *N Engl J Med* 2013;**368**:351–64. <https://doi.org/10.1056/NEJMsa1211127>
79. Britton M. The burden of COPD in the UK: results from the Confronting COPD survey. *Respir Med* 2003;**97**(Suppl. C):71–9. [https://doi.org/10.1016/S0954-6111\(03\)80027-6](https://doi.org/10.1016/S0954-6111(03)80027-6)
80. McMurray J, Hart W, Rhodes G. An evaluation of the cost of health failure to the National Health Service in the UK. *J Med Econ* 1993;**6**:99–110.
81. Sanderson H, Spiro S. Cancer of the Lung. In Stevens A, Raftery J, Mant J, Simpson S, editors. *Health Care Needs Assessment: The Epidemiologically Based Needs Assessment Reviews*. 2nd edn. Abingdon: Radcliffe Publishing; 2004. pp. 503–48.
82. Simpson EL, Stevenson MD, Scope A, Poku A, Minton J, Evans P. Echocardiography in newly diagnosed atrial fibrillation patients: a systematic review and economic evaluation. *Health Technol Assess* 2013;**17**(36). <https://doi.org/10.3310/hta17360>
83. Curtis L, Burns A. *Unit Costs of Health and Social Care 2016*. Canterbury: Personal Social Services Research Unit, University of Kent; 2016.
84. Sullivan PW, Slejko JF, Sculpher MJ, Ghushchyan V. Catalogue of EQ-5D scores for the United Kingdom. *Med Decis Making* 2011;**31**:800–4. <https://doi.org/10.1177/0272989X11401031>

85. Vogl M, Wenig CM, Leidl R, Pokhrel S. Smoking and health-related quality of life in English general population: implications for economic evaluations. *BMC Public Health* 2012;**12**:203. <https://doi.org/10.1186/1471-2458-12-203>
86. Brazier J, Czoski-Murray C, Roberts J, Brown M, Symonds T, Kelleher C. Estimation of a preference-based index from a condition specific measure: the King's Health Questionnaire. *Med Decis Making* 2008;**28**:113–26. <https://doi.org/10.1177/0272989X07301820>
87. National Institute for Health and Care Excellence. *Discounting of Health Benefits in Special Circumstances*. URL: [www.nice.org.uk/guidance/ta235/resources/osteosarcoma-mifamurtide-discounting-of-health-benefits-in-special-circumstances2](http://www.nice.org.uk/guidance/ta235/resources/osteosarcoma-mifamurtide-discounting-of-health-benefits-in-special-circumstances2) (accessed 23 January 2018).
88. Briggs AH. Handling uncertainty in cost-effectiveness models. *Pharmacoeconomics* 2000;**17**:479–500. <https://doi.org/10.2165/00019053-200017050-00006>
89. UK Centre for Tobacco and Alcohol Studies. *UKCTAS*. URL: [www.ukctas.ac.uk](http://www.ukctas.ac.uk) (accessed 23 January 2018).
90. Consolidated Standards of Reporting Trials. *Welcome to the CONSORT Website*. URL: [www.consort-statement.org](http://www.consort-statement.org) (accessed 23 January 2018).
91. Hughes JR, Keely JP, Fagerstrom KO, Callas PW. Intentions to quit smoking change over short periods of time. *Addict Behav* 2005;**30**:653–62. <https://doi.org/10.1016/j.addbeh.2004.08.011>
92. Borland R, Partos TR, Yong H-H, Cummings KM, Hyland A. How much unsuccessful quitting activity is going on among adult smokers? Data from the International Tobacco Control 4-Country cohort survey. *Addiction* 2012;**107**:673–82. <https://doi.org/10.1111/j.1360-0443.2011.03685.x>
93. Bauld L, Hiscock R, Dobbie F, Aveyard P, Coleman T, Leonardi-Bee J, *et al*. English Stop-Smoking Services: one-year outcomes. *Int J Environ Res Public Health* 2016;**13**:E1175. <https://doi.org/10.3390/ijerph13121175>
94. Anthenelli RM, Benowitz NL, West R, St Aubin L, McRae T, Lawrence D, *et al*. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. *Lancet* 2016;**387**:2507–20. [https://doi.org/10.1016/S0140-6736\(16\)30272-0](https://doi.org/10.1016/S0140-6736(16)30272-0)
95. Benowitz NL, Zevin S, Jacob P. Suppression of nicotine intake during ad libitum cigarette smoking by high-dose transdermal nicotine. *J Pharmacol Exp Ther* 1998;**287**:958–62.
96. Hawk LW, Ashare RL, Lohnes SF, Schlienz NJ, Rhodes JD, Tiffany ST, *et al*. The effects of extended pre-quit varenicline treatment on smoking behavior and short-term abstinence: a randomized clinical trial. *Clin Pharmacol Ther* 2012;**91**:172–80. <https://doi.org/10.1038/clpt.2011.317>
97. Stapleton J. Cigarette smoking prevalence, cessation and relapse. *Stat Methods Med Res* 1998;**7**:187–203. <https://doi.org/10.1177/096228029800700206>
98. West R, Shiffman S. *Fast Facts: Smoking Cessation*. 3rd edn. Abingdon: Health Press Ltd; 2016.
99. McEwen A, West R, McRobbie H. Motives for smoking and their correlates in clients attending Stop Smoking treatment services. *Nicotine Tob Res* 2008;**10**:843–50. <https://doi.org/10.1080/14622200802027248>
100. Leaviss J, Sullivan W, Ren S, Everson-Hock E, Stevenson M, Stevens JW, *et al*. What is the clinical effectiveness and cost-effectiveness of cytisine compared with varenicline for smoking cessation? A systematic review and economic evaluation. *Health Technol Assess* 2014;**18**(33). <https://doi.org/10.3310/hta18330>

## Appendix 1 Supplementary tables for the long-term cost-effectiveness modelling

The material presented here is adapted from the adapted from the Preloading Investigators.<sup>39</sup> This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See <http://creativecommons.org/licenses/by/4.0/>.

**TABLE 29** Annual death rates (per 1000 population) by age and smoking status<sup>19</sup>

Age range (years)	Smoking status		
	Current smoker	Former smoker	Non-smoker
0–34	0.11	0.11	0.11
35–44	2.80	2.00	1.60
45–54	8.10	4.90	4.00
55–64	20.30	13.40	9.50
65–74	47.00	31.60	23.70
75–84	106.00	77.30	67.40
≥ 85	218.70	179.70	168.60

**TABLE 30** Cancer prevalence in the UK: estimates for 2008<sup>77</sup>

Age range (years)	Sex (%)	
	Male	Female
0–44	0.002	0.003
45–54	0.089	0.076
55–64	0.089	0.076
65–74	0.748	0.331
≥ 75	0.748	0.331

**TABLE 31** Chronic obstructive pulmonary disease prevalence in the UK<sup>75</sup>

Age range (years)	Sex (%)	
	Male	Female
16–44	1.28	1.28
45–64	4.15	4.15
65–74	8.13	8.13
≥ 75	8.94	8.94

**TABLE 32** Coronary heart disease prevalence in the UK<sup>72</sup>

Age range (years)	Sex (%)	
	Male	Female
16–24	0.1	0.1
25–34	0.2	0.1
35–44	0.6	0.3
45–54	3.6	1.3
55–64	10.6	3.5
65–74	20.8	10.0
≥ 75	28.6	19.3

**TABLE 33** Stroke prevalence in the UK

Age range (years)	Sex (%)	
	Male	Female
0–44	0.10	0.11
45–54	0.85	0.75
55–64	2.60	1.80
65–74	6.08	4.16
≥ 75	14.55	12.17

**TABLE 34** Prevalence of smoking in the UK<sup>76</sup>

Age range (years)	Smoking status, prevalence (%)					
	Current smokers		Former smokers		Never smokers	
	Male	Female	Male	Female	Male	Female
16–24	27.5	18.9	4.3	7.0	68.2	74.1
25–34	37.4	24.5	16.2	18.0	46.3	57.5
35–44	25.1	18.6	27.2	22.3	47.7	59.1
45–54	24.6	19.2	26.9	23.2	48.5	57.5
55–64	21.4	17.2	35.2	28.6	43.3	54.2
65–74	11.7	11.6	47.2	34.3	41.1	54.1
≥ 75	7.0	4.9	56.3	32.5	36.7	62.6

**TABLE 35** Relative risks of lung cancer, COPD, CHD and stroke in current and former smokers vs. non-smokers

Disease	Age range, years	Sex	Smoking status	RR	Distribution (alpha, beta)	Reference
Lung cancer	35–54	Male	Current	14.33	Log-normal (13.00, 15.80)	Parrott <i>et al.</i> <sup>49</sup>
		Female	Current	13.3	Log-normal (12.26, 14.42)	Parrott <i>et al.</i> <sup>49</sup>
		Male	Former	4.4	Log-normal (4.05, 4.75)	Parrott <i>et al.</i> <sup>49</sup>
		Female	Former	2.64	Log-normal (2.52, 2.77)	Parrott <i>et al.</i> <sup>49</sup>
	≥ 55	Male	Current	24.97	Log-normal (22.2, 28.09)	Thun <i>et al.</i> <sup>78</sup>
		Female	Current	25.66	Log-normal (23.17, 28.40)	Thun <i>et al.</i> <sup>78</sup>
		Male	Former	6.75	Log-normal (6.06, 7.52)	Thun <i>et al.</i> <sup>78</sup>
		Female	Former	6.7	Log-normal (6.09, 7.36)	Thun <i>et al.</i> <sup>78</sup>
COPD	35–54	Male	Current	1.0		Parrott <i>et al.</i> <sup>49</sup>
		Female	Current	1.0		Parrott <i>et al.</i> <sup>49</sup>
		Male	Former	1.0		Parrott <i>et al.</i> <sup>49</sup>
		Female	Former	1.0		Parrott <i>et al.</i> <sup>49</sup>
	≥ 55	Male	Current	25.61	Log-normal (21.68, 30.25)	Thun <i>et al.</i> <sup>78</sup>
		Female	Current	22.35	Log-normal (19.55, 25.55)	Thun <i>et al.</i> <sup>78</sup>
		Male	Former	7.05	Log-normal (6.07, 8.19)	Thun <i>et al.</i> <sup>78</sup>
		Female	Former	8.09	Log-normal (7.19, 9.1)	Thun <i>et al.</i> <sup>78</sup>
CHD	35–54	Male	Current	3.88	Log-normal (3.53, 4.27)	Parrott <i>et al.</i> <sup>49</sup>
		Female	Current	4.98	Log-normal (4.44, 5.59)	Parrott <i>et al.</i> <sup>49</sup>
		Male	Former	1.83	Log-normal (1.71, 1.95)	Parrott <i>et al.</i> <sup>49</sup>
		Female	Former	2.23	Log-normal (2.02, 2.46)	Parrott <i>et al.</i> <sup>49</sup>
	55–64	Male	Current	2.5	Log-normal (2.34, 2.66)	Thun <i>et al.</i> <sup>78</sup>
		Female	Current	2.86	Log-normal (2.65, 3.08)	Thun <i>et al.</i> <sup>78</sup>
		Male	Former	1.43	Log-normal (1.37, 1.48)	Thun <i>et al.</i> <sup>78</sup>
		Female	Former	1.44	Log-normal (1.38, 1.51)	Thun <i>et al.</i> <sup>78</sup>
	≥ 65	Male	Current	2.5	Log-normal (2.34, 2.66)	Thun <i>et al.</i> <sup>78</sup>
		Female	Current	2.86	Log-normal (2.65, 3.08)	Thun <i>et al.</i> <sup>78</sup>
		Male	Former	1.43	Log-normal (1.37, 1.48)	Thun <i>et al.</i> <sup>78</sup>
		Female	Former	1.44	Log-normal (1.38, 1.51)	Thun <i>et al.</i> <sup>78</sup>
Stroke	35–54	Male	Current	1.00		Parrott <i>et al.</i> <sup>49</sup>
		Female	Current	1.00		Parrott <i>et al.</i> <sup>49</sup>
		Male	Former	1.00		Parrott <i>et al.</i> <sup>49</sup>
		Female	Former	1.00		Parrott <i>et al.</i> <sup>49</sup>
	55–64	Male	Current	1.92	Log-normal (1.66, 2.21)	Thun <i>et al.</i> <sup>78</sup>
		Female	Current	2.1	Log-normal (1.87, 2.36)	Thun <i>et al.</i> <sup>78</sup>
		Male	Former	1.16	Log-normal (1.07, 1.25)	Thun <i>et al.</i> <sup>78</sup>
		Female	Former	1.15	Log-normal (1.07, 1.22)	Thun <i>et al.</i> <sup>78</sup>
	≥ 65	Male	Current	1.92	Log-normal (1.66, 2.21)	Thun <i>et al.</i> <sup>78</sup>
		Female	Current	2.1	Log-normal (1.87, 2.36)	Thun <i>et al.</i> <sup>78</sup>
		Male	Former	1.16	Log-normal (1.07, 1.25)	Thun <i>et al.</i> <sup>78</sup>
		Female	Former	1.15	Log-normal (1.07, 1.22)	Thun <i>et al.</i> <sup>78</sup>

**TABLE 36** Annual costs of treating smoking-related diseases<sup>100</sup>

Disease	Costs (£)	Distribution <sup>a</sup>
CHD	1247.79	Gamma
COPD	1642.57	Gamma
Lung cancer	7002.65	Gamma
Stroke	5886.66	Gamma

a Standard errors estimated at 10% of the mean.

**TABLE 37** Inflation rates<sup>83</sup>

Year	Inflation multiplier	Pay and Price Index
2001	1.5115	195.5
2002	1.4383	206.5
2003	1.3898	213.7
2004	1.3212	224.8
2005	1.2785	232.3
2006	1.2329	240.9
2007	1.1890	249.8
2008	1.1556	257.0
2009	1.1124	267.0
2010	1.1057	268.6
2011	1.0734	276.7
2012	1.0513	282.5
2013	1.0338	287.3
2014	1.0224	290.5
2015	1.0133	293.1
2016	1.0000	297.0

**TABLE 38** Utility values

Model state/disease	Utility value, mean (SE)	Distribution (alpha, beta)	Reference
Current smokers	0.8497 (0.0005)	Beta(477,912, 84,525)	Vogl <i>et al.</i> <sup>85</sup>
Former smokers	0.8695 (0.0014)	Beta(47,833, 7180)	Vogl <i>et al.</i> <sup>85</sup>
Lung cancer	0.5600 (0.0430)	Beta(74, 58)	Sullivan <i>et al.</i> <sup>84</sup>
CHD	0.6210 (0.0110)	Beta(1207, 737)	Sullivan <i>et al.</i> <sup>84</sup>
COPD	0.7320 (0.0070)	Beta(2930, 1073)	Sullivan <i>et al.</i> <sup>84</sup>
Stroke	0.5500 (0.0160)	Beta(531, 435)	Sullivan <i>et al.</i> <sup>84</sup>



A decorative graphic consisting of numerous thin, parallel green lines that curve from the left side of the page towards the right, creating a sense of movement and depth.

**EME  
HS&DR  
HTA  
PGfAR  
PHR**

Part of the NIHR Journals Library  
[www.journalslibrary.nihr.ac.uk](http://www.journalslibrary.nihr.ac.uk)

*This report presents independent research funded by the National Institute for Health Research (NIHR). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health*

***Published by the NIHR Journals Library***